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RESEARCH AIMS 
 
The aim of this thesis by Prior Published Work is to highlight, in a series of six 
interlinked papers, the extent to which the quality (paper n.1, 2), the usefulness (n. 2, 
4, 5) and the clinical relevance (n. 3, 5, 6) of population-based cancer registries’ data 
can be enhanced.  
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THESIS SUMMARY 
 
Introduction 
The activity of cancer registries represents a multistep process that starts by gathering 
information from a variety of sources. Such information is checked, linked, enriched 
and handled to produce high-quality original data capable of being informative enough 
to prove useful in answering specific epidemiological and clinical questions.  
This thesis is part of a PhD by Prior Publication grounded in six published papers. These 
papers deal with different steps in the production of cancer registry data, enhancing 
the contribution of registries to cancer epidemiology. Skin melanoma has been used 
as an example, but all the presented methods and concepts apply to any cancer type. 
 
Materials and methods 
1.            The first paper (related to cancer registry data quality) tests the hypothesis 
whether the distribution of the first digit (from one to nine) of crude incidence rates 
obeys Benford law. Pearson’s coefficient of correlation and different distance 
measures were applied to compare the theoretical distribution to the observed one in 
a sample of 43 population-based cancer registry populations randomly drawn from 
the volume X of Cancer Incidence in 5 Continents.  
2.            In the second paper, an innovative index for measuring the amount of internal 
variability among the sub-areas underlying an overall incidence rate is presented. The 
measure is a ratio, where the numerator is the difference between the highest and 
the lowest age-adjusted standardised rate in sub-areas. The denominator is the overall 
area age-adjusted standardised rate. Such measure was applied to age-standardised 
incidence rates for ‘all cancer sites excluding non-melanoma skin cancer’, for men, in 
2014, for Nordic countries as a whole, for each country (Denmark, Faroe Islands, 
Finland, Greenland, Iceland, Sweden and Norway) and their regions.  
3.            In paper three, to make cancer registry data useful in the clinical setting, 
melanoma incidence during 1985–2004 in the Tuscan cancer registry (Italy) was 
analysed including both standard (site, morphology, sex, age, calendar period) and 
clinically relevant variables, as in situ melanoma and Breslow’s thickness. For the time 
trend analysis, the annual percent change (APC) of the rates was computed. 
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4.            Paper 4 presents the results of an age-period-cohort model applied to 1977 
skin melanomas, incident in the Tuscan cancer registry. Such a method allows us to 
understand the time trend better and to forecast future change. Moreover, a non-
linear regression model was applied to estimate the expected number of new cases in 
a more recent period. 
5.            Paper 5 shows a skin melanoma survival analysis based on 1403 patients from 
two Italian registries (Tuscan and Reggio-Emilia). The focus was on two different 
approaches: the multivariate Cox proportional hazard model and the Classification 
And Regression Trees analysis. The latter is an automatic method that splits data 
through a recursive process creating a ‘tree’ of groups with different profiles of risk of 
death. Both ways were applied to the following variables: age, sex, Breslow thickness, 
Clark level, Registry, sub-site and morphologic type. 
6.            In Paper 6, the quality of melanoma diagnosis and care in the Tuscan region 
is measured based on 13 newly realised process indicators, which encompassed early 
diagnosis, pathology reporting and surgical treatment. We evaluated the clinical 
adherence to these indicators in two years: 2004 and 2008, using a population-based 
series of incident skin melanomas, measuring the possible changes in the indexes 
following the implementation of specific regional recommendations. 
 
Results 
1. The distribution of the first significant digits of cancer incidence rates was 
shown to belong to numbers that abide by Benford law, in the whole dataset (146,590 
rates) by sex and cancer registries. The correlation coefficient between observed and 
expected distributions was extremely high (0.999), and the distance measures very 
small.  
2. The index for internal variability highlighted a quite relevant heterogeneity 
among Nordic countries (index 57.1% = the difference between the Nordic country 
with the highest and the one with the lowest rate is 57.1% of the Nordic overall age-
adjusted rate). Within countries, the variability was negligible in Iceland (9.6%), and 
high in Sweden (37.1%).  
3. During the four analysed periods standardized melanoma incidence rose 
significantly, for both invasive (APC = + 5.1%) and in situ lesions (APC = + 11.1). Over 
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time, the median value of thickness decreased from 1.68 to 0.8 mm (P < 0.001), but 
only for <=1.00 mm melanomas. Although the rates of thin melanoma have increased, 
rates for thick ones did not decrease. 
4. The model that best fitted the data included age and ‘drift’. The linear effect 
(‘drift’) showed, in each age group, an increase of the risk of malignant melanoma 
diagnosis of about 36.6% every five years of period or cohort. For the period 2002–
2006, 1112 new cases were predicted with a standardised rate (age 15–84 years) of 
19.2 × 100.000. In the Tuscany Cancer Registry area, no clues for malignant melanoma 
incidence rates levelling off were documented. Growing rates and numbers of 
malignant melanoma are expected soon.  
5. The Cox proportional hazard model found sex, age, Breslow thickness, Clark 
and morphologic type to have a significant independent prognostic value. The 
Classification And Regression Trees analysis identified six groups of different risks 
based on Breslow thickness, age and sex. The best prognostic group (5-year observed 
survival, 98.1%) included those subjects with Breslow less than 0.94 mm and age 19–
44 years. The same thickness but an older age (50–69 years) was associated with a 
statistically significant different prognosis (5-year observed survival, 92.8%).  
6. As regards the quality of care, there were statistically significant increases in 
the percentage of thin (<= 1 mm) melanomas from 2004 to 2008 (from 50.7 to 61.3%) 
and in the number of pathology reports that mentioned ulceration (from 61.4 to 
84.6%) and margin statuses (from 76.8 to 84.3%). The percentage of patients staged 
by sentinel lymph node biopsy was stable (63%) and was higher for patients younger 
than 75 years of age (74%). The number of lymph nodes almost invariably exceeded 
the proposed site-specific cut-off reference, and, in 2008, the number of nodes 
removed was always reported for lymphadenectomy. From 2004 to 2008, surgical and 
pathological waiting times increased.  
 
Conclusions 
The six presented papers cope cohesively with consecutive steps in the procedure of 
cancer registration.  
1. The check for Benford law abidance may become a preliminary test in the process 
of data quality.  
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2. The heterogeneity index offers a new, simple (to be produced and to be 
understood) and noteworthy information.  
3. The analysis of some clinically crucial variables raises the interest of clinicians and 
makes cancer registries closer to the real world. 
4. The use of methods with higher statistical involvement, e.g., the age-period-cohort 
model, provided further information on melanoma time trends in the area. Moreover, 
estimates were projected to a more recent period bridging the Registry’s timeliness 
gap.  
5. Prognosis is a piece of vital information for both patients and clinicians. Hazard 
ratios and patients grouping showed almost the same risk patterns but conveyed by a 
different message (relative vs absolute), with a different understandability.  
6. Population-based quality indexes allow to check the practical application of 
guidelines and recommendations, highlighting critical situations to be improved.  
 
Cancer registration is a unique process made by different but connected steps. The 
improvement of each of them positively affects others. It is a sort of virtuous circle in 
which new methods, new uses and new users are all involved in a common aim: 
exploiting cancer registries’ activity. 
Registries can have a real informative power only if the whole process, from the 
collection of raw data to the provision of relevant information for various 
stakeholders, is accomplished. 
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1. INTRODUCTION 
 
1.1. Population-based cancer registries 
The usefulness of data series on patients with cancer has been appreciated for a very 
long time. For example, thanks to the London Bills of Mortality based on the 
information gathered from parishes at the time of burials, and in which the cause of 
death was added in 1629, we know that altogether "Cancer, Gangrene, and Fistula" 
caused 56 deaths in the monitored population in 1665, while “the Great Plague” of 
the same year had a death toll of 68,596 (Bread, 1908).  
Brilliant researchers, as John Grant and, later, Sir William Petty, showed their ability to 
perform pioneering statistical investigations on the growing batches of information 
collected in the Bills (Graunt, 1662). 
 
For a very long time, any information on cancer, as on any other diseases, was only 
available after patients’ death. This limit did not discourage ingenious scientists from 
speculating on them cleverly. An example, probably one of the first in the world, 
comes from Italy, where Rigoni-Stern, a medical officer reviewing the deaths caused 
by uterine cancer in women living in the city of Verona from 1760 to 1839 related the 
frequencies to personal characteristics in a causal relationship which would become 
clear only after the identification of the Human papillomavirus (Rigoni-Stern, 1842). 
 
Information from death certificates represents a reliable estimate for the incidence 
(diagnosis) of lethal diseases, as cancer was considered until recently, but not of 
benign lesions. Furthermore, death certificates provide no information on diagnosis 
and clinical course. 
 
Therefore, the interest in collecting information also on cancer diagnosis (incidence) 
and people affected by cancer (prevalence) grew, and an extensive list of pioneer 
attempts have been described by some of those who are among the fathers of cancer 
registration - Clemmenson in Denmark and Wagner in Germany (Clemmenson, 1965; 
Wagner, 1985; Wagner, 1991). 
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Their comprehensive descriptions portray many efforts in several European countries, 
with Germany playing a leading role. However, such attempts were, on the whole, 
substantially unsuccessful. The results of these laboured European trials did not 
prevent Americans from entering the struggle, and in 1927, in Massachusetts, they 
encountered the identical problems of limited participation of medical practitioners 
and low completeness of cancer series collection already experienced in Europe 
(Hoffman, 1930).  
 
However, the process had started, and although slowly and with difficulty, precious 
lessons came from some of these experiences. In Germany, what we can consider a 
cancer registry was set up in 1926 in Hamburg. There, a group of trained nurses 
actively collected nominative information for each diagnosed cancer patient from 
both general practitioners and hospitals (Keding, 1973). 
 
The USA chose a different strategy and performed a survey aimed at collecting cancer 
incidence, mortality and prevalence data to produce national estimates based on a 
sample of ten areas. The first survey took place in 1936-37 and again in 1947-48 and 
1969-71 (Haenszel, 1975). 
 
Despite the difficulties and the many frustrating failures, some of those attempts and 
experiences settled durably: e.g. the Connecticut registry in the USA set up in 1935 
and the Danish national registry in 1943.  
 
The epochal event which turned cancer registration from an activity of some odd 
personalities to a harmonised procedure able to produce comparable data started in 
1950 when the World Health Organisation (WHO) appointed a committee to address 
cancer registration and data analysis.  
 
The purpose of an international association committed to cancer registration was, in 
the idea of its first proponent, Sidney Cutler of the US National Cancer Institute, to 
improve and harmonise the quality of data on cancer incidence and comparability 
between registries by standardisation of methods (Whelan, 2010). The process 
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initiated in 1950 by the WHO, which involved all the most eminent personalities who 
had been active in the field, moved forward. The committee was established in 1964 
by the Union for International Cancer Control (UICC) with the task of producing a 
technical report on cancer incidence, finally published in 1966. It was the first volume 
of Cancer Incidence in Five Continents (CI5) and included data from 32 Registries in 29 
countries (Doll, 1966). 
 
During the same years in France, there was an intense political initiative aimed at 
fighting cancer which eventually gained the support of President de Gaulle and in May 
1965 resulted in the establishment of the International Agency Against Cancer (IARC), 
which has acted in Lyon as a technical body of the WHO in this specific field 
(https://www.iarc.fr/en/about/iarc-history.php) ever since. 
 
In 1966 also, the International Association of Cancer Registries (IACR) was founded to 
foster the aims and activities of cancer registries worldwide (Whelan, 2010).  
 
Therefore, the scenario changed sensibly with the involvement of the World Health 
Organisation and especially of its specialised cancer agency, IARC. WHO has had an 
active and growing role in supporting the activities of IARC, and more in general, the 
registries. IARC has become not only the centre of data collection and analysis for the 
production of the “Cancer Incidence in 5 Continents” (CI5) but also a renowned centre 
of expertise in cancer registration and epidemiology providing training courses, 
software and references (https://www.iarc.fr).  
 
CI5 became the example to follow for all registries, a source of reliable information 
and a reference for data quality evaluation. 
 
Concurrently with the gradual diffusion of registries, scientific associations were 
founded to coordinate and support their work. The Group for cancer registration and 
epidemiology in Latin language countries (Grell) (www.grell-network.com) was 
founded in 1975, the Association of the Nordic Cancer Registries 
(https://www.ancr.nu/ancr-p2/ancr/important-dates/) followed in 1984, and the 
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European network of cancer registries (ENCR) was then established 
(http://www.encr.eu) in 1989. Finally, in Europe, the United Kingdom and Ireland 
Association of Cancer Registries (UKIACR) (http://www.ukiacr.org/about/about-
ukiacr) was founded in 2002. In 1973 in the USA, the National Cancer Institute 
established the Surveillance, Epidemiology and End Results (SEER) programme 
(https://seer.cancer.gov/), and in 1987 the North American Association of Central 
Cancer Registries (NAACCR) was established (https://www.naaccr.org/). 
 
The number of registries has grown over time and, in 2017, they were overall 343, 
present in 65 countries over five continents (Bray, 2017).  
 
Quoting the words of Ratnam K. Shanmugaratnam in a book which has been a 
landmark for generations of registrars (Shanmugaratnam, 1991), a population-based 
cancer registry, "is the maintenance of a file or register of all cancer cases occurring in 
a defined population in which the personal particulars of cancer patients and the 
clinical and pathological characteristics of the cancers, collected continuously and 
systematically from various data sources, are documented."  
 
To know the source population makes the difference between registries and hospital-
based cancer registries which collect the clinical series of a specific department, 
hospital, or institute (Young, 1991). The information on the population to which the 
patients belong makes the difference between the two types of registries glaringly 
obvious: only registries can compute population-based indexes (Shanmugaratnam, 
1991). 
 
The newly diagnosed cancers are the base for computing the incidence (of the 
disease), and once diagnosed a person contributes to prevalence until death because 
the definition of a cured cancer patient is still under debate (Essig, 2019). 
The definition of cancer cure has been proposed differently by oncologists and 
epidemiologists since it has implemented for individual patients or populations of 
patients. Furthermore, some definitions apply for specific cancer types, as the 
complete biochemical remission for thyroid cancers (Pacini, 2012). Moreover, for 
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some other cancers after initial treatment patients may also remain relapse-free, or 
without any measurable sign of disease, for several years (e.g., breast cancer patients) 
with a small long-term excess risk of relapse or death (Janssen-Heijnen, 2014; 
Mariotto, 2018). 
An epidemiological definition is to consider cured those patients who have reached 
the same death rates of the general population (Dal Maso, 2014). However, although 
these patients may reach the same risk of death than the general population (at the 
time-to-cure) and die from other causes than cancer (‘cured’ from a statistical point 
of view) (Romain, 2019), some of them may die with cancer (Dal Maso, 2014). 
 
Registries produce incidence, prevalence and survival for any cancer type, and at least 
in theory for any other collected variable (e.g., sex, age, morphology, as well as stage 
at diagnosis, sub-groups of patients defined by the combination of biomarkers). 
 
The population represents the denominator of all the measures of frequency and 
severity produced by registries, and such measures provide, at least theoretically, 
unbiased estimates of the average values in the whole population. The continuous 
activity of registries also allows to measure trends of the epidemiological indicators 
over time. 
 
The information input to registries is clinical and demographic data routinely produced 
for clinical and administrative needs (e.g., hospital discharge notes, death certificates, 
pathology reports) (Powell, 1991). 
 
Over time, digitalisation has made it possible to retrieve information from many other 
sources, both clinical (e.g., laboratory, hospice, radiotherapy, screening, drug 
prescriptions) and administrative (e.g., insurance records, tax exceptions).   
 
Each source of information is useful for two purposes: to confirm the information 
coming from other sources and to provide original contribution. Therefore, increasing 
the number and type of sources improves the completeness of the registry (Parkin & 
Bray, 2009). 
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Any source is linked with all the others belonging to the same person, using the most 
reliable personal identification variable available, then different tumours diagnosed in 
the same person have to be identified and coded separately if they are independent 
of each other. 
 
For each case (patient and cancer) a minimum set of information to be collected has 
been identified in technical manuals, with primary and desirable variables 
(MacLennan, 1991; Menck, 1994; Hutchinson, 1997). However, information 
availability has varied over time and from country to country due to technical, legal, 
and economic accessibility.  
 
Although registries generally include all invasive cancers, some of them avoid 
collecting data on non-melanoma skin cancer (especially basal epitheliomas) (Ferlay, 
2014) while others include non-malignant tumours which, for example, are 
particularly relevant during childhood and are indeed included in the International 
Classification of Childhood Cancer (Steliarova-Foucher, 2005). Moreover, some 
registries collect information about in situ tumours for those cancers for which 
organised, or spontaneous screening programmes are active (Bray, 2014). Finally, the 
inclusion of cancers diagnosed at the autopsy is not homogeneous among countries 
and registries (Bray, 2014). 
 
Irrespective of these differences in inclusion criteria, which may distinguish one 
registry from another but are usually minor (Bray, 2014), CRs strategy is to look for the 
footprints left in the healthcare system by cancer patients during their clinical 
experience. This information is collected and converted into epidemiological indexes 
at the end of the registration process. Theoretically, registries aspire to 100% 
completeness which means identification of all the cancers diagnosed in a defined 
population. To reach this goal, they have to use as many sources of information as 
possible. However, clinical paths may be similar, but they are nonidentical for all 
cancer types, all cancers of the same type (e.g. for differences in the stage of the 
disease at diagnosis which usually require different treatments) and all patients (e.g. 
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differences in age at diagnosis, which may cause different intensity of the diagnostic 
and therapeutic process due to coexistence of comorbidity) (Powell, 1991). 
Life has incredibly changed over time, with a succession of technological revolutions. 
Computers have replaced sheets of papers and calculators, and the web has made 
traditional ways of communications obsolete and mobile phones have become such 
smart to be used as health information devices (Min, 2014). In the meantime, while 
technology has made giant leaps, registries have kept their traditional pace, causing 
frustrations for the delay in data production, the scarcity of information provided, the 
scarce use of the data by registries, the weak interest in these data shown by 
policymakers and even more by clinicians. Moreover, for several years, legislation on 
data protection hampered registry activity very significantly and only recently clear 
and standard rules been introduced (EU, 2016). 
 
Registries may be considered systems which monitor cancer at the population level, 
able to identify risk groups, document changes over time, predict future disease 
burden, show improvements, but also identify emerging groups at risk and differences 
in quality of care and unmet needs. 
 
CRs must produce reliable information to carry out all these functions properly. 
Registrars invest a lot of time and resources for providing valid, comparable and 
complete data and consequently trustworthy epidemiological measures.  
 
Once the high quality of a dataset is proven, epidemiological parameters may be 
computed. These may be raw numbers, crude-, specific- and age-adjusted rates, 
cumulative rates, proportions for incidence and prevalence and different types of 
survival rates. 
 
Since the beginning of my experience, the expectation of the scientific community 
from registries was limited, and their fate has seemed doomed: slow but sure death. 
On the contrary, I had the impression registries were only beginning, and it was up to 
researchers to exploit their potential.  
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I accepted this challenge, and I herein present my research, hoping it can help 
registries to be more actively involved in healthcare systems. 
 
2. Quality of cancer registry data  
 
2.1. Quality of cancer registry data - Introduction 
Quality evaluation of registry data includes checking several dimensions: validity (the 
accuracy of the registered data: the correspondence between what should be 
measured and what is actually measured); completeness of cancer data collection; 
timeliness (interval between clinical diagnosis and availability of epidemiological 
estimates); and comparability (in the same registry over time, and among different 
registries, which implies the use of standard rules and procedures) (Bray&Parkin, 
2009; Parkin&Bray, 2009). 
 
The quality of collected data has been considered a pivotal issue throughout the 
history of registration. The low completeness achieved weakened the first pioneer 
attempts at cancer registration (Wood, 1930). Only more recently, data from registries 
were favourably judged by Sir Richard Doll who wrote: “In many instances, there is 
now reason to believe that the figures that have been obtained in this way (routine 
cancer registration) correspond very closely to the true incidence of disease" (Doll, 
1972). 
  
The evaluation of the quality of registry data, assessable at the level of each single 
registry (Ryzhov, 2018), has improved since the implementation of ‘Cancer Incidence 
in 5 Continents’ that compared data from different registries and developed a section 
of competence on cancer registration at the IARC. 
 
The evaluation of the quality of registry data, crucial in this comparative publication, 
produced a series of rules and methods which have spread widely and been 
increasingly applied, contributing to the establishment of harmonised standards and 
procedures (Bray, 2014; Bray&Parkin, 2009; Parkin&Bray, 2009). 
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Recently, a collaborative project coordinated by the ENCR together with the Joint 
Research Centre (JRC) of the European Commission and with the involvement of the 
leading European consortia and stakeholders in cancer registration (e.g. IARC, 
Eurocare, Concord) adopted a list of standard variables to be collected to fulfil various 
projects (e.g., incidence and survival computation) and corresponding data quality 
checks (Martos, 2014). Moreover, data checking software includes these agreed rules 
(JRC-ENCR Quality Check Software - QCS, https://www.encr.eu/download). 
 
As briefly mentioned above, evaluating the quality of registry data remains a complex 
process requiring the assessment of diverse aspects: validity, comparability, 
completeness and timeliness. 
 
2.1.1. Quality of cancer registry data - Validity 
Validity is the correspondence between what is registered in a registry and the actual 
value of the feature to be registered (Kearney, 2015). This parameter is evaluated 
within the dataset measuring the internal correspondence (consistency) among 
different variables (e.g., sex and cancer sites, or age and cancer sites). The availability 
of specific software, has simplified this process considerably (e.g., JRC-ENCR QCS, 
https://www.encr.eu/tools-for-registries; IARCcrgTools, 
http://www.iarc.com.fr/index.php?option=com_content&view=article&id=72:iarccrg
tools&catid=68&Itemid=445). 
 
Moreover, the reliability of information provided by a registry depends on the 
reliability of the source of such information. Therefore, the higher the proportion of 
cases confirmed by microscopic verification (MV%, histology or cytology or peripheral 
blood cells examination), the higher the validity. However, an extremely high MV% 
(close to 100%) may be the clue for an excessive reliance of registry from such 
information source with insufficient attention to others, which may result in a 
selection of a sub-group of cases (Parkin, 1994).   
 
Conversely, the higher the proportion of cases known from the death certificate only 
(DCO), the lower the validity. However, death certificates are one of the traditional 
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sources of information and all registries which have access to such data employ it to 
improve completeness and update follow-up information (Parkin, 1994).  
 
Ordinarily, any death certificate notified case (DCN) should be coded as DCI (cases 
identified by death certificate). After that, a traceback procedure is performed to 
detect any missing information in all the other available sources. If traceback is 
successful, the case is registered with the supplementary information (e.g., date of 
incidence, source of information). Only those cases for which traceback fails to 
pinpoint another appropriate date of incidence and source of information become 
DCO.  
 
Therefore, in case a registry does not register DCI but only DCO, a low proportion of 
DCO may not be very significant, because we do not know how many of these cases 
the registry would have initially acknowledged as DCI (Parkin, 1994).  
 
Among the measures of validity, there is also the proportion of missing values for 
significant variables, usually age at diagnosis and site of the tumours (coded in the 
group Other & Unspecified cancer site, O&U). A considerable proportion of O&U or 
DCO may be the indicator of poor cancer control in a jurisdiction, or of limited 
precision in cancer registration. 
 
2.1.2. Quality of cancer registry data - Comparability 
Comparability implies the use by different registries of the same language and 
grammar, represented by the adoption of the same classifications for defining cancer, 
and the same definitions for those aspects of cancer registration which may have a 
substantial effect on the estimate of incidence, like the definition of 'date of diagnosis' 
or the discrimination between recurrence and second independent cancer diagnosis.  
 
The classifications used for defining cancer have changed and developed over time 
(WHO, International Classification of Diseases, ICD, 
http://www.who.int/classifications/icd/en/). Moreover, a specific classification for 
cancer, the International Classification of Disease for Oncology (ICD-O) has been 
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introduced and continuously updated (ICD-O 1,2,3, http://codes.iarc.fr/) according to 
the updates of the ICD to which it is related. The ICDO-3 represents the state-of-the-
art for registries and enables them to encode data on cancer site, morphology, 
behaviour and grade of tumour differentiation (Ferlay, 2014). 
The trustworthiness of registry data depends on that of the sources of information. 
Therefore, such information is necessary and has to be classified and coded, according 
to IARC (http://www.iacr.com.fr/images/doc/basis.pdf), or ENCR 
(http://www.encr.eu/images/docs/recommendations/basisd.pdf), or SEER 
(https://seer.cancer.gov/manuals/2016/SPCSM_2016_maindoc.pdf) in ways which 
make it possible to find a minimum common denominator.  
 
The rules for the dates of incidence, the occurrence of multiple primaries and cancers 
detected in asymptomatic people may all affect incidence. 
 
2.1.2.1. Quality of cancer registry data – Comparability – Date of incidence 
The availability and application of innovative technology, e.g., Prostate-Specific 
Testing and subsequent biopsy for prostate cancer, may sensibly anticipate the date 
of cancer diagnosis (Schroder, 1995). 
 
The Registries collect and code the basis of diagnosis. Some classifications have 
proposed updating the rules for date of diagnosis definition according to the 
development of technology. On the other hand, publications like CI5, which compare 
countries with radically different levels of technology development, apply 
classifications stable overtime to assure comparability. This reason may have 
contributed to the adoption of slightly different rules for IARC (Jensen, 1991), and the 
USA (Adamo, 2018). 
 
In Table 1 the summary recommendations for coding incidence date in SEER (for solid 
tumours) (Adamo, 2018) and IARC (Jensen, 1991) are compared. Both systems request 
to choose the date with the highest priority. A broader use of the laboratory testing 
and/or imaging without biopsy or surgical removal of the lesions or hospitalisation may 
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increase the completeness and the timeliness with SEER rules for some types of cancer 
patients (e.g., extremely elderly patients or cases diagnosed in advanced stage). 
 
 
Table 1: Comparison of the summary recommendations for coding incidence date in 
SEER and ENCR. The priority decreases from top to bottom. 
 
Priority SEER IARC 
1 
(higher) 
Positive histology Consultation at, or admission to, a 
hospital, clinic or institution for the 
cancer in question 
2 Positive cytology First diagnosis by a physician or first 
pathology report 
3 Positive microscopic 
confirmation (MV), method not 
specified 
Death (when the cancer is first 
ascertained from the death certificate 
and follow-back attempts have been 
unsuccessful) 
4 Positive laboratory test / 
marker study 
Death preceding an autopsy, when 
cancer is first found and was 
unsuspected clinically  
5 Direct visualisation without MV  
6 Radiology and other techniques 
without MV 
 
7 Clinical diagnosis only  
8 
(lower) 
Unknown whether or not MV; 
death certificate only 
 
 
 
2.1.2.2. Quality of cancer registry data – Comparability – Multiple primaries 
The rules for defining when multiple primary cancers diagnosed in the same person 
may be counted in incidence as independent cases may vary from registry to registry. 
Also, in this field, the effect of adopting various rules may produce not a negligible 
variability in incidence rates. The main difference is between the rules of the IACR-
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IARC-ENCR (http://www.ia.com.fr/images/doc/MPrules_july2004.pdf) and those 
adopted by the SEER (Johnson, 2007). The former considers only one tumour for a 
specific topography (or groups of topography) including bilateral organs unless the 
morphologies of two or more cancers are different enough to belong to distinct 
groupings (Berg, 1996). The US rules are more extensive and allow the inclusion of 
more tumours in bilateral organs (e.g., breast) and in sub-sites of some other tissues 
(e.g., colon). The application of these two types of rules may cause considerable 
differences in age-adjusted incidence rates for specific cancers sites (from +2 to +8% 
for the colon, lung, skin melanoma, testis, female breast, kidney, and from +1% to +3% 
for all sites except non-melanoma skin cancers) (Bray, 2014).    
 
2.1.2.3. Quality of cancer registry data – Comparability – Screening and autopsy  
The last group of conditions includes screening (Morrison, 1985) and the autopsy that 
both may affect incidence for cancers diagnosed incidentally in people without 
symptoms or symptomatic but undiagnosed before death.  
 
2.1.2.3.1. Quality of cancer registry data – Comparability – Screening 
The effect of screening is to increase both incidence for earlier diagnosis and the 
detection of some cancers which would not have come to clinical evidence (Morrison, 
1985). The latter point is usually called over-diagnosis, "the diagnosis of a "cancer" 
that would otherwise not go on to cause symptoms or death" (Welch, 2010). 
Therefore, different cancer screening modes - either organised (mammography for 
female breast, Pap test or HPV testing for cervix uteri, and faecal blood detection or 
sigmoidoscopy for colorectal cancers) or spontaneously performed (e.g., for the 
thyroid, melanoma, lung, or prostate cancer) - may have to be considered when 
comparing registries. Screening tends to anticipate the time of diagnosis, causing an 
increase in incidence during the first rounds of its implementation (Bray, 2009).  
Moreover, when screening is addressed to detect premalignant lesions (e.g., for the 
cervix and colorectal cancer), this may cause a decrease in incidence (Bray, 2009). A 
similar result may be due to variation in the intensity of clinical investigation among 
jurisdictions (Carsin, 2010). 
 
  31 
2.1.2.3.2. Quality of cancer registry data – Comparability – Autopsy  
The frequency of post-mortem examination may vary from country to country (Start, 
1995; Burton, 2003). In registries which include cases incidentally detected at autopsy 
- without any suspicion of malignancy before death (Bray, 2009) - incidence rates may 
inflate when this practice is frequent (Bieri, 2015) or marginally if it is more 
uncommon. 
 
2.1.3. Quality of cancer registry data – Completeness 
Completeness refers to the number of cases diagnosed in the target population in a 
specified year, included in the registry's dataset. The capability of a registry to express 
the true incidence in the target population increases with completeness. 
 
A comprehensive set of parameters may be used to evaluate completeness: 
 
2.1.3.1. Quality of cancer registry data – Completeness - Steadiness of rates  
Within a registry, the case-series is expected not to change abruptly from one year to 
the next. Incompleteness may be higher (and the number of cases lower) for data 
collected in more recent years (Parkin, 1994). 
 
2.1.3.2. Quality of cancer registry data – Completeness - Homogeneity in the area  
Cancer incidence is not expected to change from one area to a neighbouring one, 
unless there are local exposures (Bruno 2014) or actions (e.g., screening) (Waldmann 
2012) capable of modifying it. Therefore, a reference for completeness may be the 
comparison of incidence levels in adjacent registries (Parkin, 1994). 
 
2.1.3.3. Quality of cancer registry data – Completeness - Steadiness in age-specific 
curves 
Sudden drops in age-specific rates for specific cancer sites may be a clue for 
incompleteness in data collection or a problem in the denominator in specific age-
groups (Parkin, 1994). 
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2.1.3.4. Quality of cancer registry data – Completeness - Number of sources of 
notification per case  
More sources make the information more reliable (if the information is concordant 
among them). The same is true for the number of independent notifications for each 
source (which reduces the risk of grounding the decision on the same possible coding 
error) (Parkin, 1994). This method implies that linkage among sources and 
notifications avoids duplications and errors (Brenner, 1996). 
 
2.1.3.5. Quality of cancer registry data – Completeness – Childhood cancer incidence 
Childhood cancer incidence was traditionally considered quite stable over time and in 
neighbouring registries. However, recent analysis has documented geographical and 
temporal variations which call for a reconsideration of this index as a measure of 
completeness (Steliarova-Foucher, 2017). Several reasons may cause differences in 
rates between areas. For example, a different prevalence of genetic (Walsh, 2013) or 
environmental risk factors (Gupta, 2012; Ward, 2009; Hernandez, 2016). Moreover, 
an important role may be performed by differences in registration techniques and the 
availability and access to data sources (Steliarova, 2017). Besides, incidence 
registration and consequently incidence rates may be affected by the availability of 
diagnostic facilities (Amayiri, 2014; Hadley, 2012) and once available, by 
socioeconomic barriers to their access (Magrath, 2013, Steliarova, 2017). 
 
2.1.3.6. Quality of cancer registry data – Completeness - Proportion of microscopic 
verification 
This parameter, already described for validity (section 2.1.1.), is equally useful to 
evaluate completeness comparing the MV%, overall and for specific cancer sites, 
overtime for the same registry and with neighbouring registries. 
 
2.1.3.7. Quality of cancer registry data – Completeness - The mortality to incidence 
ratio 
The mortality to incidence ratio (M/I) represents the comparison of the number of 
registered cancer deaths with cancers cases, for all cancer’s sites together and for 
specific cancer sites. It depends on the validity of the definition of the cause of death. 
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The ratio should be reasonably stable when compared with neighbouring registries in 
areas with similar organisation of the health care system (e.g., availability of screening 
programmes, diffusion of campaigns for early diagnosis, etc.) and values above the 
expected ones are suggestive of incompleteness. 
 
2.1.3.8. Quality of cancer registry data – Completeness - The death certificates method 
Cases identified from death certificate (DCO) have been already mentioned for their 
role in the validity evaluation (section 2.1.1.). The same index may be used to ascertain 
completeness: the proportion of DCO cases evaluated together with the proportion of 
cases identified by the death certificate (DCI) in a situation in which death certificates 
are of good quality may suggest incompleteness. 
 
2.1.3.9.  Quality of cancer registry data – Completeness - The DCI and M/I method  
This method entails knowing the DCI status and mortality to incidence ratio (M/I) to 
estimate the fatality rates of originally unregistered cases (Parkin, 1994). Ajiki has also 
proposed an original formula for such a method (Ajiki, 1998). 
 
2.1.3.10. Quality of cancer registry data – Completeness - Independent case 
ascertainment method  
This method compares the result of the registration procedure with an independent 
cancer case-series. The missing data proportion is an estimate of completeness 
(Parkin, 1994). Several different independent sources have been utilized: e.g., in 
Denmark incompleteness of around 2% was detected by linking the registry with 
different datasets, e.g., 5,674 Danish invasive cervical cancer patients enrolled in an 
international clinical follow-up study (Storm, 1988), or Northern Ireland General 
Practitioners  (only 15 out of 17.102 cancer patients were not known by the Northern 
Ireland Cancer Registry, equal to a 99.9% completeness) (Kearney, 2015). 
 
2.1.3.11. Quality of cancer registry data – Completeness - Capture-recapture method  
The method uses the same approach applied initially to estimate the size of wild 
animal populations. It requires at least two phases: one in which those captured are 
identified (branded) and then released, and another in which a new catch based on 
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the numbers of those already known and the new ones constitute the basis for 
estimates (Parkin, 1994). Over time the method has been employed by registries and 
has been improved to take into account of the sources of information used by 
registries are not independent (Brenner, 1995; Crocetti, 2001).  
 
2.1.3.12. Quality of cancer registry data – Completeness - Flow-method  
This method (Bullard 2000) estimates the proportions of unregistered patients from 
the time distributions of three probabilities which can be computed using registry 
data: the probability of survival, probability of registration of cancer during the 
patient's life, and probability for cancer to be mentioned on the death certificate for 
cancer patients who die (Parkin 1994). This method implies a continuous and timely 
flow of the source information with no delay from their clinical production. Moreover, 
the improvement in the availability of source information may also improve timeliness 
of registration (Donnelly, 2017). 
 
2.1.4. Quality of cancer registry data –Timeliness 
The process of cancer registration, briefly described before, implies many consecutive 
phases (e.g., data collection, linkage, patient definition, case/s definition, exclusion of 
prevalent cases, exclusion of duplicates, data coding, quality evaluation, error 
amendment). Only after all these steps is it possible to perform data analysis, 
interpretation and publish results. Moreover, the original data sources may become 
available for some registries only after some time from their production (weeks, 
months, one or even more years) (Zanetti, 2015).  
 
Therefore, a certain amount of delay depends on the registration procedure and may 
vary from registry to registry according to the local organisation and the resources 
available. Moreover, another part is independent of the registries (being related to 
the availability of sources) and may vary as well among registries.  
 
Timeliness is related to completeness and to the fact that data are publicly released 
when they are considered complete (Zanetti, 2015). Therefore, a certain amount of 
reporting delay is inevitable (Donnelly, 2017). The open issue is how to reduce this 
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delay and how varies among registries. Also, during the production of incidence data, 
for a certain number of years, some new cases incident in the previous years are still 
discovered. This phenomenon is as unavoidable as a certain degree of reporting delay. 
In Northern Ireland, the proportion of cases reported after the first year of incidence 
varied between 1% and 13% for different cancer sites (Donnelly, 2017). The SEER 
programme provides estimates which consider the reporting delay to avoid the 
related bias, especially in more recent incident years (Lewis, 2015; Huang, 2013; Clegg, 
2002). 
 
2.1.5. Quality of cancer registry data – Population 
The quality of incidence rates does not depend only on the quality of the numerator 
of rates (number of cases). Moreover, it also depends on the quality - mainly the 
completeness - of the denominator (population). Usually, registries are uninvolved in 
the estimation of resident populations. They receive such data from the official 
Institutions in the area which enumerate the resident people based on census or ad 
hoc estimates. 
 
Therefore, CRs have to check also the completeness of population data, including 
consistency among ages and sexes, in comparison with previous years. 
 
2.1.6. Quality of cancer registry data – Survival 
Until now, the description of registry activity, data handling and quality evaluation has 
focused on incidence. However, the date of incidence is also the starting point for 
measuring the time of survival. Therefore, the checks for incidence have to be 
performed before any survival studies. 
 
Further, for survival there are other evaluations specifically related to the internal 
consistency between survival-related variables: e.g. vital status/autopsy, 
autopsy/basis of diagnosis, and autopsy/survival/dates of incidence and follow-up 
(Martos, 2014). The endpoint of survival is the time of follow-up at which the life status 
of any patient has to be defined (dead, alive, or lost). 
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What affects the date of incidence also influences survival, lengthening or shortening 
it according to different definitions. Possible registration flaws (Wilkinson, 2009) have 
been claimed to explain the reported lower survival rates in the UK than in other 
European Countries (Berrino, 2007). In particular, Beral and Peto, in their editorial in 
BMJ, attributed such results to a considerable proportion of cancer cases initially 
known in UK from death certificates for which the traceback failed to find information 
on the actual date of diagnosis confusing it with the date of recurrence, that is clearly 
closer to date of death (Beral, 2010).  
 
Moreover, a selective incompleteness in the collection of some long-term survival 
patients has been proposed as another possible explanation for the supposed 
inferiority of the UK healthcare system (Beral, 2010). However, a simulation 
performed within the National Cancer Registry of England and Wales, supported the 
truthfulness of low survival in the UK, estimating that errors would have been 
implausibly extensive to produce the evidenced differences between UK and Sweden 
(Woods, 2011).  
 
Furthermore, specific checks are necessary to evaluate the quality of the status of life 
definition, and they are dependent on the availability of certificates of death and the 
type (active or passive) of the search for the information on the status of life. 
Subgroups of people may request specific evaluation, e.g., cases known from death 
certificate only, cases lost to follow-up, patients recorded as alive and aged over 100 
years or long-term survivors affected by lethal cancers (Rossi, 2015; Allemani, 2017). 
 
 
The following Paper (1) proposes a new application of a mathematical law for the 
evaluation of the quality of cancer registry data.  
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2.2. Paper 1 
 
The paper has been published in Front Public Health. 2016; 4: 225 with the following 
title: 
 
"Using the Benford's Law as a First Step to Assess the Quality of the Cancer Registry 
Data". 
 
Authors: Emanuele Crocetti, Giorgia Randi 
Affiliation: European Commission, DG Joint Research Centre (JRC), Institute for Health 
and Consumer Protection, Public Health Policy Support Unit, Ispra (VA), Italy 
Author Contributions: EC conceived the idea of the study, planned and designed it, 
and prepared the first draft. GR made substantial contributions to the statistical 
analysis and critically revised the paper. Both authors edited and approved the final 
version of the manuscript. Both authors are accountable for all aspects of the work. 
 
Abstract 
Background: Benford’s law states that the distribution of the first digit different from 
0 [first significant digit (FSD)] in many collections of numbers is not uniform. The aim 
of this study is to evaluate whether population-based cancer incidence rates follow 
Benford’s law, and if this can be used in their data quality check process. 
Methods: We sampled 43 population-based cancer registry populations (CRPs) from 
the Cancer Incidence in 5 Continents-volume X (CI5-X). The distribution of cancer 
incidence rate FSD was evaluated overall, by sex, and by CRP. Several statistics, 
including Pearson’s coefficient of correlation and distance measures, were applied to 
check the adherence to Benford’s law. 
Results: In the whole dataset (146,590 incidence rates) and for each sex (70,722 male 
and 75,868 female incidence rates), the FSD distributions were Benford-like. The 
correlation coefficient between observed and expected FSD distributions was 
extremely high (0.999), and the distance measures low. Considering single CRP (from 
933 to 7,222 incidence rates), the results were in agreement with Benford’s law, and 
only a few CRPs showed possible discrepancies from it. 
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Conclusion: This study demonstrated for the first time that cancer incidence rates 
follow Benford’s law. This characteristic can be used as a new, simple, and objective 
tool in data quality evaluation. The data analyzed had been already checked for 
publication in CI5-X. Therefore, their quality was expected to be good. In fact, only for 
a few CRPs several statistics were consistent with possible violations.  
 
Introduction 
The Benford’s law (Benford, 1938), originally identified by Newcomb (Newcomb, 
1882), states that in many numerical series the distribution of the first significant digits 
(FSDs) (the first non-zero digit on the left side of a number) is not uniform. In fact, for 
numbers which adhere to this law, the probability of 1 to be the FSD is 30.1%, and this 
probability steadily decreases for the following digits up to 9, which is the least 
common leading digit (4.6% of the cases). A distribution abides by Benford’s law if the 
frequency [F(x)] of the FSD, x ∈ {1, . . ., 9}, follows the logarithmic relation, F (x) = log10 
1 + 1/x (Benford, 1938). The law of “anomalous numbers” applies also to the frequency 
of digits in other positions (Benford, 1938). 
Not all the numbers abide by Benford’s law, but for those which do, violations raise 
concerns. For example, in accounting and auditing, also at governmental level, 
Benford’s law has been widely used to detect possible frauds (Tödter, 2009; Rauch, 
2011; Slijepcevic, 2014). 
 
Population-based cancer registries produce a great amount of numbers (the cancer 
incidence rates). The evaluation of their quality is rather complex, involving different 
aspects, and it is mainly based on the knowledge of the clinical, diagnostic, and 
therapeutic pathways of patients and on the process of data collection and 
registration (Bray&Parkin 2009, Parkin&Bray 2009). 
 
The most renowned publication on cancer incidence is Cancer Incidence in 5 
Continents (CI5) (Forman 2014). The cancer registries submitting their data to CI5 have 
to pass a formal quality evaluation before being accepted. The data quality assessment 
implies checking the internal coherence, consistency, completeness, and 
comparability with the final decision taken by a group of experts in the field. 
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The aim of this study is to evaluate if cancer incidence rates adhere to Benford’s law 
to use this mathematical characteristic as a further objective tool for their quality 
evaluation. 
 
Materials and methods 
The website of the CI5 volume X (CI5-X) (Forman, 2013) provides the data of the 290 
population-based cancer registries included in the publication, detailed by all the 424 
cancer registry populations (CRPs), as each cancer registry can provide information 
not only for the whole population but also for different racial and/or ethnic subgroups 
within the same population. 
The CI5-X data include aggregated information for 244 combinations of cancer site 
and morphological group, specified for 19 age groups (5-year age groups from 0–4 to 
85+, plus unknown age) and for the two sexes. 
 
We drew a pseudorandom sample of 10% of the available CRPs, stratified by continent 
(considering South and North America separately), setting a random number seed to 
make the sampling reproducible. 
 
Overall, 43 CRPs (from 40 cancer registries) were sampled and included in the analysis: 
1 from Africa (Malawi,  Blantyre), 3 from Central and South America (Argentina, Tierra 
del Fuego; Brazil, San Paolo and Ecuador, Quito), 18 from USA (Virginia, Asian and 
Pacific Islanders; Nebraska, Black; Ohio; Vermont; Montana; Michigan; Georgia; 
Indiana, White; Missouri, White; NPCR-National program of cancer registries – 
including 42 States; Colorado, Asian and Pacific Islanders; Arkansas, Black; Alabama, 
White; Arkansas, White; California, Asian and Pacific Islanders; Connecticut, Black; 
Virginia, Black; and California), 7 from Asia (India, Karunagappally; Singapore, Malay; 
Turkey, Edirne; Israel, Jews; Japan, Hiroshima Prefecture; Japan, Fukui Prefecture; and 
Israel), 11 from Europe (France, Isère; Germany, North Rhine – Westphalia; France, 
Hérault; UK, England; Estonia; Switzerland, St Gall-Appenzell; Bulgaria; Malta; Ukraine; 
Spain, Navarra; and Italy, Sondrio), and finally 2 from Oceania (New Zealand; Other 
and USA, and Hawaii). 
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The cancer data corresponding to age group 19 (age unknown) were excluded from 
the analysis. 
After the exclusion of those combinations of cancer morphology and site with no 
cases, 146,590 combinations were included in the analysis. 
Crude incidence rates were computed for each sex, age group, and topography and 
morphology combination dividing the number of cases by the corresponding 
population and expressed per 100,000 inhabitants.  
 
The FSD distribution for crude incidence rates was then calculated for all the CRPs 
together, by sex, and by CRP. Moreover, a sensitivity analysis has been performed 
randomly excluding half of the most important cancer sites (prostate, lung, breast, and 
colon–rectum). 
 
For checking the adherence of observed FSD distributions to Benford’s one, we used 
different methods. 
Since Benford’s distribution has mean greater than median and is positively skewed 
(Wallace, 2002), these figures have been evaluated for cancer incidence rates. 
Theoretical and observed distributions were plotted for graphical comparison. 
Following literature, we did not use those tests (e.g., χ2 and Kuiper’s statistic) that are 
extremely sensitive in rejecting the null hypothesis (being a distribution Benford-like) 
for large samples (Rauch, 2011; Gollbeck, 2015; Judge, 2009; Kienle, 2015). To test the 
goodness of fit, we used the following tests: 
r: the Pearson correlation. This is commonly used to measure how closely a 
distribution follows Benford’s law (Gollbeck, 2015; Judge, 2009). The closer the 
coefficient “r” is to +1 the higher the correlation between Benford’s law and the 
observed FSD distribution. 
- "#-/n: "# divided by the sample size (Rauch, 2011; Leemis, 2000). 
− m: the maximum distance in absolute terms between expected and observed 
frequencies for each of the nine digits (1–9). The statistics may vary between 0 (no 
differences between the two distributions) to + (maximum difference) and the 
corresponding formula is m = maxi = 1, 2, . . ., 9{|bi-ei|} (Judge 2009), where bi is the 
frequency expected by Benford and ei is the observed frequency for each digit i. 
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- d*: the normalised Euclidean distance between the two distributions divided by the 
maximum possible distance, which would occur when the FSD was 9 for all the 
numbers. The corresponding formula is: 
- d∗ = 		(∑ (b,-,./ − e,)#/(∑ (b,4,./ )# + (1 − e-)# 
 
where bi is the frequency expected by Benford and ei is the observed frequency for 
each digit i. The statistic may vary between 0 (no differences) to 1 (maximum 
difference) (Judge 2009). 
Z statistic: the average of the Z values for each comparison between the nine observed 
and theoretical digits distributions (Slijepcevic, 2014): 
 
Z = 19	9√n-,./ <|b, − e,| −
12n?b,(1 − b,) @ 
 
where i = 1, . . ., 9 is a fixed digit, bi is the frequency expected by Benford, and ei is the 
observed frequency for each digit i. The cut-off value for statistical significance, with 
alpha = 0.05 and one side tail, is 1.64. 
For providing an inter-CRP comparison, the mean, the median, and the 10th or the 
90th (the one including the most extreme values) percentile of each statistic were 
computed. 
 
A summation index has been computed for rating the CRPs according to the statistics’ 
results. Each CRP received one point for each statistic in the 10th or 90th percentile 
(whichever represents the worst values). The summation index could vary from 0 (no 
statistic beyond the threshold) up to 5 (all statistics beyond the threshold). The 
probability for each statistic to be in the most extreme decile was 0.1 (approximately 
4/43) assuming independence between statistics, considering that the summation 
index follows a binomial distribution (pr = 0.1, n = 5) the random probability for a CRP 
to have the summation index equal to 0 is 0.59, to 1 is 0.33, to 2 is 0.07, to 3 is 0.008, 
to 4 is 0.0005, and to 5 is 0.00001. The analysis has been performed with Stata v. 12, 
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using specific commands for extracting the sample (“sample” and “seed”) and for 
computing observed and Benford FSD distributions (“digdis”). 
 
Results 
When considering all cancer incidence rates together (146,590 observations), the 
distribution of the FSDs appeared to be positively skewed (0.84), with the mean (3.38) 
greater than the median (3.0). These values were close to those of the theoretical 
Benford’s distribution (skewness 0.8, mean 3.44, and median 3.0), as were the ratios 
between 1st vs. 9th (observed 6.6 vs. Benford 6.6), and between 1st vs. 2nd (1.8 vs. 
1.7) FSD. 
 
These results suggest that the FSD distribution of cancer incidence rates might adhere 
to Benford’s pattern. In fact, when the observed FSD distribution was graphically 
compared to the theoretical one, as shown in Figure 1, they were almost overlapping. 
 
 
 
Figure 1: Benford (line) and observed (columns) distributions of first digits for all 
crude cancer incidence rates. 
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Pearson’s correlation coefficient, r, showed an almost perfect direct correlation 
between the observed FSD distribution and the expected one (0.999); moreover, all 
the measures of the distance between the distributions were very low (m = 0.014 and 
d* = 0.015), and the average Z was below the significance level. Finally, the χ2 test, 
weighted on the number of observations (χ2/n), was also very low (0.002). 
 
The analysis has been repeated by sex and the same results were confirmed (results 
added in Appendix 2 [Supplementary information for Paper 1]; data not shown in the 
original paper). Also, after the exclusion of half of the rates for the major cancer sites 
the overall results confirmed the adherence of the FSD distribution to Benford’s law (r 
= 0.999, m = 0.014, d* = 0.016, χ2/n = 0.002). 
 
When single CRPs were evaluated, each FSD distribution was positively skewed, and 
the mean was greater than the median (results added in Appendix 2 [Supplementary 
information for Paper 1]; data not shown in the original paper). 
 
In Figure 2, the FSD distribution of all cancer incidence rates and the Benford 
distribution were compared for each of the 43 analysed CRPs. The shapes of all 
distributions generally resembled Benford’s, with a decreasing percentage of FSD from 
1 to the 9. However, a few possible differences were shown. 
 
The Pearson correlation coefficients were very high for the majority of the CRPs 
(median = 0.97); however, some values were relatively low (0.85 representing the 10th 
percentile). Also, the other measures of distance were generally low (median: m = 
0.05, d* = 0.07), but still the corresponding 90th percentiles reached rather higher 
values (0.10 and 0.12, for m and d*, respectively). For the ratio between the χ2 and 
the number of rates, the 90th percentile was almost 3 times the median (90th 
percentile = 0.14 and 50th percentile = 0.05), and, finally, for the average Z, the value 
of the 90th percentile corresponded to the value of statistical significance (1.64). 
Although the majority of the CRPs reported statistics showing an agreement with 
Benford’s law, for a few of them the values seemed to indicate possible discrepancies. 
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For 35 CRPs, the summation index was 0, for 4 CRPs was 1, and for 2 CRPs was 2. Only 
one CRP (Argentina, Tierra del Fuego) reported a summation index of 3 (r = 0.839; d* 
= 0.125; χ/n = 0.146) and another one (USA, Virginia, Black) had all the five statistics in 
the worst classes (r = 0.82; m = 0.13; d* = 0.147; χ/n = 0.182; Z = 1.88). The probability 
for the two latter results to happen by chance is very low. Therefore, for such CRPs, a 
possible violation of Benford’s law should be *considered. 
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Figure 2: Theoretical (line) and observed distributions (columns) of first digits for all 
the analysed incidence rates, by registries and populations. 1: Malawi, Blantyre; 2: 
Argentina, Tierra del Fuego; 3: Brazil, San Paolo; 4: Ecuador, Quito; 5: USA, Virginia, 
Asian and Pacific Islanders; 6: USA, Nebraska, Black; 7: USA, Ohio; 8: USA, Vermont; 9: 
USA, Montana; 10: USA, Michigan; 11: USA, Georgia;12: USA, Indiana, White; 13: USA, 
Missouri, White; 14: USA, NPCR- National program of cancer registries 
(including42States); 15: USA, Colorado, Asian and Pacific Islanders; 16: USA, Arkansas, 
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Black; 17: USA, Alabama, White; 18: USA, Arkansas, White;19 :USA, California, Asian 
and Pacific Islanders; 20: USA, Connecticut, Black; 21: USA, Virginia, Black;22: USA, 
California; 23: India, Karunagappallyp; 24: Singapore, Malay; 25: Turkey, Edirne;26: 
Israel, Jews; 27: Japan, Hiroshima Prefecture; 28: Japan, Fukui Prefecture; 29: Israel; 
30: France, Isère; 31: Germany, North Rhine–Westphalia; 32: France, Hérault;33: UK, 
England; 34: Estonia; 35: Switzerland, St. Gall-Appenzell; 36: Bulgaria; 37: Malta; 38: 
Ukraine; 39: Spain, Navarra; 40: Italy, Sondrio; 41: Germany, Brandemburg; 42: New 
Zealand: Other; 43: USA, Hawaii.  
 
Discussion 
In the present study, a considerable and heterogeneous sample of CRPs included in 
CI5-X was analyzed to evaluate, for the first time to our knowledge, if the FSD 
distribution of cancer incidence rates abided by Benford’s law. 
The results showed a substantial adherence of FSD distribution of cancer incidence 
rates to Benford’s law. 
 
This was not surprising. In fact, FSD distribution of cancer incidence rates had a priori 
some characteristics for being Benford prone. Indeed, they are the second generation 
distribution, being the result of the division of the number of cases diagnosed in a time 
span by the corresponding resident population, they comprise a large range of 
numbers covering several orders of magnitude (from units to thousands per 100,000 
people, according to different ages and cancer types), and they are not influenced by 
human thought (Hill, 1995; Durtschi, 2004). 
 
We verified that cancer incidence rates respect the quantitative measures suggested 
by Wallace (Wallace, 2002) to assess whether a distribution may be expected to 
respect Benford’s law. In fact, the mean of their observed FSD is greater than the 
median, and their distribution has a positive skewness. 
 
In the present study using graphic visualization, correlation coefficient, and some 
distance statistics, we observed that FSD distribution of cancer incidence rates abide 
by Benford’s law when analyzed overall, by sexes, excluding half of the rates for the 
major cancer sites (female breast, colon–rectum, and lung and prostate cancers) and 
generally by CRP. 
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We have analyzed data which had been already examined for their quality and proved 
good for publication in CI5-X (Forman 2014). Therefore, no major problems in data 
quality were expected. Our results showed that for almost all the CRPs the FSD 
distribution substantially adhere to Benford’s law. When the 43 CRPs were analyzed 
individually, the plot of their FSD distribution seemed to be in agreement with 
Benford’s law.  It must be mentioned that, due to sampling, two CRPs were sub-groups 
of the same registry (USA, Arkansas Black and White; USA Virginia, Asian and Pacific 
Islanders and Black) and another two included a subgroup and the whole population 
of the same registry (Israel and Israel, Jews and USA California and USA California, 
Asian and Pacific Islanders). No large difference within those cancer registries has been 
shown. Therefore, quality of cancer registry data and related activity (in terms of data 
availability, data collection, etc.) seemed unrelated to racial/ethnic subgroups at least 
in the analyzed registries. 
 
The cancer registry data quality evaluation is not a perfect process, and some residual 
heterogeneity could exist also in CRPs included in CI5-X. In fact, in the introduction of 
CI5-X, it is stated that in the registry specific pages for some CRPs “an asterisk 
preceding the registry title indicates that special considerations (which may include 
underregistration) must be taken into account in interpreting the published rates or 
indicators of quality. . .” (Forman, 2014). Overall, asterisks were reported for 114/424 
CRPs in CI5- X (26.9%), and in 11/43 (25.6%) in our sample. One of the two CRPs which 
had three or more statistics with the worst values for Benford’s compliance had the 
asterisks (50%), in comparison with the others in the sample (10/31, 24.3%). 
 
We highlighted that, although the majority of CRPs seemed to comply with Benford’s 
law, at least two of them showed possible violation. Random fluctuations could have 
driven the observed results (Leemis, 2000) even though probability was low, but the 
coherence across the different applied statistics made inconsistency with the 
Benford’s distribution more probable for these CRPs. 
According to our experience, based on the analyzed dataset that has been already 
checked for data quality and accepted for publication (CI5-X), cancer registries 
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showing the poorest results had r value below 0.9 and m, χ2/n, and d* values higher 
than 0.10; presumably in a wild situation greater values are expected. 
 
Adherence to Benford’s law has been widely used not only to detect fraudulent data 
in business and administration (Tödter, 2009) but also to test data irregularities in 
scientific research (Hein, 2012). Frauds in cancer incidence data are not expected. 
However, non-adherence to the law may be a clue for further evaluation. The distance 
from the expected distribution may be the consequence of selections or 
incompleteness of the data collection, of rounding of small rates (Diaconis, 1979), of 
errors in data recoding or in data transfer. 
 
The meaning of Benford’s violation is a red flag showing an unusual behavior 
requesting further data examination (Leemis, 2000). Once a violation is suspected, a 
CRP, which owns more data than those we analyzed, should try to find out clues for 
the possible origin of the problem. Our suggestion is to look for the Benford pattern 
for incident cases based on different (combinations of) sources of information 
(pathology reports, hospitalization, death certificate, etc.) to detect any source-
specific pattern. Moreover, the stability over time of the data flow for each 
information source and cancer site should be evaluated. 
 
References: The original references of the paper have been included in the general list 
of the thesis. 
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2.2.1. Comment 
 
The current quality control in the data registration of cancers is based on checking 
many of the indexes that have been described in chapter 2 (Quality of cancer data 
registry) and summarised in Table 2. 
 
Table 2: Quality dimensions and parameters usually checked during the process for CR 
data quality evaluation. 
 
 
These traditional indexes follow the individual steps of the clinical course of each 
patient, e.g., diagnosis, microscopic confirmation, death, and they are based on 
epidemiological measures (numbers or rates) calculated for each patient group (e.g., 
by age, sex, cancer type). 
 Comparability Validity Completeness Timeliness 
Classification & coding X    
Incidence definition X    
Multiple primary X    
Incidental diagnosis X    
DCO  X X  
DCI  X   
Histology verification  X X  
Missing information  X   
Internal coherence  X   
Time to report data    X 
Historic data method   X  
Homogeneity in the 
area 
  X  
Steadiness in age 
curves 
  X  
Incidence among 
children 
  X  
M:I   X  
n. sources / 
notifications 
  X  
Independent case 
ascertainment 
  X  
Capture-recapture 
method 
  X  
DCN/M:I method   X  
The flow method   X  
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The quality evaluation of the cancer registry’s data implies a comprehensive 
examination of these indexes. 
The evaluation of these indexes is not homogeneous worldwide. 
For example, in North America, the North American Association of Central Cancer 
Registries (NAACCR) sets different quality levels for the data (Gold and Silver) and gives 
each one of them clear cut-offs for a series of measures regarding validity, 
completeness and timeliness (https://www.naaccr.org/certification-criteria/). 
 
On the contrary, an Editorial Board, which includes members of IARC and IACR selects 
out of the many submissions received, which data will be published in the CI5. As 
regards CI5-X, 80 out of the 370 cancer registries that had submitted data, did not pass 
the quality control (Forman, 2014). Furthermore, among the accepted data, some of 
them are marked with an asterisk. The asterisk “indicates that some circumstances 
may require special considerations (e.g. incomplete registration) when interpreting 
the published rates or indicators of quality” (Forman, 2014).  
 
The rules applied for CI5 are inexplicit. 
When clear cut-offs for the indexes are missing the quality evaluation process cannot 
be reproduced, and the role of experts cannot be contested. Moreover, the whole 
quality evaluation process and the role of single the indexes in determining quality 
remains unclear.  
 
For example, in Table 3, the quality indexes for 'All sites except non-melanoma skin 
cancer', in men and women, made available from CI5C-XI (http://ci5.iarc.fr/CI5-
XI/Pages/Indices_sel.aspx) are presented. The percentages indicate: microscopic 
verification (MV%), cases known by a death certificate (DCO%) and cases coded in the 
topography as 'Other & Unspecified' (O&U%). For each index and each continent, the 
extreme values (the highest and the lowest) are shown, and there is also a symbol to 
indicate missing information (^). Moreover, the table includes the number of 
registries/populations for which there is a warning (asterisk). 
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Table 3: Some indices of data quality for ‘All sites except non-melanoma skin’, CI5-XI 
(C00-96 excl. C44) based on original data from Cancer incidence in 5 continents XI, are 
available at http://ci5.iarc.fr/CI5-XI/PDF/INDICES/21.pdf. Distribution for each 
continent (C&S= Central&South) of CR/populations with asterisks, range of proportion 
of microscopic verification (MV), death certificates only cases (DCO), and unspecified 
cancer site (O&U), in men and women. ^= missing value. 
 
First of all, it is worthwhile mentioning that the definitions of data quality for 
IARC/IACR and of NAACCR are not coherent. Several of the CRs accepted for CI5-XI do 
not reach the Silver qualification standard required by NAACCR (that requests 
DCO<5%). 
 
Moreover, each of the indexes presented in Table 3 shows an incredibly broad range 
of values. For example, MV% varies among men by 20-50 percentage points, and the 
same is true for women. 
As regards DCO%, the size of variation is up to 100 times (from 0.1% to 14.7%). Finally, 
for the 'Other & Unspecified sites, there is also a variation of 100 times (from 0.1% to 
23.2). 
These values belong to the CR which have passed the CI5C-XI quality evaluation. 
The heterogeneity of the values of some of the quality indexes used in CI5 in CRs data’s 
evaluation shows that extreme values can be compatible with high-quality data.  
Continent 
*/ MV % DCO % 
(min-max) 
O&U 
CR (min-max) (min-max) 
    Men Women Men Women Men Women 
Africa 6 /7 53.9-97.8 54.5-98.7 ^1.4-13.3 ^0.8-9.6 2.2-5.6 1.7-3.1 
America 
C&S 
10/31 69.3-95.8 71.0-95.9 ^0.9-14.9 ^0.5-12.1 0.9-7.7 1.4-6.7 
America 
North 
41/171 77.1-97.7 76.1-97.5 ^0.4-8.6 ^0.2-7.9 1.2-4.3 0.7-3.8 
Asia 31/96 44.2-96.9 58.2-98.3 ^0.0-11.8 ^0.0-11.9 0.1-23.4 0.1-13.6 
Europe 23/128 73.0-93.9 75.7-97.2 ^0.1-13.0 ^0.1-14.5 0.7-4.7 0.7-4.4 
Oceania 9/32 73.0-94.8 83.5-97.8 ^0.1-14.7 ^0.0-10.1 1.2-2.8 1.5-3.9 
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The purpose of Benford’s law is, through a preliminary check, to address the following 
traditional process. In case of violation, the evaluation of traditional indexes has to be 
stricter than in the case of abidance. 
Benford’s law applies a mathematical law which is not influenced by the examiner’s 
level of knowledge regarding the process of cancer registration. 
It does not require the involvement of experts. 
 
Furthermore, this law may be tested and applicated in other phases of registration, 
e.g., to check the digital sources of information or the population data. 
 
The very nature of this law is at the heart of the evaluation process, helping the 
reviewer divide presumably poor quality CRs from good quality ones. 
 
The reason I analysed CRs already accepted for publication is because I did not have 
access to ‘raw’ data. 
I proposed using the N-B law to Freddy Bray and Eva Steliarova from IACR. However, 
IARC’s quality check methods will not be incorporating this method for the time being. 
Big International projects, such as CI5, should include data from different countries 
and continents. This, though, implicates a variability in quality due to variability of 
resources, access to data, legal barriers involved in accessing documentation, etc. For 
such studies, other reasons not only those related to the strict quality standards must 
to be taken into consideration. In fact, in the introduction of CI5-X, this point has been 
raised “… the editors also have to accept that some datasets from registries in less-
developed countries may be less complete than those from registries in more 
developed ones because of problems of underdiagnosis due to local medical and 
economic situations (as opposed to under registration) and/or problems with the 
enumeration of the population. But these datasets are nevertheless of great interest 
because they describe cancer incidence in populations for which no other information 
is available and which maintain unique cultural habits that could provide valuable clues 
to cancer aetiology” (Forman, 2014). 
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However, I hope to have the opportunity to test Benford’s law on the data collected 
by ENCR-JRC (https://www.encr.eu/sites/default/files/ENCR-JRC2015_Protocol.pdf), 
and reviewed with the traditional methods. The application of Benford’s law would 
make it possible to evaluate its effectiveness in a real setting. 
 
In the meantime, N-B law has been applied in digital gene expression datasets (Karthik, 
2016), in ‘soiled’ numbers in known scientific fraudulent articles (Hüllermann, 2017), 
and also for evaluating the reasons for changes in large datasets homogeneity over 
time (Lee, 2019). 
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2.3. Original material: an example of the application of Benford's law to skin melanoma 
in the German registries’ data published in CI5-XI. 
 
The compliance of the distribution of incidence rates to Benford's law can be helpful 
for a preliminary check of registry dataset quality. It is critical to use the most 
considerable number of incidence rates (age, site, morphology, sex, etc.) to retain a 
considerable amount of values for checking the correspondence between expected 
and observed distribution of the first significant digits (FSD).  
 
If we select a subset of data, for example, one cancer site or one incidence period, we 
may manage too few numbers to test abidance to Benford's law reliably. 
 
However, considering the linking theme of this thesis is skin melanoma, Benford's law 
has been applied equally to a sample of skin melanoma cases. 
Data came from those published in CI5-XI and made freely available 
(http://ci5.iarc.fr/CI5-XI/Pages/download.aspx). An extended data set, including 241 
categories, based on a combination of ICD-10 three- or four-character site codes and 
ICD-O-3 morphological groups, was chosen. 
Among these groups, all the codes available for skin melanoma (Melanoma of skin: 
C43; Head: C43.0-4; Trunk: C43.5; Upper limb: C43.6; Lower limb: C43.7; Other and 
unspecified: C43.8-9) were selected.  
 
As a sample dataset, I chose the nine available German registries: Bavaria, Bremen, 
Hamburg, Lower Saxony, Munich, North Rhine-Westphalia, Rhineland-Palatinate, 
Saarland, Schleswig-Holstein. All of them contributed to the publication with incidence 
data for the period 2008-2012. Age- and sex-specific incidence rates for the period 
2008-2012 were available. In theory, the maximum number of expected incidence 
rates from each registry (if there was at least one case for each combination) was: 1 
(period 2008-2012) X 2 (sexes) X 18 (age-classes) X 6 (site and subsites skin 
melanoma), adding up to 216. 
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The same tests described and used in the previous paper (Paper 1) checked the 
correspondence between the first significant digit distribution of incidence rates and 
Benford' s law, in this series. 
 
Results 
Considering the nine German registries collectively (1,652 observations), the 
distribution of the FSDs of melanoma incidence rates appeared to be positively 
skewed (0.66), with the mean (3.65) higher than the median (3.0). These values were 
close to those of the theoretical Benford’s distribution (skewness 0.8, mean 3.44, and 
median 3.0.) The same was mostly valid for the ratios between 1st vs 9th (observed 
5.2 vs Benford 6.6) and between 1st vs 2nd (2.1 vs 1.7) digits. The graphic distribution 
of observed FSDs for incidence rates for the nine German registries reproduces the 
theoretical Benford's distribution quite well. Figure 3. 
 
 
Figure 3: Benford (line) and observed (columns) distributions of the first digit for skin 
melanoma incidence rates for the nine German registries included in CI5-XI. Data 
retrieved from the extended dataset available at http://ci5iarc.fr/CI5-
XI/Pages/download.aspx. 
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Pearson’s correlation coefficient, r, was extremely close to 1 (0.98) demonstrating a 
strong correlation between the observed FSD distribution and the expected one. 
Moreover, all the measures of the distance between the distributions (theoretical and 
observed) were minimal (m=0.027 and d*=0.042), and the average Z was below the 
significance level for alpha=0.05 and one side tail (1.64, z=0.49). Finally, the "# test, 
weighted on the number of observations ("# /n), was low (0.022) as well.  
 
The FSDs distributions confirmed that melanoma incidence rates broadly follow 
Benford's curve shape, Figure 4, for each German registry, with data sets varying from 
157 to 211 observations. 
 
 
Figure 4: Benford (line) and observed (columns) distributions of the first digit for skin 
melanoma incidence rates for each of the nine German registries included in CI5-XI. 
Data retrieved from the extended dataset available at http://ci5.iarc.fr/CI5-
XI/Pages/download.aspx. 
 
In Table 4 the results of the applied tests are presented.  
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Table 4: Measures of correspondence between Benford and observed distributions of 
the first digit in the incidence rates for skin melanoma for the nine German registries 
included in CI5-XI. Data retrieved from the extended dataset available at 
http://ci5.iarc.fr/CI5-XI/Pages/download.aspx. 
 
CR r m d* X2/n zeta 
1 0.91 0.066 0.094 0.09 0.25 
2 0.91 0.05 0.09 0.13 0.19 
3 0.95 0.055 0.078 0.067 0.13 
4 0.95 0.039 0.077 0.075 0.19 
5 0.98 0.037 0.059 0.029 0.09 
6 0.98 0.029 0.053 0.036 0.12 
7 0.98 0.052 0.067 0.032 0.10 
8 0.90 0.078 0.11 0.11 0.22 
9 0.96 0.039 0.063 0.064 0.11 
 
r = Pearson’s correlation; m = maximum distance in absolute terms between expected and 
observed frequencies for each of the nine-digit ; d* = normalised Euclidean distance between 
the two distributions divided by the maximum possible distance; X2/n = Chi-squared divided 
by the number of observation; zeta = average Z value for each comparison between the nine 
observed distributions of FSD and the theoretical one. 
 
The evaluation of melanoma incidence rates FSD distribution should be tested against 
Benford’s law at the beginning of the registries' quality of data evaluation process as 
the aim is to detect notable distortion which may suggest a selective loss of data.  
 
In this example, the analysed dataset was already checked for data quality and 
accepted for publication in CI5-XI. Therefore, no critical violations to Benford's law 
were expected. 
In case a violation of Benford’s law is suspected, the traditional tools must be 
implemented very carefully, including the evaluation of the completeness of the 
sources of information. 
Finally, although for a specific cancer site the number of observations (incidence rates) 
may be relatively low, also incidence rates for skin melanoma in the 9 German 
registries published in CI5-XI revealed an FSD distribution which abides by Benford's 
law, both altogether and individually. 
  
  58 
3. Publication of registry data 
 
Once the data of a registry are of good quality, epidemiological indexes are computed.  
Registry data are published in various forms to fulfil diverse purposes. 
 
As regards incidence, the number of new cases is relevant to quantify the burden of 
diagnosis and first treatment needed in the area. The same information comes from 
the crude rate for units of the population at risk, usually per 100,000 people per year.  
Furthermore, incidence rates may be specific for sub-groups of the case series: for 
cancer type (topography and morphology), for age-group, for sex, etc.  
 
Finally, age-standardisation (a method for performing reliable comparisons between 
two or more registries, or in the same registry over time), allows, with a direct or 
indirect approach, the consideration and adjustment for the age-group composition 
of the population under examination (Boyle, 1991). 
 
Each measure may be complemented by the estimate of the error (the standard 
error), and/or confidence intervals. 
 
Table 5 is an example of the traditional way of presentation of incidence data. For 
selected registries from CI5-XI and sex, there is the number of cases (all cancer sites 
except non-melanoma skin), the age-adjusted incidence rate (ASR based on the World 
standard population), and the corresponding standard error (s.e.).  
Besides, this is the traditional approach applied for prevalence and survival, with their 
specific indexes. 
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Table 5: All sites except non-melanoma skin (C00-96 excl. C44). Distribution of the 
number of cases, age-adjusted incidence rate (ASR on the World standard population) 
and standard error (s.e.) for selected registries and sexes, 2008-2012. Based on 
primary data from Cancer incidence in 5 continents XI, available at 
http://ci5.iarc.fr/CI5-XI/PDF/INDICES/21.pdf. *= missing value. 
 
 Women Men 
registry cases ASR s.e. cases ASR s.e. 
Belgium 6187 15.3 0.21 4345 10.5 0.17 
Cyprus 142 4.6 0.40 156 5.3 0.44 
Czech Republic 4766 10.7 0.17 5278 12.7 0.18 
Ireland 2342 14.6 0.32 1835 12.1 0.29 
Italy, Romagna 680 12.6 0.56 750 13.7 0.56 
Malta 140 9.4 0.86 111 6.9 0.70 
The Netherlands 12950 20.6 0.19 11070 17.2 0.17 
Portugal, Azores 38 5,2 0,91 43 6.7 1.05 
Ukraine 9435 4,7 0.05 6573 4.5 0.06 
 
 
The following Paper (2) presents an innovative method which complements the 
traditional ways of giving incidence data and provides a measure of heterogeneity in 
sub-areas.  
  
  60 
3.1. Paper 2  
The paper was published in Eur J Cancer Prev. 2017; 26: 442-446 with the following 
title: 
 
"Variability of cancer risk within an area: time to complement the incidence rate. 
 
Authors Crocetti E, Giusti F, Martos C, Randi G, Dyba T, Bettio M. 
Affiliation: European Commission, DG Joint Research Centre (JRC), Institute for Health 
and Consumer Protection, Public Health Policy Support Unit, Ispra (VA), Italy 
Author Contributions: I (EC) declare to have conceived the idea of the study, planned 
and designed it, performed the analysis and drafted the first draft. The other Authors 
revised critically the paper and approved the final version of the manuscript 
 
Abstract 
The aim of this study was to show that age-adjusted cancer incidence rates for an area 
may not be representative of the incidence in subareas. We propose a simple measure 
to show the amount of geographical variability. European age- standardised incidence 
rates (ASRs) for ‘all sites excluding non melanoma skin cancer’, for men, in 2014, for 
Nordic countries as a whole, for each country (Denmark, Faroe Islands, Finland, 
Greenland, Iceland, Sweden and Norway) and for their regions, were retrieved from 
the Nordcan with corresponding standard errors (SEs). We compared the ASR for 
Nordic countries versus single country and single country versus specific regions. The 
overlapping of 95% confidence intervals was used for ASRs comparisons. As a measure 
of variability, we computed the range between the highest and the lowest ASR within 
an area and the ratio between this range and the ASR of the overall area, r/R = 
(range/ASR) × 100. The 95% confidence interval of the ASR for Nordic countries as a 
whole did not overlap those of the majority of the single countries; in fact, the r/R – 
which provides a clue for the amount of underlying geographical variability – was 
rather large (57.1%). Within countries, the variability was negligible in 
Iceland (r/R = 9.6%), whereas the highest value was found in Sweden (37.1%). The ASR 
does not provide any information on underlying geographical variability. Therefore, its 
interpretation could be misleading. When data for subareas are available, the r/R, 
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which is simple to compute and to understand, should be added to the ASR for 
providing more truthful information. 
 
Introduction 
As a standard practice worldwide, population-based cancer registries (CRs) express 
the occurrence of cancer in a defined population in a certain period as the ratio 
between the newly diagnosed cancers and the at-risk resident population. This ratio 
is called the crude incidence rate (Boyle and Parkin 1991). Cancer incidence increases 
with the ageing of the population. Therefore, incidence rates are strongly dependent 
on the age structure of the underlying population. Consequently, rates are computed 
using a standard age structure as a reference (age-standardised rate, ASR) to enable 
reliable comparisons across time and countries (Boyle and Parkin 1991). Crude rates 
and ASRs are the standard indicators reported by all CRs independent of the size of 
the population at risk. These statistics are usually complemented by a measure of 
precision, the standard error (SE) of the rate and/or the 95% confidence intervals (CIs). 
 
An incidence rate expresses the summary probability of developing cancer in the area 
covered by the CR. It provides no clues on the homogeneity or the heterogeneity of 
incidence rates across subareas. 
 
To gain more insight into this topic and to explore the possible variability in ASRs 
among subareas of CRs, we analysed the data of the Association of the Nordic Cancer 
Registries, which makes data available in the Nordcan project (Engholm 2016). 
 
Methods 
We retrieved from the Nordcan the European ASRs for ‘all sites excluding non 
melanoma skin cancer’, for men, in 2014. 
ASRs are available for three geographical layers as presented in Table 6 (n. 1 in the 
original paper): (a) Nordic countries as a whole; (b) single country: Denmark, Faroe 
Islands, Finland, Greenland, Iceland, Sweden, Norway; and (c) regions: five in 
Denmark: North Jutland, Central Jutland, Southern Denmark, The Capital and Zealand 
region; five in Finland: Helsinki, Kuopio, Oulu, Tampere and Turku region; two in 
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Iceland: Reykjavik-Reykjanes and Outside The Capital; six in Sweden: Northern, 
Stockholm–Gotland, Southern, South-Eastern, Uppsala-Örebro and Western region; 
and four in Norway: Central, Northern, South-Eastern and Western region,  Figure 5 
(not present in the original paper) (from http://www-dep.iarc.fr/NORDCAN). 
 
 
 
Figure 5: Countries and regions belonging to the Nordcan project (http://www-
dep.iarc.fr/NORDCAN). 
 
The overall male resident population in Nordic countries in 2014 was 13 075 123. 
Residents in single countries and regions are shown in Table 6 (n.1 in the original 
numeration). 
ASRs express the number of new cases diagnosed among 100 000 men in 2014 
according to the observed age- specific rates and the age-groups of the European 
standard population. 
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We also retrieved from Nordcan the SE of the ASRs and we computed the 95% CIs 
according to the method of the binomial approximation (Boyle and Parkin, 1991) 
(Table 6 [n.1 in the original numeration]). 
We evaluated whether two rates were different inspecting the overlap between 
specific 95% CI (Schenker and Gentleman, 2001). The precision of the age-specific 
rates that concur in the calculation of ASR increases when the number of cases in this 
group increases. This applies to each age group and thus to ASR as the whole entity. 
The overall numbers observed yearly in the analysed series (Table 6 [n.1 in the original 
numeration]) were, with the exception of Faroe Islands and Greenland, in the order of 
several hundreds or even thousands. SEs of the ASR are greater when the numbers on 
which they are based are small. 
 
We compared the ASR at each geographical level with the level underneath: Nordic 
countries versus Denmark, Faroe Islands, Finland, Greenland, Iceland, Sweden, 
Norway and single country versus specific regions. 
 
Moreover, we computed the absolute difference (range) between the highest and the 
lowest ASR within a nested layer (the range between countries for Nordic countries 
and between regions for a specific country). Then we calculated the percent ratio 
between this range and the ASR of the level above interpreted as a summary value of 
the subareas (for Nordic countries or a single country, respectively), r/R = (range/ASR) 
× 100. 
The r/R provides a measure of the variability across the available ASRs of the nested 
level for which the ASR represents the summary measure. The smaller the r/R 
(minimum 0%), the lower the variability across subarea ASRs. 
 
Results 
In Figure 6 (n.1 in the original numeration), the ASRs for Nordic countries as a whole, 
for single countries and for country-specific regions, are shown with the 
corresponding 95% CI. The ASRs for countries appear to be scattered in the picture.  
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In fact, the ASR for Nordic countries (453.1) is compatible with the Greenland's one 
only (384.1) because of the wide range of variability of the latter, because of the small 
number of cases on which it is based and the resulting imprecision in its computation 
(wide 95% CI). In contrast, Denmark (504.4) and Norway (509.9) showed greater ASRs 
that the Nordic countries one and Faroe Islands (251.0), Finland (404.5), Iceland 
(387.2) and Sweden (428.5) have lower values than the supranational summary ASR. 
 
 
Figure 6 (n.1 in the original numeration): European age-adjusted incidence rates for 
‘all sites excluding nonmelanoma skin cancer’, for men, in 2014, for Nordic countries, 
single countries and regions. From Nordcan (http://www-dep.iarc.fr/NORDCAN). 
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In Table 6 (n.1 in the original numeration), for each area (Nordic countries, country 
and region), the number of cancer cases for ‘all sites excluding non melanoma skin 
cancer’, for men, in 2014 and the resident population are reported together with the 
ASR, the SE and the 95% CI. 
The inverse relationship between number of observed cases and the SE is evident. In 
fact, the SE is only 1.6 (cases per 100 000 men in 2014) for Nordic countries (on the 
basis of 79 441 analysed cases), whereas it is 40.6 for Greenland (99 cases). 
 
In Table 6 (n.1 in the original numeration), the r/R is also reported for geographical 
level 1 (Nordic countries vs. countries) and 2 (single countries vs. regions). 
 
When the ASR of Nordic countries is evaluated together with the r/R, the value of r/R 
= 57.1% provides a clear hint of a huge inter-countries variability in ASRs, clearly shown 
in Fig. 6. ([n.1 in the original numeration) In fact, this r/R means that the range 
between the lowest and the highest country-specific ASR is almost 60% of the Nordic 
country ASR. 
Also, within single countries, the overall ASR may not represent the regional ASRs and 
the amount of internal variability (Fig. 6 [n.1 in the original numeration]) is well 
described by r/R (Table 6 [n.1in the original numeration]). 
 
The smallest r/R value (9.6%) was observed in Iceland, where the small numbers of 
observed cases led to a non-negligible uncertainty in the regional estimates whose 
wide 95% CI overlapped the national one. A minor amount of variability (r/R = 13.9%) 
was present in Norway, where the Northern region (ASR = 468.8) had a lower value 
and the Western region (539.8) had a higher ASR than the summary one. Almost the 
same r/R was present in Denmark (14.4%), where North Jutland (474.8) showed an 
ASR lower than the national value and Zealand (547.5) showed a greater one. Finland 
showed a greater inter-regional variability (31.9%), with Kuopio (345.5) and Turku 
(348.5) below and Helsinki (427.2) and Tampere (474.6) above the national mean. 
Finally, the slightly higher internal variability was found in Sweden (RR = 37.8%) where 
three regions, Northern (364.5), Uppsala-Örebo (385.8) and Western (407.1), were 
below the national ASR and Stockholm–Gotland (526.3) higher than the country one. 
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Table 6 (n.1 in the original numeration): Country layers, number of incident  cases of 
'all sites excluding non-melanoma skin cancer', in men, in 2014, resident population, 
European age-standardised incidence rates (ASR), standard error (SE) of the ASR, 
lower (LCI) and upper (UCI) 95% confidence intervals and R/R (Range/Rate : Range is 
the absolute difference in ASRs between the greatest and lowest ASR for areas in the 
lower layer; Rate is the ASR) [The smaller the r/R the lower the variability across 
subareas ASRs. range/Rate% (r/R): range is the absolute difference in ASRs between 
the greatest and the lowest ASR of subareas in the lower layer; rate is the ASR. ASR, 
age-standardised incidence rate; LCI, lower 95% confidence interval; UCI, upper 95% 
confidence interval.] Data from Nordcan (http://www-dep.iarc.fr/NORDCAN). 
 
Layer Area n. 
cases 
resident 
population 
ASR (E) SE LCI LCS R/R 
1 
Nordic 
countries 79,441 13,075,123 453.1 1.6 449.9 456.3 0.46 
2 Denmark 19,031 2,799,895 504.4 3.7 497.1 511.7 0.14 
3 
North 
Jutland 2,004 292,697 474.8 10.9 453.4 496.2   
3 Central 
Jutland 
4,165 639,192 496.5 7.8 481.2 511.8   
3 Southern 4,230 600,667 493.0 7.8 477.7 508.3   
3 The capital 5,245 860,818 507.1 7.1 493.2 521.0   
3 Zealand 3,387 406,521 547.5 9.7 528.4 566.6   
2 
Faroe 
Islands 78 25,039 251.0 28.8 194.6 307.4   
2 Finland 15,142 2,686,119 404.5 3.4 397.9 411.1 0.32 
3 Helsinki 4,849 922,582 427.2 6.2 415.0 439.4   
3 Kuopio 2,194 403,920 345.5 7.7 330.5 360.5   
3 Oulu 1,970 372,534 382.2 8.8 364.9 399.5   
3 Tampere 3,811 545,749 474.6 7.9 459.1 490.1   
3 Turku 2,303 441,350 348.5 7.5 333.7 363.3   
2 Greenland 99 29,742 384.1 40.6 304.5 463.7   
2 Iceland 694 164,257 387.2 14.8 358.1 416.3 0.10 
3 Reykjavik 481 115,443 401.2 18.5 365.0 437.4   
3 Outside 213 48,818 364.1 25.4 314.3 413.9   
2 Norway 15,865 2,581,421 509.9 4.1 501.9 517.9 0.14 
3 Central 2,362 357,476 526.9 11.0 505.3 548.5   
3 Northern 1,489 242,918 468.8 12.4 444.6 493.0   
3 South-
Eastern 
8,685 1,433,445 502.9 5.5 492.2 513.6   
3 Western 3,329 547,582 539.8 9.4 521.3 558.3   
2 Sweden 28,709 4,843,303 428.5 2.6 423.4 433.6 0.38 
3 Northern 2,521 444,391 364.5 7.6 349.6 379.4   
3 
Stockholm
-G. 6,735 1,111,680 526.3 6.5 513.6 539.0   
3 Southern 5,375 872,866 438.1 6.2 425.9 450.3   
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3 
South-
Eastern 
3,130 510,943 415.8 7.7 400.6 431.0   
3 Uppsala-    
Örebro 
5,852 1,002,193 385.8 5.3 375.5 396.1   
3 Western 5,096 901,258 407.1 5.9 395.6 418.6   
 
 
Conclusion 
This epidemiological exercise underlines that ASRs, which clearly provide the level of 
cancer incidence in a specific area and time for geographical and time comparisons, 
do not provide any information on possible internal variability. In fact, the SE, which 
usually accompanies ASR, refers only to the precision of the estimate and does not 
reflect the possible heterogeneity in cancer incidence in the area. 
 
Therefore, the ASR of a CR, although correct from the computational point of view, 
and informative for geographical and time comparisons, could represent the incidence 
level only in some subareas or even in none. 
If a CR also provides ASR for subareas, r/R is not necessary because the information 
on possible geographical heterogeneity is available. In contrast, if a CR only publishes 
a summary ASR, as happens for many CRs in Cancer incidence in five continents (Ferlay 
2014), which is the most well-known and authoritative publication in the field, r/R is 
invaluable to have a clear impression of the variability behind the ASR. 
 
When incidence data are available for different geographical layers, it is possible to 
add to the ASR a summary measure about the underlying variability. The Nordic 
countries dataset provided the invaluable chance of evaluating three sub-geographical 
levels: supranational, national and regional. 
 
We propose to compute the range between the highest and the lowest underlying 
ASRs to divide it by the ASR (r/R) and to express the result as a percentage. 
The inde 
x r/R has been chosen among other more formal statistics (e.g. extreme quotient) 
(Gumbel and Keeney, 1950) because it only relies on ASRs and provides a direct 
measure of the effect of internal heterogeneity (range between maximum and 
minimum ASR in subareas) on the overall summary ASR. 
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In our example, on the basis of long-standing high- quality Nordic countries incidence 
data (Ferlay, 2014), the r/R for the Nordic countries was quite high (57.1%), suggesting 
that the national ASRs could vary notably. In fact, the overall ASR for Nordic countries 
did not correspond with any of the national ASRs, with the exception of Greenland’s 
one (Fig. 6 [n.1 in the original numeration]). 
Also at a national level, when regional estimates are available, it is possible to add to 
the national ASR the r/R based on regional ASRs to express how well the national ASR 
represents the regional ones. In the dataset analysed, we showed that country ASR 
may reflect more (Iceland, Denmark and Norway) or less accurately (Finland and 
Sweden) the incidence of cancer in the different regions within a country. 
The comparison between ASRs using the 95% CI overlap is simple and intuitive 
(Schenker and Gentleman 2001) and showed major differences in ASRs between and 
within areas. 
 
This study was based only on one incidence year. To check the reliability of r/R, we 
repeated the exercise also for the year 2012. The r/R in 2012 were similar to that in 
2014 (results added in Appendix 2 [Supplementary information for Paper 2]; data not 
shown in the original paper) for almost all the countries, with the exception of Sweden, 
for which r/R showed in 2012 a smaller heterogeneity (r/R = 16.6%) than in 2014 
(37.8%). The reason for this strong change was the change in the incidence ASR in the 
Stockholm–Gotland region from 2012 (420.5 cases/100 000) to 2014 (526.3). This 
change was the effect of a study on prostate cancer carried out in the county between 
2012 and 2014 (Grönberg ,2015). The ASR for all causes except skin and prostate 
cancer were 268.3 and 266.7, respectively. This example confirms that r/R reflects the 
true variability within an area. 
 
Heterogeneity was identified among countries (areas between around 25 000 and 4 
800 000 resident men) and among regions of several hundred thousand inhabitants, 
except for Iceland, where the population is smaller than in any of the other countries 
with regional information available. 
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It is possible to identify slight differences in cancer incidence between two 
geographical areas if the number of cases (population) is large (i.e., thousands). Then, 
the ASRs are precise and the 95% CI is narrow. Thus, it is easier to detect a slight 
difference between two large (populated) regions than between two small ones. For 
example, between the ASRs of Kuopio and Oulu (highly populated), there is the same 
difference as that between the two Icelandic regions (poorly populated), but only the 
first two do not have overlapping CIs. 
 
In general, the unavailability of a unique population-unit for subareas (countries, 
regions, provinces, counties, etc.) makes comparisons across areas difficult. 
With the increase in the number of subareas, the variability among them is expected 
to increase and consequently the r/R. The aim of r/R is exactly to offer summary and 
straightforward information on possible outliers. In case r/R is small (∼ < 10–15%) it is 
immediately clear that all the ASR for each of the subareas are concentrated in a quite 
narrow range and if it is large (>30%) it underlines that at least one of them is rather 
different from the overall ASR. 
 
The r/R is a measure intended as a macro indicator of major heterogeneity among 
quite large subareas (e.g. regions in a country). For small areas and cluster analysis, 
other methods have to be chosen (Colonna and Sauleau, 2013). 
 
CRs should start to provide also general information on internal cancer incidence 
geographical variability in addition to standardised incidence rates. This would 
make the information more complete and clearer for readers, avoiding 
misinterpretations. When incidence for subareas is available, r/R, which is very simple 
to compute, could be presented together with the general ASR as a first attempt to 
raise the issue. 
The interpretation of incidence ASR requires the combined reading of ASR, SE and 
r/R: the ASR shows the level of incidence, the SE shows the precision of the ASR and 
r/R shows the amount of internal geographic variability. The r/R will be smaller if the 
ASR for subareas are quite similar to each other (more or less precisely estimated) or 
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greater if they are rather different. This is the original and useful contribution 
provided by the r/R. 
 
References The original references of the paper have been included in the general 
list of the thesis.  
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3.1.1. Comment 
 
The previous paper (Paper 2) addresses the topic of informativeness and usefulness. 
 
The proposed innovative index provides, when necessary, a measure of the variability 
in cancer incidence in addition to an average ASR. 
 
It is straightforward to calculate and therefore does not require further variables. 
It is also straightforward to interpret. 
 
The paper perfectly addresses the objectives of this thesis, illustrating how it is 
possible to exploit the potentiality of CR, enhancing the amount of information 
provided, improving the readability of a theoretically complex issue, and providing the 
stakeholders with a more comprehensive message. 
 
This method has been implemented and presented in recent scientific meetings on 
cancer registries (Contiero 2018, Martos 2018, Rashid 2018). 
 
The heterogeneity within an area in cancer incidence may also concern survival or 
prevalence. Therefore, this approach, tested with incidence, could also be exploited 
for other epidemiological indexes. 
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3.2. Original material: an example of the application of the new index of internal 
variability (r/R) to skin melanoma incidence 
 
Since the core theme of this thesis is skin melanoma, the r/R method has also been 
applied to a skin melanoma case-series. The aim is to complement a summary age-
adjusted rate (ASR) with this index of internal variability to provide a straightforward 
clue of variability of incidence in macro sub-areas. 
The computation of the method implies that age-adjusted rates for sub-areas are 
known but not published. 
 
I utilised data from Nordcan (http://www-dep.iarc.fr/NORDCAN/english/frame.asp), 
the same source of information used in the original paper, which provides information 
at three geographical levels: supranational, national and regional (Engholm, 2016). I 
selected ASR (European standard population) and standard error for skin melanomas 
incident in 2015 among men for All Nordic Countries, for each Country, and Regions, 
when available. I computed the r/R index to the Nordic Countries to provide a measure 
of inter-Countries variability, and to each Country for which Regional information was 
available to evaluate Regional variability. 
 
Table 7 summarises results. 
 
Variability is exceptionally high for Nordic Countries as a whole (r/R=1.10). The value 
means the underlying difference between the Countries with the highest and lowest 
ASR exceeds the ASR for Nordic Countries; such results are primarily due to the low 
rate in Greenland, 1.9, which is far from that of all other Countries. 
 
However, age-standardised incidence for skin melanoma among men varies 
remarkably also among various regions of each country, in particular in Sweden where 
the internal variability, according to the index, is about 70% of the Swedish ASR, and 
in Finland, for which the r/R value is 0.55. These results confirm the usefulness and 
informativeness of the r/R index, which expresses supra-national or national ASR data 
representativeness for national and regional sub-areas incidence. 
  73 
Geographical heterogeneity in Nordic countries was also documented in 1978-1982 
and 1983-1987, with the highest incidence in Norway and the lowest in Finland and 
Iceland, and with regional high-risk areas in the south of Norway and the south of 
Sweden (Aase, 1994). The present results are in agreement with this previous paper 
(Aase, 1994). The Authors related the geographical difference mainly to variations in 
estimated local levels of UV radiation. Therefore, the Authors warned the readers 
about the effect of the on-going stratospheric ozone depletion. However, also 
difference in social level and the associated patterns of behaviour, and genetically 
determined susceptibility to exposure to UV were considered (Aase, 1994). The in-
deep analysis of melanoma trends in Norway suggested that the documented increase 
in melanoma incidence could have been a result of more active outdoor recreation – 
and therefore UV exposure – from the end of the last century (Aase, 1996). The 
regional variability documented in Sweden, with more elevated rates in Western 
Sweden and in particular in the city of Gothenburg, was also related to the high 
average duration of the sunshine in the area, but also high sun exposure of citizens on 
holidays abroad (Claeson, 2012). 
 
The difference in melanoma incidence among the leading five Nordic countries has 
also been documented by Hèry and colleagues who discovered broader differences in 
the risk than in prognosis of melanoma. However, the reasons for such heterogeneity 
were not clear (Hèry, 2010). As regards the relevant increase observed in Iceland 
among women from the late-1980s, and among men it was attributed at least in part 
to the very high prevalence of sunbed use, as well as considerable increase in travel 
abroad to southern areas during the past four decades and partly because of increased 
diagnostic activity due to a nationwide cancer prevention programme which came into 
action in 1990 (Hèry, 2010). A survey on tanning bed use put the participant 
Scandinavian countries at the first ranks among 30 European countries for people 
younger than 20 years. To be specific, the prevalence was 33.3 % in Norwegian 
adolescents, 23.9% in Denmark and 23.5 % in Sweden (Suppa, 2019). This result raises 
concerns. However, educational actions are on-going. For example, in Denmark, a 
successful campaign against the use of sunbeds has been carried out among 
adolescents (Køster, 2011) with beneficial effects that have increased from 2007 to 
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2015 (Køster, 2018). Such effects have pushed for more stringent legislation and/or 
enforcement of the existing regulations in those countries, especially for young 
individuals. In Denmark, efforts have been developed in recent years to reduce sunbed 
use among adolescents. An anti-sunbed campaign raised awareness of the sunbed-
related risks among Danish adolescents, and indeed, sunbed use decreased 
substantially; until now, it has remained considerable (>30%) (Køster, 2011; Køster, 
2018). 
 
Moreover, an educational intervention in Danish schools produced a significant 
reduction in sunbed use but failed to change pupils’ intentions and attitudes towards 
artificial tanning (Køster, 2011). Importantly, all three Scandinavian countries 
displayed elevated rates of long-term sunbed users (>10 years) in our analysis. 
A survey was carried out by the Danish Cancer Society 
(https://www.ancr.nu/dyn/resources/File/file/7/4247/1412940269/total_document
_survey_optimeret.pdf) in 2010 to evaluate the comparability of data among the 
Nordic cancer registries. 
 
As regards melanoma screening, there were no programs in Denmark, Finland, Iceland 
and Norway. In Sweden, in the region of Lund, a particular "out-patient"-project, in 
which people had their "dots" checked, was organised in 1990. Moreover, still in Lund, 
random screening was offered by Cancer society at, e.g., beaches during the summer 
(https://www.ancr.nu/dyn/resources/File/file/7/4247/1412940269/total_document
_survey_optimeret.pdf). 
 
In conclusion, some of the Nordic countries have taken part in the Euromelanoma 
initiatives, Sweden since 2000, Denmark since 2011 and Finland since 2015. These 
actions include public awareness campaign, early detection and treatment, and public 
screenings during an annual ‘Euromelanoma Screening 
Day’(https://www.euromelanoma.org/intl). 
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Table 7: Skin melanoma. Data from Nordcan (http://www-dep.iarc.fr/NORDCAN): 
Country layers, European age-standardised incidence rates (ASR), standard error (SE) 
of the ASR, and r/R (range/ASR:  range is the absolute difference in between the 
greatest and lowest ASR for areas in the lower layer; ASR is the one of the upper layer). 
 
Layer Area ASR(E) SE r/R 
1 Nordic countries 27.8 0.42 1.10 
2 Denmark 29.3 0.93 0.44 
3 North Jutland 27.9 2.8   
3 Central Jutland 23.1 1.7   
3 Southern 28.9 1.97   
3 The capital 35.9 1.9   
3 Zealand 27.9 2.3   
2 Faroe Islands 4.8 2.8   
2 Finland 22.7 0.82 0.55 
3 Helsinki 25.6 1.5   
3 Kuopio 18.9 1.9   
3 Oulu 14.7 1.8   
3 Tampere 27.2 2.0   
3 Turku 20.4 1.9   
2 Greenland 1.9 1.9   
2 Iceland 10.7 2.49 0.35 
3 Reykjavik 12.0 3.2   
3 Outside 8.3 3.9   
2 Norway 32.6 1.04 0.36 
3 Central 28.8 2.62   
3 Northern 23.3 2.81   
3 South-Eastern 35.1 1.44   
3 Western 33.2 2.33   
2 Sweden 28.0 0.68 0.70 
3 Northern 14.1 1.59   
3 Stockholm-G. 26.4 1.43   
3 Southern 32.0 1.73   
3 South-Eastern 33.8 2.32   
3 Uppsala-Örebro 27.3 1.48   
3 Western 31.0 1.67   
 
   
  76 
4. Data from the registry: beyond topography and morphology 
 
As shown in the previous table, the way registries publish data has not sensibly 
changed since the beginning of their history. The topography is still the primary way 
in which CRs present numbers and rates. Therefore, such information may raise 
limited interest among clinicians who diagnose and treat cancers for which new 
prognostic and predictive factors are available every day. 
 
The interest of clinicians in registry data has to be encouraged. 
 
The process of production of high-quality data is demanding in terms of time and 
resources. The inclusion of any extra variable in a registry opens a new front for 
validity, completeness and comparability evaluation and reduces timeliness. As a 
consequence, most registries plan their primary activity to meet the demands and 
deadlines of the big international projects (e.g., CI5, Concord, Eurocare). 
 
Therefore, basic registries' information is mainly provided to those who ask exactly for 
them, for purposes based on their known availability.  There is a high degree of 
recursion within the world of registries. 
 
Further, big projects involving registries from different countries and even continents 
must have a global point of view with the need to find out the minimum data set, 
which allows the majority of registries to participate.  
In case extra variables are needed, as started to happen with the High-Resolution 
studies of the Eurocare project, specific funds or just analysis on samples or both 
should be planned.   
 
Besides, the data format has been kept simple and stable over time, also for making 
trend evaluations possible. Furthermore, big International projects have also marked 
the time; for example, CI5 publishes new data with a minimum delay of 5 years from 
the clinical diagnosis. This interval is partly due to the amount of work necessary in 
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CI5, but also to the timeliness of registry data production. This delay causes another 
critical recursive phenomenon: there is no pressure to shorten timeliness.   
 
In conclusion, registry data may be of interest for those who want to compare 
incidence, prevalence, or survival in the world but may not be for the clinicians who 
work in the publishing registry’s area. 
 
The following Paper (3) presents a fruitful collaboration between registries and 
dermatologists in the analysis and interpretation of skin melanoma. 
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4.1. Paper 3  
 
The paper has been published in Melanoma Res. 2010; 20: 422-6 with the following 
title: 
 
"The thickness of melanomas has decreased in central Italy, but only for thin 
melanomas, while thick melanomas are as thick as in the past". 
 
Authors Crocetti Ea, Caldarella Aa, Chiarugi Ab, Nardini Pb, Zappa Ma. 
Affiliation: a) Clinical and Descriptive Epidemiology Unit and b) Melanoma Early 
Diagnosis Service, Institute for Cancer Study and Prevention ISPO, Florence, Italy 
Author Contributions: I (EC) declare to have conceived the idea of the study, planned 
and designed it, performed the analysis and drafted the first draft. The other Authors 
revised critically the paper and approved the final version of the manuscript 
 
Abstract 
The objective of this study was to evaluate the time trend of melanoma thickness in a 
population-based case series. All invasive (n = 2862) and in situ (n = 605) cutaneous 
melanoma incident cases diagnosed in 1985–2004 were retrieved from the Tuscany 
Cancer Registry, central Italy. 
Standardized (European population) incidence rates were computed for four periods: 
1985–1989, 1990–1994, 1995–1999, 2000–2004, and for Breslow thickness classes (r 
1, 1.01–2.00, > 2 mm). The annual percent change (APC) of the standardized rates was 
computed. Thickness was evaluated on the basis of sex, age, morphology type, site 
and period of time. Median thickness was evaluated by means of a nonparametric K-
sample test. The incidence rate of melanoma rose significantly for both invasive (APC 
= + 5.1%) and in situ lesions (APC = + 11.1). The sex distribution of patients with 
invasive melanoma did not change over time (mean male/female ratio 0.95). The 
mean age at diagnosis did not change (57.2 years; SD = 17.2 years). From 1985–1989 
to 2000–2004 the median value of thickness decreased from 1.68 to 0.8 mm (P < 
0.001). Within the Breslow categories the median value of thickness decreased 
significantly for thin melanomas 
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Introduction 
The incidence of melanoma has notably increased over the last decades in all western 
countries (Linos 2009, De Vries 2004) and also in Italy (Crocetti 2004). A major cause 
for this increase has been early diagnosis. In addition, most of the diagnosed lesions 
are now in situ (Criscione 2009) or thin melanomas (Garbe 2009, Baumert 2009, 
Lipsker 1999), especially of the superficial spreading melanoma type (SSM) (Linos 
2009, Warycha 2008); therefore, their prognosis is very good. 
In contrast, the incidence of thick melanomas has not decreased (Criscione 2009, 
Lipsker 1999, Richardson 2008, Crocetti 2003, Tejera-Vaquerizo 2008) or increased  
(Linos 2009). 
 
Thickness is the most relevant prognostic factor. Moreover, a great proportion of thick 
melanomas is of the nodular type (Tejera-Vaquerizo 2008, Galler 2009, Crocetti 2006). 
Against the background of stable or even rising rates for thick melanomas, melanoma 
mortality has not significantly decreased (Linos 2009). 
In recent years, health-care professionals have focused on how to cope with thick 
deadly melanomas, but the problem is still unsolved (Murray 2005). 
 
The aim of this paper is to evaluate the incidence trend of cutaneous melanomas with 
special reference to thickness in an Italian population-based case series 
 
Materials and methods 
We retrieved all the invasive (n = 2862) and in situ (n = 605) cutaneous melanoma 
incident cases diagnosed in 1985–2004 from the archives of the Tuscany Cancer 
Registry (RTT). RTT is a population-based cancer registry active in the provinces of 
Florence and Prato (approximately 1161000 residents in the 2001 census), central Italy 
(Paci 2007). 
 
We arranged Breslow thickness in three classes, thin (<= 1 mm), intermediate (1.01–
2.00), and thick (> 2 mm), as indicated by Balch et alii (Balch 2009). As for thick 
tumours, we also analysed thick (>= 3 mm or >= 4 mm) lesions. 
We used median to measure thickness because of the skewness of its distribution. 
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Thickness categories were evaluated according to the following variables: 
(1) Sex 
(2) Age (0–49, 50 + years) 
(3) Morphological type (the International Classification of Diseases for Oncology 
morphology codes): 
SSM(ICDO-M = 8743), nodular melanoma (NM; ICDO-M = 8741), lentigo maligna 
melanoma (LMM, ICDO-M = 8742), not otherwise specified (NOS, ICDO-M = 8720), 
‘other types’ (ICDO-M = 8722, 8730, 8740, 8744, 8770, 8771, 8772). 
(4) Site: head and neck, trunk, upper limb, lower limb, others and unspecified 
(5) Period of time: 1985–1989, 1990–1994, 1995–1999,2000–2004. 
 
Statistical methods 
Incidence rates were age-standardised through the direct method using the European 
standard population. 
We computed the annual percent change (APC) of the standardised rates using the 
weighted least squares method, on the basis of single incidence year. We performed 
the above-mentioned computations by means of the SEER*Stat 6.3.6 software 
(www.seer.cancer.gov/seerstat). We compared proportions by means of the X2 test, 
or the Fisher’s exact test, when we expected less than five observations. 
 
As regards the median, we used the Stata command ‘median’ that performs a 
nonparametric K-sample test that evaluates the null hypothesis that those samples 
were drawn from populations with the same median (www. stata.com). In the case of 
two samples, the X2 statistic test is calculated with and without a continuity correction. 
 
Results 
From 1985 to 2004, 3467 patients residing in the RTT area had a diagnosis of malignant 
melanoma (2862 invasive and 605 in situ). The standardised incidence rate of invasive 
malignant melanoma rose from 6.4 per 100 000 in 1985–1989 to 13.6 in 2000–2004, 
with a mean annual pace of + 5.0% [95% confidence intervals (CIs), + 4.0/ + 8.2], Table 
8. The growth of incidence was statistically significant for both men (APC = +5.3, 95% 
CI, +4.2/+6.5) and women (APC =+4.9, 95% CI, +3.5/+6.3). 
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In the analysed period the sex ratio was stable, with a slight predominance of women. 
The median age at diagnosis did not change over time, being 58.1 years (range 21.2–
100.6 years). 
 
Table 8 (n.1 in the original numeration):  Tuscany Cancer Registry: invasive melanoma, 
absolute numbers, proportion of females, standardised (European population) 
incidence rates, annual percent change (APC) of standardised rates. In situ melanoma, 
absolute numbers, proportion of females, standardised (European population) 
incidence rates. Annual percent change of standardised rates (APC) are computed on 
single years of diagnosis. Probability (P) for APC to be equal to 0 or for proportions 
that each sample has the same proportion of observations. LM, lentigo melanoma; 
N.o.s., not otherwise specified; NM, nodular melanoma; SSM, superficial spreading 
melanoma. 
 
  1985-1989 1990-1994 1995-1999 2000-2004 n/p 
Invasive 
melanoma 
(n) 
442 565 835 1020 2862 
% females 54.5 54.0 55.3 50.2 P=0.13 
Incidence 
rate 
6.4 8.0 11.4 13.6 P<0.01 for 
APC 
Breslow 
thickness 
     
>0 to <= 
1mm, n (%) 
92 (20.8) 182 (32.2) 375 (44.9) 476 (46.7) 1125 
Incidence 
rate 
1.4 2.7 5.5 6.7 P<0.001 for 
APC 
1.01-2.00 
mm n (%)  
76 (17.8) 93 (16.5) 112 (13.4) 129 (12.8) 410 
Incidence 
rate 
1.1 1.3 1.5 1.9 P=0.006 for 
APC 
>2mm n (%) 117 (26.5) 134 (23.7) 153 (18.3) 200 (19.6) 604 
Incidence 
rate 
1.6 1.8 1.8 2.2 P=0.016 for 
APC 
Unknown, n 
(%) 
157 (35.5) 156 (27.6) 194 (23.4) 215 (21.0) 723 
Incidence 
rate 
2.2 2.2 2.5 2.8 P=0.07 for 
APC 
In situ 
melanoma 
N 
55 72 182 296 605 
% females 61.8 63.9 52.2 51.4 P=0.15 
Incidence 
rate 
0.8 1.0 2.7 4.0 P<0.01 for 
APC 
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Morphology 
type 
     
SSM 2.9 4.5 7.3 9.0 P<0.01 for 
APC 
NM 0.8 0.8 0.8 0.8 P=0.96 for 
APC 
LM 0.2 0.2 0.2 0.2 P=0.14 for 
APC 
Other 0.3 0.3 0.4 0.4 P=0.15 for 
APC 
N.o.s. 2.2 2.2 2.7 3.2 P=0.006 for 
APC 
 
 
With regard to invasive melanomas, a statistically significant growing incidence was 
detected for thin (APC = +9.5; 95% CI, +7.1/+11.9), for intermediate (APC = + 3.1; 95% 
CI, +1.1/+5.2) and for thick melanomas (APC = + 2.1; 95% CI, +0.4/+3.7), and it was 
almost statistically significant for those melanomas without the information on 
Breslow's thickness (APC = +1.9; 95% CI, –0.3/+4.1; Table 8 (n.1 in the original 
numeration). 
 
Six hundred and five in situ melanomas were diagnosed with a statistically significant 
growing trend (APC = +11.1; 95% CI, +8.1/+14.3); standardised incidence rates for in 
situ melanomas rose from 0.8 per 100000 in 1985–1989 to 4.0 in 2000–2004. The 
incidence trend for in situ melanomas was statistically significant for both men (APC = 
+12.7; 95% CI, +8.7/+16.9) and women (APC = + 9.4; 95% CI, +6.1/+12.8). In situ 
invasive melanomas did not show any statistically significant change, either in sex ratio 
(percentage of women 54.1) or in the median age at diagnosis (57.8 years). 
 
The mean age at diagnosis for in situ melanomas was lower than for invasive 
melanomas (55.5 vs. 57.2 years; P = 0.02). However, among invasive melanomas (<= 
1 mm) the mean age at diagnosis (52.7 years) was lower than for in situ melanomas 
(P=0.001), whereas the mean age of 60.2 years for melanomas (>1 mm) was higher 
than for both in situ melanomas (P<0.001) and those with a thickness of 1mm or less 
(P=0.001).  
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According to types of morphology, the increasing incidence trend was statistically 
significant for SSMs (n= 1655, APC= +7.0; 95% CI, +5.2/+8.8) and for the group ‘other 
types’ (n=155, APC= +6.7%; 95% CI, +2.6/+11.0), whereas for NMs (n=238), LMM 
(n=79) and for NOS melanomas (n=775), the trends did not reach any statistical 
significance, Table 8 (n. 1 in the original numeration). 
 
From 1985–1989 to 2000–2004 the median value of thickness, for invasive 
melanomas, decreased from 1.68 to 0.8 mm (P<0.001). The median thickness 
decreased statistically significantly for both men (from 2.1 to 0.8 mm) and women 
(from 1.3 to 0.75 mm); Fig. 7 (n.1 in the original numeration).  
 
The decrease over time in median thickness was not present in all Breslow categories. 
In fact, the median value of thickness decreased statistically significantly for thin 
melanomas (<=1 mm) but not for intermediate (1.01–2.00mm) or thick melanomas 
(>2 mm) Table 9 (n.2 in the original numeration). 
Figure 7 (n.1 in the original numeration): Tuscany Cancer Registry. Invasive melanoma: 
median Breslow thickness for men and women by calendar years. 
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Median thickness did not decrease among thick melanomas in other Breslow 
categories either (>=3 mm, >=4mm; (results added in Appendix 2 [Supplementary 
information for Paper 3]; ‘data not shown’ in the original paper).  
 
The decrease in median thickness was statistically significant only for SSM (from 1.20 
to 0.68 mm) and for other types (from 2.75 to 1.10), whereas it did not reach statistical 
significance for the other morphological types of melanoma (Table 9 [n. 2 in the 
original numeration]). In the most recent period (2000–2004), SSM represented the 
largest proportion of melanomas (62.6%; 639/1020), followed by melanomas NOS 
(17.5%; n=179), the group ‘other’ (10.7%; n=109), nodular melanomas, (6.2%; n = 62) 
and LMMs (2.9%; n = 30). Among the 208 thick melanomas diagnosed in 2000–2004, 
45.7% were SSM and 24.5% of nodular type. 
 
Table 9 (n.2 in the original numeration): Tuscany cancer registry. Invasive melanoma: 
median thickness by period of diagnosis for males and females, for Breslow’s thickness 
categories, for morphology type (LM, lentigo melanoma; N.o.s., not otherwise 
specified; NM, nodular melanoma; SSM, superficial spreading melanoma), and site. P 
shows the probability that the medians in different groups are medians of samples 
drawn from the same population. 
 
  1985-1989 1990-1994 1995-1999 2000-2004 p 
Overall 1.68 1.2 0.8 0.8 <0.001 
Males 2.1 1.3 0.8 0.8 <0.001 
Females 1.3 1.15 0.8 0.75 <0.001 
Breslow 
thickness 
     
<=1mm 0.66) 0.57 0.55 0.50 0.001 
1.01-2.00 1.50 1.45 1.40 1.30 0.239 
>2mm 3.4 3.5 3.7 3.8 0.418 
Morphology 
type 
     
SSM 1.20 0.85 0.70 0.68 <0.001 
NM 3.33 3.39 3.30 4.00 0.517 
LM 1.80 0.81 0.67 0.79 0.398 
Other 2.75 3.20 1.10 1.10 0.003 
N.o.s. 2.25 2.35 1.79 1.80 0.675 
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With regard to age, the increase in incidence was present and statistically significant 
for both younger (0–49 years) men (APC = +5.0, 95% CI, +2.7;+7.2) and women (APC = 
+6.2, 95% CI, +4.0;+ 8.5) and for older (50 + years) men (APC = +5.6, 95% CI, +4.1;+7.0) 
and women (APC = +3.5, 95% CI, +2.2;+4.8). 
 
With regard to skin sub-sites, by age group and sex (Table 10 [n. 3 in the original 
numeration]), melanomas of the head and neck did not show any statistically 
significant change either in incidence or in Breslow thickness in both sexes and age 
groups. The incidence of melanoma of the trunk increased significantly in both sexes 
and age groups, and the median thickness showed a statistically significant change 
towards a decrease, with the exception of younger women. The incidence of 
melanomas of the upper limbs increased in all age groups and both sexes, whereas 
their median thickness decreased statistically significantly only among younger 
subjects. With regard to melanomas of the lower limbs, there was a significant 
increase in incidence and a statistically significant decrease in median thickness among 
women. The group of melanomas of NOS sites increased over time, whereas their 
median thickness was stable. 
 
Table 10 (n.3 in the original numeration): Melanoma, number of cases according to 
sex, age (0–49, 50 + years and all ages), annual percent change (APC) of standardised 
incidence rates 1985–2004 with corresponding 95% Confidence Intervals (95% CI), 
median thickness during 2000–2004, probability (P) that the median thicknesses for 
the periods 1985–1989, 1990–1994, 1995–1999 and 2000–2004 belong to 
populations with the same medians according to a non-parametric k-sample test. 
N.o.s., not otherwise specified. 
 
 Males Females 
 <=49  
years 
50+  
years 
All  
ages 
<=49  
years 
50+  
years 
All  
ages 
HEAD&NECK        
Number 32 132 164 28 125 153 
APC 85-04 -1.3 +2.6 +0.4 -1.9 +0.3 -0.3 
95% CI -5.8+1.4 -1.6+4.9 -
2.6+3.5 
-5.3+1.7 -3.5+4.3 -
3.8+3.4 
Thickness 00-
04 
0.55 2.7 2.3 0.7 1.19 0.9 
p thickness 
change 85-04 
0.10 0.64 0.54 0.20 0.17  
TRUNK       
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Number 179 472 651 200 184 384 
APC 85-04 +4.7 +4.8 +4.8 +6.9 +4.5 +6.1 
95% CI +1.3+8.2 +2.7+2.1 +2.9+6.
7 
+3.1+10.
8 
+1.1+8.1 +2.8+9.
5 
Thickness 00-
04 
0.86 0.7 0.8 0.7 0.7 0.7 
p thickness  
change 85-04 
0.005 <0.001 <0.001 0.69 0.01 0.02 
UPPER LIMB       
Number 54 102 156 79 128 207 
APC 85-04 +4.7 +7.5 +7.6 +5.7 +5.1 +5.3 
95% CI +0.9+8.3 +4.0+11.
2 
+4.7+1
0.5 
+1.2+10.
4 
+1.8+8.7 +2.7+8.
0 
Thickness 00-
04 
0.54 0.85 0.65 0.8 0.9 0.88 
p thickness  
change 85-04 
0.054 0.20 0.03 0.07 0.60 0.12 
LOWER LIMB       
Number 71 132 203 204 423 627 
APC 85-04 +8.3 +4.4 +5.3 +4.3 +1.8 +3.0 
95% CI +3.8+13.
0 
+0.6+8.3 +2.5+8.
1 
+1.2+7.5 0+3.6 +1.1+4.
9 
Thickness 00-
04 
0.8 1.8 1.1 0.71 1.3 1.1 
p thickness  
change 85-04 
0.10 0.40 0.09 0.06 0.04 0.06 
N.O.S.       
Number 58 110 168 56 93 149 
APC 85-04 +7.4 +8.9 +7.9 +12.2 +11.1 +14.2 
95% CI +2.0+13.
0 
+3.7+14.
3 
+3.9+1
2.1 
+3.8+21.
8 
+5.4+17.
2 
+7.6+2
1.1 
Thickness 00-
04 
0.53 0.5 0.5 0.52 0.72 0.52 
p thickness  
change 85-04 
0.51 0.23 0.16 0.47 0.68 0.56 
 
 
Discussion 
The increasing incidence of invasive melanomas observed from 1985 to 2004 in 
central Italy was mainly supported by increasingly thinner lesions, especially of the 
SSM type. Therefore, the overall median thickness of melanomas has decreased over 
time, being in recent years 0.8 mm. This result was supported by the decrease in the 
median thickness of thinner melanomas (<= 1 mm; 0.5 mm during 2000–2004). 
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However, the shift in thickness observed for thin melanomas does not affect thick 
melanomas, which in Italy are now as thick as they were in the past. In fact, the median 
thickness of intermediate (1.01–2.00 mm) and thick melanomas (> 2 mm) did not 
decrease over the analysed period. 
 
Moreover, although the proportion of intermediate and thick melanomas has reduced 
over time, their incidence rates show a statistically significant increasing trend (Linos 
2009). In addition, their absolute number has increased (Lipsker 1999, Murray 2005). 
In agreement with the literature, we observed a strong increasing trend for in situ 
melanomas in central Italy (Criscione 2009), and almost half of the invasive 
melanomas are now thin. Such lesions have a very good prognosis, in so much as the 
UK recently proposed a change in guideline recommendations for those < 0.5 thick, 
suggesting less frequent follow-up (Einwachter-Thompson 2008). The mean age at 
diagnosis was lower for <= 1 mm melanomas than from in situ melanomas. This would 
indicate that in situ melanomas are not a precursor lesion of melanoma but have a 
different pathway than invasive melanomas. 
 
As observed in other reports, we did not detect any decrease in the thickness of NMs 
at diagnosis (Lipsker 1999). We documented that in this population-based series a 
significant percentage (24.5%) of thick melanomas are NMs, reaching around 30% 
when melanomas NOS are excluded (Blach 2009). 
 
There was an increase in incidence for all skin sites, with the exception of head and 
neck, for which the rates were stable over time. The trends for skin sites were similar 
for younger (0–49 years) and older (50+ years) patients of both sexes. A statistically 
significant change (decrease) in median thickness was present for melanomas of the 
trunk in men and older women, for upper limbs only in younger patients, and for lower 
limbs only in women. 
 
The epidemiology of melanoma is further divided into different groups of lesions 
(Lipsker 2007). A first group includes those melanomas easily detectable by enhanced 
early diagnosis, increasingly thinner, mainly of a SSM type, with a very good prognosis 
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and presumably with some amount of over-diagnosis (Welch 2005). There is a second 
group of melanomas, more aggressive, thick at diagnosis, and often of a nodular type 
(Betti 2005). The relationship between these two types of lesions is still unknown. 
Therefore, it is crucial to further investigate the biological history of thick melanomas 
References The original references of the paper have been included in the general list 
of the thesis. 
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4.1.1. Comment 
 
The previous paper (Paper 3) highlights a crucial step to make the activity of a CR more 
fruitful and useful to the healthcare system and the entire community: including the 
collaboration with clinicians.  
This collaboration represents a win-win strategy, being beneficial to both clinicians 
and CRs, as well as for all the other stakeholders (e.g. patients). 
 
The main advantage for the CR is having contact with the Real World (Aguiar, 2018; 
Crocetti, 2019). However, it is necessary to collect all the specific oncological variables 
that clinicians use in order to define the treatment and the prognosis of patients 
(Costa, 2019). 
For their part, the CRs offer a population point of view. Therefore, the advantage to 
physicians is having access to theoretically complete and unselected datasets for a 
particular type of patient population (for example, by age, stage, therapy) (Verdasca, 
2018). 
In addition, CRs usually have more experience in data analysis and statistical methods 
which could be useful to clinicians. 
 
CRs need to take advantage of this type of collaboration with the numerous 
professionals involved in cancer diagnosis and treatment. They should follow the 
exemplary contributions of many experts from different fields: screening experts 
(Vicentini, 2019), molecular and cellular biochemists (He, 2019), radiologists (Lehnich, 
2019), pathologists (Roscher, 2018), surgeons (Bergvall, 2019), oncologists (Zijlstra, 
2019), radiotherapists (Mullins, 2019), and other specialists. 
 
Collaboration implies reciprocal knowledge and if fruitful, the appreciation of specific 
abilities. The use of CR’s data by clinicians increases the visibility of CR in the scientific 
community and encourages the development of further collaborations. 
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Collaborations are indispensable for the improvement of CRs and the fulfilment of 
their potentiality. Working together usually results in gathering more clinical variables 
for producing epidemiological indexes customised to the needs of clinicians.  
 
If the CRs are able to increase how informativeness of their data, this in turn will 
improve their usefulness as well as generate more interest among doctors and the 
other parties involved.  
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5. Time trend and projections  
 
Incidence trends are essential when they are based both on frequency of cases (the 
real burden for the health system) and on age-standardised rates (the real risk of 
developing cancer) (Boyle, 1991), both of which are presented in Paper 3 to show the 
growth of the burden and the trend of incidence for skin melanoma.  
 
In its most straightforward representation cancer trends are a plot of age-adjusted 
incidence rates for the following years or periods. 
 
According to the numbers on which rates are computed, fluctuations due to random 
variability may make interpretation difficult. Therefore, observed data may be 
included in a model and presented as an estimated line. This computation is the base 
for log-linear models which express the slope of the time trend of cancer incidence as 
the beta coefficient of the time variables (Estève, 1994). In this way, it is possible to 
offer a summary measure of the trend that is easily interpretable as the annual 
average percent change of age-adjusted incidence rates (APC, as used in paper 3) with 
a statistical evaluation of its difference from a flat trend. 
 
However, a limit for this approach may be the over-simplification of complex 
tendencies (e.g., sequences of increases and decreases) which, on the contrary, may 
be relevant to detect. 
 
The purpose of the so-called ‘joinpoint analysis’ is to identify, within a defined period, 
those points in time when the tendency changes between periods having different 
slopes (Kim, 2000). Join-point analysis is widely used by registries also for the 
availability of the free software provided by the US NCI within the SEER programme 
web-site (https://surveillance.cancer.gov/joinpoint/). 
Independently from the methods described until now, it is noteworthy to remember 
that a reasonable interpretation of age-standardised rates is possible only when the 
trends by age-groups for successive cohorts of birth or periods are parallel on a log 
scale (Estève, 1994). 
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This nudges us that time trends are not as straightforward to interpret as a unique line 
in a graph could enable one imagine. 
 
IARC also presents cancer incidence trends. The extensive series of data published in 
the volumes of Cancer Incidence in 5 Continents are available in CI5plus 
(http://ci5.iarc.fr/CI5plus/Pages/online.aspx). In CI5plus data may be analysed as: time 
trends by period, time trends by age, time trend by birth cohort. This alternative way 
of analysing trends clarifies that time trends represent the combined effects of 
numerous variables: age, period and cohort (Clayton & Schiffers, 1987a,b).  
 
• Age (cancer incidence typically increases with age). It may express an accumulation 
of carcinogenic effects and exposure or a weakening of the immune system or both. 
The risk of epithelial cancers, which comprise 90% of all cancers worldwide, increases 
approximately as the fifth power of age (Armitage & Doll, 1954). 
 
• Period (when there are changes in risk in all individuals at the same point in time, 
regardless of age). It is ‘cross-sectional’ as it involves all ages and cohorts within a given 
period, e.g., a change in detection practice. 
 
• Cohort (when there are changes in risk in successive generations of birth cohort). It 
is longitudinal. 
 
Therefore a specific age-period-cohort analysis which includes all these components 
is necessary for an appropriate interpretation of time trends in general 
(Clayton&Schiffers, 1987a,b) and also for cancer (Rosenberg, 2011). 
 
A broader use of such models in the interpretation of cancer trends was limited by the 
so-called 'drift' or the identifiability problem. Due to the relationship among the three 
terms (the calendar year is the sum of age and year of birth) the components of this 
model are collinear, and therefore the model cannot be uniquely determined 
(Clayton&Schiffers, 1987a,b). 
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 Different methodological options may be implemented to overcome the identifiability 
problem: exclude one of the three components of trend, define constraints, compute 
estimations of second-order differences (Clayton&Schiffers, 1987a,b) or use the 
principle components approach (Tu, 2011). The parametrisation of the age-period-
cohort model is not straightforward either for the factors (Holford, 2006; Carstensen, 
2007) or if we choose to smooth with parametric functions, with splines, fractional 
polynomial or restricted cubic splines (Cartstensen, 2007). 
 
Coping with identifiability is not easy for registrars. However, an efficient way to define 
constraints is based on the epidemiology/biology of the disease. As a consequence, 
the more constraints are epidemiology-based, the more results are interpretable by 
non-statisticians (and the model is simple.) For example, Vaccarella et al., having 
observed that the incidence of cervical cancer was broadly constant after the age of 
45, solved the identifiability problem by constraining the incidence rate to be the same 
at age 45-69 and 65-69 years (Vaccarella, 2013). In another example seeking to analyse 
thyroid cancer trends in Italy, the cohort effect function was set to 1 on average with 
0 slope (Dal Maso, 2011).  
 
Age-period cohort models allow to evaluate the different components underlining 
cancer time trends. The availability of methods for providing more accurate time trend 
estimates increases over time, together with their complexity.  
 
Moreover, changes in incidence are not usually unexpected or sudden (like those due 
to the introduction of screening programmes). Therefore, time trends based on high-
quality data support reliable forecasting of the future short-term burden. 
 
 
In the following Paper (4) the age-period-cohort model is applied for trend analysis, 
and time projections are additionally provided.  
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5.1. Paper 4 
 
The paper has been published in Eur J Cancer Prev. 2007;16: 50-4 with the following 
title: 
 
"Melanoma incidence in central Italy will go on increasing also in the next future: A 
registry-based, age–period–cohort analysis". 
 
Authors: Emanuele Crocettia, Paola Carlib, Guido Miccinesia  
Affiliation: a) Clinical and Descriptive Epidemiology Unit, CSPO, Florence, Italy, b) 
Dermatology Department, University of Florence, Italy. 
Author Contributions: I (EC) declare to have conceived the idea of the study, planned 
and designed it, performed the analysis and drafted the first draft. GB gave a 
substantial contribution to the statistical analysis. The other Authors revised critically 
the paper and approved the final version of the manuscript 
 
Abstract 
The aim of the study was to evaluate malignant melanoma incident trend in central 
Italy by means of an age–period–cohort approach. A total of 1977 malignant 
melanoma (15–84 years) incidents in the area of the Tuscany Cancer Registry between 
1987 and 2001 were analysed. Poisson regression has been used to estimate age, 
cohort and period effect. A nonlinear regression model was used to estimate the 
expected number of new cases in the period 2002–2006. Incidence rates increased in 
all age, period and cohort groups. The model that best fitted the data included age 
and ‘drift’. The linear effect (‘drift’) showed, in each age group, an increase of the risk 
of malignant melanoma diagnosis of about 36.6% every 5 years of period or cohort. 
For the period 2002–2006, 1112 new cases were predicted with a standardised rate 
(age 15–84 years) of 19.2 × 100.000. In the Tuscany Cancer Registry area, no clues for 
malignant melanoma incidence rates levelling off were documented. Growing rates 
and number of malignant melanoma are expected in the next future.  
 
Introduction 
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Malignant melanoma (MM) incidence has increased over the last decades in almost 
all Western countries (Lens and Dawes, 2004). In central Italy also incidence trends 
showed a significant increasing trend in both men and women (Crocetti and Carli, 
2003). More recently, levelling of or even decreasing trends in incidence have been 
identified among young participants in Denmark, in the Netherlands, in Switzerland 
and in the United Kingdom (De Vries et al., 2003). A decrease in incidence among 
young cohorts predicts a future overall decline in rates as soon as these participants 
will contribute to older age groups. 
 
The aim of the present paper was to explore incidence trends for cutaneous MM in 
central Italy focusing on the age, period and cohort effect. 
 
Materials and methods 
Incidence data were retrieved from the Tuscany Cancer Registry (RTT), a population-
based cancer registry active in the provinces of Florence and Prato (about 1160000 
residents in the 2001 census), central Italy, since 1985. The description of the criteria 
for collection, and registration followed by the Registry, has been presented 
elsewhere (Paci 2002). 
 
During 1987–2001, 2071 incident cutaneous melanomas were registered in the RTT; 
in the present analysis, we selected age range 15–84 years and 1977 incident cases 
were included. 
Number of cases and person-years were aggregated in 5- year age groups (from 15–
19 to 80–84 years), 5-year periods (1987–1991, 1992–1997, 1998–2001). Five-year 
cohorts of birth were computed according to age and period. In the figure, cohorts are 
labelled according to the central year of the cohort of birth. 
The incidence rates were standardized using direct method with the European 
standard population as the reference. 
 
Poisson regression has been used to estimate age, cohort and period effect. We may 
consider cohort effects as influences that affect rates in a specified generation or birth 
cohort throughout life, whereas period effects affect rates equally across all age 
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groups at a specified period (Clayton and Schifflers, 1987a). When there is a regular 
temporal trend, which cannot be ascribed to either period or cohort influences, it is 
called ‘drift’. Only when we observe irregular or sudden changes, we can ascribe the 
observed temporal trend to either period or cohort influences. The goodness-of-fit of 
different models was assessed by the deviance. The closer the deviance with the 
degree of freedom, the better the fit of the model. Differences between deviances 
allowed us to compare nested models (e.g. age alone vs. age + cohort) (Clayton and 
Schifflers, 1987b). 
 
The expected number of new cases for the years 2002– 2006 was estimated according 
to a nonlinear regression model, proposed by Dyba et al., (Dyba 1997), including the 
effect of age and age-specific temporal trends. Friendly STATA macros for the 
application of such method for short-term prediction are available on the Web site of 
the European Network of Cancer Registries (http:// www.encr.com.fr/stata-
macros.htm). This model assumes that the absolute change in incidence rate over time 
for a given age group is often larger when the baseline rate is larger. The age-specific 
absolute change of incidence is proportional to the corresponding age-specific 
baseline rate, whereas for a given time period the relative change in incidence is the 
same for all age groups. Owing to these characteristics this model preserves in the 
period of prediction the age pattern of incidence existing in the data, and the age-
specific predicted rates are substantially more precise than those for a linear model 
(Dyba, 1997). 
 
Several methods have been used for making predictions of the future cancer burden; 
the one used in the present analysis showed good performance when compared with 
other methods (Moller, 2003). 
We used the annual sex-specific and 5-year age-specific population for the years 
2002–2006 based on the official data and future estimates of the Regional Office of 
the National Institute of Statistics (years 2002–2003,  2008) and the estimates based 
on the Waring method for 2004– 2006 (Shryock, 1976). 
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Total number of expected cases and prediction intervals are presented. Predictions of 
incidence for each age group are also presented. 
 
Results 
Table 11 (n.1 in the original numeration), shows age-specific and age-standardised 
melanoma incidence rates from the Tuscany Cancer Registry area for three periods 
(1987–1991, 1992–1996 and 1997–2001). 
 
Table 11 (n.1 in the original numeration): Malignant cutaneous melanoma. Number of 
incident cases, age-specific (males and females) and age- standardised (European 
population) incidence rates in the Tuscany Cancer Registry, according to time period. 
a Standardized rates are computed in the population 15–84 years. 
 
   Period  
  1987-1991 1992-1996 1997-2001 
Age (years)    
15-19 0.8 1 2.4 
20-24 2 5.7 6.1 
25-29 3.9 7 10.2 
30-34 5.7 7.6 13 
35-39 5.1 8.4 12.9 
40-44 8.9 11.1 15.2 
45-49 9.5 13.1 18.4 
50-54 10.3 16.3 23.1 
55-59 14.5 17.9 26 
60-64 14.8 19.1 19.4 
65-69 16.2 18 23.5 
70-74 16.2 19.4 25.1 
75-79 15 25.9 31.1 
80-84 14.2 19.7 28.9 
n. of cases 449 636 892 
Standardized 
ratesa 
8.3 11.6 15.9 
 
 
Incidence rates increased in all age groups. The age- specific incident rates increased 
in participants born in more recent years (Figure 8 [n. 1 in the original numeration]), 
and they also increased from the first to the third analysed period (1987–1991, 1992– 
1996, 1997–2001) (Fig. 9 [n.2 in the original numeration]). 
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The model approach used to disentangle age, period and cohort effect showed that 
the model that best fitted the data was the one including age and ‘drift’ (deviance of 
the ‘age + cohort’ model – deviance of the ‘age + drift’ model = 15.7; number of 
parameters of the ‘age + cohort’ model – number of parameters of the ‘age-drift’ 
model = 14; P-value of 15.7 on a X2 distribution with 14 degrees of freedom = 0.392; 
for the age + period model vs. age + drift model; P-value = 0.808). 
 
 
 
Figure 8 (n.1 in the original numeration): Tuscany Cancer Registry, malignant 
melanoma 1987–2001. Age-specific incident rates according to the cohort of birth, 
men+women. 
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Figure 9 (n.2 in the original numeration): Tuscany Cancer Registry, malignant 
melanoma 1987–2001. Age-specific incident rates according to three different periods 
(1987–1991, 1992– 1996, 1997–2001), men+women. 
 
The linear temporal effect (‘drift’) showed that in each age-group, there was an 
increase of the risk of MM diagnosis of about 36.6% every 5 years of period or cohort 
(mean annual increase 6.4%). The model including age and drift resulted the best also 
for explaining incidence data for men and women, when analysed separately (results 
added in Appendix 2 [Supplementary information for Paper 3]; ‘data not shown’ in the 
original paper). 
 
The predicted standardised incidence rate (age 15–84 years) for the period 2002–
2006 was 19.2; the predicted number of new cases was 1090 (95% prediction intervals 
984–1196). 
Figure 10 (n.3 in the original numeration), reports age-specific incidence predictions 
for 2002–2006, together with their prediction intervals. 
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Figure 10 (n.3 in the original numeration): Melanoma of both sexes, Tuscany Cancer 
Registry area. Five-year mean number of observed incident cases in 1987–2001 (solid 
line) and incident cases predicted for 2002–2006 (dashed line) with approximate 95% 
prediction intervals; by age. 
 
Discussion 
The results of the present study indicate that MM incidence rates in the population 
covered by the Tuscany Cancer Registry, central Italy, are still increasing. This trend is 
present in all age groups, and also younger participants, both men and women, do not 
show any sign of levelling off. 
 
The present figure contrasts with that recently found in some northern European 
populations. According to data extracted from the EUROCIM database 165 cancer 
registries, a deceleration in incidence trends occurred recently in Northern European 
countries among persons younger than 70 years; whereas in eastern and southern 
Europe incidence rates were still increasing (De Vries et al., 2003). Therefore, we are 
probably observing a shift between northern and southern European populations in 
terms of future scenarios about the melanoma ‘epidemic’. Earlier detection and a 
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growing public awareness about risk associated with excessive sun exposure are the 
most plausible explanations for the deceleration found in northern Europe (De Vries 
et al., 2003). 
Little is, however, known on the factors still holding up the increasing incidence trends 
in Mediterranean people. 
 
In this study, models including the effects of age, period and birth cohort were used 
to adequately analyse the rising trends. 
 
As known, cohort effect reflects exposures that affect rates in a specified cohort 
equally throughout life, whereas period effect affects rates equally across all age 
groups at a specific period (Clayton and Schifflers, 1987a). An age effect (increasing 
risk according to ageing) and a linear effect are causing the increasing incidence. 
Owing to the linear dependence between the linear part of cohort and period (and 
age) however, the interpretation of regular incidence trend is not possible.  Indeed, 
only when we observe irregular changes we must consider age-period or age-cohort 
models. On the contrary, this so- called ‘drift’ effect represents a situation equally well 
described by two models, age and period (linear) or age and cohort (linear) and cannot 
be ascribed to either period or cohort effect (Clayton and Schifflers, 1987a). 
Although statistics does not allow to disentangle period from cohort effect, some 
suggestions may come from the epidemiological knowledge. 
 
The major environmental risk factor for MM is the intermittent exposure to ultraviolet 
radiation (UV) (Elwood and Jopson, 1997), especially during childhood (Naldi 2000). 
Such exposure has become popular after the Second World War, and in Italy, 
particularly from the second-half of the ‘50s to the early ‘60s as a consequence of a 
rapid economic growth. 
 
The present data are, however, not fully explained by the hypothesis of increasing risk 
for UV exposure during childhood only. In fact, the increase in incidence was 
evidenced in all birth cohorts, also in the oldest ones, in participants who during the 
50ths–60ths were middle-aged. Our results are consistent with the hypothesis that UV 
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exposure increases the MM risk independently from the age of exposure (Elwood and 
Jopson, 1997). Recent data suggest that cutaneous melanomas may arise through two 
pathways, one associated with melanocyte proliferation and the other with chronic 
exposure to sunlight (Whiteman, 2003). Australian patients with head and neck 
melanomas – lentigo maligna melanoma excluded – compared with patients with 
melanomas of the trunk, were statistically significantly less likely to have more than 
60 nevi [odds ratio (OR) = 0.34, 95% confidence interval (CI) = 0.15–0.79] but were 
statistically significantly more likely to have more than 20 solar keratoses (OR = 3.61, 
95% CI = 1.42–9.17); moreover, they were more prone to a past history of excised 
solar skin lesions (OR = 1.87, 95% CI = 0.89–3.92) (Whiteman, 2003).This finding has 
been confirmed in Italian patients (Carli and Palli, 2003). This means that not only 
exposure in early life, generally intermittent, but also cumulative lifelong exposure 
may contribute to melanoma development. Recent data from Creta show that in the 
relatively dark-skinned population, sun exposure indices represent the most 
important risk markers for cutaneous melanoma, which contrast with data from fair-
skinned Caucasian populations in which melanocytic naevi are the main risk factors 
(Lasithiotakis, 2004). Therefore, the change in lifestyle with increasing exposure to UV 
owing to the growing popularity of sunbathing and tanning seem to have affected all 
age-groups as a period effect presumably occurred during late ‘50s–early ‘60s. 
 
On the other hand, more frequent excision of pigmented skin lesions may contribute 
to explain the increasing number of melanomas diagnosed overtime in the Tuscany 
Cancer Registry area by means of a period effect. In the Tuscany area, the awareness 
among population and the development of early diagnosis activity has increased over 
the last decades; a preventive campaign addressed both to family doctors (general 
practitioners) and the general population for the surveillance of pigmented skin 
lesions is active in the RTT area since the late 1980s (Carli, 2002). A Pigmented Lesion 
Clinic working in the Dermatology Department of University of Florence was also 
implemented for rapid referral of participants with self-detected or GP-detected 
suspicious lesion (Carli, 2002). A clue for the effect of early diagnosis was the growing 
rates of ‘thin’ lesions (<= 1 mm) that showed a mean annual increase of about 16.1% 
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from 1985 to 1997 (Crocetti and Carli, 2003). This situation probably explains the role, 
if any, of the period-effect in sustaining the incidence rates. 
 
In conclusion, in the Tuscany Cancer Registry area MM rates will probably go on 
increasing in the next future. According to prediction model, the standardised 
incidence rate (age 15–84 years) for the period 2002–2006 will be 19.2 cases per 
100000, approaching that observed in northern European populations. Although the 
increasing trend was explained by an age-drift model, the two major explaining factors 
– changes in lifestyle with increasing exposure to UV and increased early diagnosis 
seem to have acted more as period than as cohort effects. 
 
References: The original references of the paper have been included in the general list 
of the thesis. 
  
  104 
5.1.1. Comment 
 
The previous paper (Paper 4) shows an example of how the CR’s activity can be 
improved and its potentiality exploited. 
 
The potentiality of the information included in CR’s data is superior to that which is 
normally presented. For example, the data necessary for the analysis of skin 
melanoma cancer (MM) time trends using the method of age-period-cohort are 
already included in those used for traditional annual ASR plotting and provide further 
insights into trend interpretation. 
Therefore, in this example, the limit to overcome is not the quality (looked at in Paper 
n. 1) or quantity (look at in Paper n.3) of the collected data, but it is the ability of CR’s 
personnel to use the most appropriate statistical approach to better address a specific 
topic. 
 
Moreover, high-quality data can also be used, as exemplified in the previous paper 
(Paper 4), to make reliable projections about future cancer burden. These types of 
estimates fulfil a dual objective. On one side, they fill the time gap between cancer 
diagnosis and the availability of cancer incidence rates. Furthermore, if projected in 
the near or far future, they help policymakers in their decision making regarding the 
distribution of the resources needed to satisfy a given population (Erdmann, 2013; 
Nguyen, 2019; Jung, 2019). Projections address specific age-groups, i.e. the elderly 
(Clèries, 2018; Pilleron, 2019), children (Ward, 2019), cancer sites (Araghi, 2018; 
Earnest, 2019; Lewis, 2018; Yu, 2019). 
Projections have not only been applied to cancer incidence, but also to prevalent cases 
(Colonna, 2018; Guzzinati, 2018) and cancer survival (Gondos, 2009). 
 
CRs need to use their data to the best of their potentiality, taking advantage of 
statistical methods. 
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Short-term projections should become the normal praxis for all CRs. Furthermore, 
reliable, high-quality data series’ may be used as estimates of cancer burden (Bray, 
2018) and on specific types of cancer and the stages of disease. (Crocetti, 2018). 
 
A greater understanding of the data and knowing how to better use that which is 
available will make the CR more informative and more useful to the various 
stakeholders. 
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6. Survival estimates from cancer registry data 
 
Cancer survival based on CR data represents a measure of the quality of the healthcare 
system. It refers to the average cancer patient in the population, provided all patients 
have the same access to a similar level of care (Donnelly, 2017). Survival is affected by 
both the time of diagnosis (e.g., availability of screening programmes), and the 
availability and accessibility of effective treatments. 
 
For this reason, survival is among the essential measures provided by registries.  
 
Survival has been particularly valued by the US National Cancer Institute, which in 
1973 planned and financed the Surveillance, Epidemiology and End Results Program 
(SEER), which is still ongoing (Parkin, 2006). 
 
Conceptually, survival represents the length of time between the onset of the disease 
(for registries the date of incidence) and the time an outcome (alive/dead) is verified. 
Death is part of human nature. Therefore, the interest in the investigation of cancer 
survival is to evaluate how cancer affects 'natural' survival (Parkin & Hakulinen 1991; 
Estève 1994). 
 
Any survival analysis needs at least one specific extra variable: the status of life of the 
patients at a certain point in time since diagnosis, identified through high-quality 
follow-up of patients (Capocaccia, 2003). 
 
Many alternative methods have been developed to measure survival in cancer 
patients. They measure the role of cancer in causing death (splitting those patients 
dying from cancer from those dying with cancer but from other unrelated causes). The 
fact that cancer patients also die for different reasons, just as cancer-free people, have 
made the computation and the comparison more complex (Parkin&Hakulinen, 1991; 
Estève, 1994). 
Observed survival measures the real survival of patients who die from their cancer or 
other causes. 
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The aim of analysing survival in a group of cancer patients is to measure all-cause 
survival. The interest is evaluating whether this estimate is lower than what we would 
have observed if the same subjects were unaffected by the disease. If we consider two 
groups of cancer patients with diverse ages, survival will likely be lower for the more 
elderly ones due to the mortality for non-cancer causes. The same occurs when we 
compare survival in two populations of distinct areas, where death due to other 
reasons, may differ. 
Therefore, observed survival is specific for the case-series on which it is computed and 
cannot be directly compared with others or even with the general population without 
cancer. 
The probability of surviving is the result of two components: the effect of the disease 
under study and the overall impact of other conditions. 
 
Net survival is the survival that would be observed if the risk of dying from all causes 
other than the one under study were eliminated (Estève, 1994). 
 
Two methodological approaches allow us to estimate net survival: the cause-specific 
survival and the relative survival measurements. 
 
In cause-specific survival, patients who die from cancer contribute to computation, 
while others do not (Parkin&Hakulinen, 1991). 
 
The other approach, which takes into account the mortality from other causes, is 
relative survival. It is the ratio between observed survival and the survival expected in 
the age-sex-period-area- specific population. Its computation has changed with 
alternative suggested methods (Ederer I, II, Hakulinen) (Ederer 1961 and 1959; 
Hakulinen, 1982). 
 
The effect of demographic characteristics, e.g., age, must also be considered and 
standardised to carry out reliable comparisons (Corazziari, 2004). 
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Not long ago, an alternative framework for the estimation of net survival has been 
proposed (Pohar Perme, 2006). The Pohar Perme method does not estimate relative 
survival (the marginal observed divided by the expected marginal survival.) It does, 
however, estimate net survival in a relative survival setting (rather than a cause-
specific setting). Among the estimators in a relative survival setting, Pohar Perme 
represents the only unbiased estimator of net survival. It assumes the only possible 
cause of death is cancer, eliminating, in comparisons, the distortion which may arise 
from the chance of dying from other causes (Crocetti 2017b). 
 
All these methods, and presumably also others, have been applied by registries to 
describe the experience of a group of cancer patients, by cancer topography, age, sex, 
time since diagnosis, etc. 
 
The study of survival has been exploited by several big consortia which produce 
changes in survival over time and differences across countries (e.g., Concord, 
Eurocare).  
 
The focus on the role in survival of cancer-specific variables has been underlined by 
the so-called high-resolution studies which compared results within and among 
European countries (Eurocare) and worldwide (Concord) (Sant, 2003; Coleman, 2008). 
 
In such studies, the most frequently used approach is the Cox proportional model 
which takes into account the joint effect of numerous variables (Cox, 1972). This 
method is famous not only among registries but also among clinicians (Barraclough, 
2011). 
 
However, the Cox proportional model has a relative approach. For each analysed 
variable, the risk of dying is expressed in comparison with a reference level (risk put 
equal 1). Moreover, when Cox evaluates the independent effect of multiple variables, 
the overall risk is computable using the specific parameters of each variable, which 
requires some mathematical computation. The parameters of the Cox model and its 
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relative approach are unstraightforward to interpret for clinicians and especially for 
cancer patients. 
 
For example, a multivariable Cox model needs some complex computations based on 
the coefficient of the model (exp (coefficient [e.g., sex] + coefficient [e.g., age] 
+coefficient [e.g., Breslow] + coefficient [e.g., Clark] + etc.)) in comparison with all the 
variables in the reference category. 
 
A diverse approach might be to split cancer patients into subgroups in which people 
possess similar characteristics which affect the dependent variable of interest (e.g., 
survival). Belonging to a specific group: e.g., with a particular cancer, sex, age, stage, 
the same for all the people who exhibit these characteristics, corresponds to a specific 
probability of surviving at a certain time since diagnosis. There would not be 
coefficients to sum up, the approach would not be relative, but it would be a clear and 
straightforward answer to a vital question. 
 
One of these methods is the classification and regression tree (CART) analysis, 
proposed by Breiman, as a decision tree methodology (Breiman, 1984 and 2001). The 
method, based on non-parametric statistics, if applied to a group of data, uses a binary 
recursive process to create a tree of subgroups. These subgroups are mutually 
exclusive and exhaustive. Each of them includes subgroups of patients (all with the 
same characteristics in each group) with different profiles for a given outcome. For 
example, more or less aggressive prostate cancer (Spurgeon, 2006), lower limb 
lymphedema (Spillane, 2010), melanoma histotype associated with CDKN2A genotype 
(Sargen, 2015), a serum biomarker panel which predicts nodal status in lung cancer 
patients (Borgia, 2009), and also differences in terms of survival, including melanoma 
(Garbe, 1995; Staut, 2010), just to mention some of the relatively few examples 
available in literature. 
 
The topic of understandability of scientific information has to be considered for 
providing to cancer patients not only reliable but also useful information. 
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The following Paper (5) deals with the way cancer prognostic information are provided 
with alternative approaches: Cox model and CART analysis. 
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6.1. Paper 5  
The paper has been published in Melanoma Res. 2006;15: 429-33 with the following 
title: 
 
"Prognostic variables and prognostic groups for malignant melanoma The information 
from Cox and Classification And Regression Trees analysis: an Italian population-based 
study". 
 
Authors: Crocetti Ea, Mangone Lb, Lo Scocco Gc, Carli Pd. 
Affiliation: a) Tuscany Cancer Institute, Tuscany Cancer Registry, Clinical and 
Descriptive Epidemiology Unit, Centre for the Study and Cancer Prevention, b) Reggio 
Emilia Cancer Registry, Epidemiology Unit, Public Health Department, Reggio Emilia, 
c) Dermatology Unit, Hospital, Prato, Italy, d) Dermatology Department, University of 
Florence, Florence, 
Author Contributions: I (EC) declare to have conceived the idea of the study, planned 
and designed it, performed the analysis and drafted the first draft. The other Authors 
revised critically the paper and approved the final version of the manuscript 
 
Abstract 
The common way to analyse the prognostic role of selected variables in cutaneous 
melanoma patients is by means of Cox proportional hazard model. The prognostic 
effect of the simultaneous presence of more than one independent variables in the 
same patients is, however, difficult to establish. This hampers the possibility of 
tailoring a survival expectance for a selected patient as well as to communicate it to 
the patient himself/herself. The objectives of the study were to compare information 
on cutaneous melanoma prognosis from multivariate Cox proportional hazard model 
and from Classification And Regression Trees analysis. Classification And Regression 
Trees analysis is an automatic method that splits data by means of a binary recursive 
process creating a ‘tree’ of groups with different profiles according to the analysed 
outcome, for example, the risk of death. This approach automatically produces data 
easy to be interpreted by clinicians. A total of 1403 invasive cutaneous melanoma, 
1100 from the Tuscan Cancer Registry and 293 from the Reggio Emilia Cancer Registry, 
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Italy, were included. Cases were incident during 1996–2001 and followed up at the 
end of 2003. Cox proportional hazard model and Classification And Regression Trees 
analysis were applied to the following variables: age, sex, Breslow thickness, Clark 
level, Registry, sub-site and morphologic type. The Classification And Regression Trees 
analysis identified 10 categories with statistically different survival; this results were 
summarized into six classes of different risks based on Breslow thickness, age and sex. 
The best prognostic group (5-year observed survival, 98.1%) included those subjected 
with Breslow less than 0.94 mm and age 19–44 years. The same thickness but an older 
age (50–69 years) was associated with a statistically significant different prognosis (5-
year observed survival, 92.8%). The Cox proportional hazard model found sex, age, 
Breslow thick- ness, Clark and morphologic type to have a significant independent 
prognostic value. In conclusion, compared with conventional approach based on Cox 
hazard model, Classification And Regression Trees analysis produces data closer to the 
clinical need of defining the prognostic profile of a specific patient. This may help the 
clinician both in the communication of risk and in the follow-up strategy.   
 
Introduction 
For malignant cutaneous melanoma (CM), the identification of prognostic factors has 
a crucial value for both dermatologists and patients. According to new evidence on 
effective prognostic factors, the CM staging system has changed during recent years 
(Balch 2000; Balch 2001; Black 2003; Black 2004). 
 
Usually, more factors act together, for example, thickness, age, site, Clark’s level of 
invasion, ulceration, sex, etc., (Balch, 2001), and therefore their cumulative effect 
should be evaluated by means of multivariate models. The use of multivariate Cox 
proportional hazard model for survival analysis is common in the scientific literature 
(Cox, 1972). For example, in the PubMed library, more than 900 papers matched a 
search for the terms ‘Cox AND survival AND cancer’, among those published during 
the year 2005 (overall 671163). By means of this statistical approach however, the 
clinical relevance of the simultaneous presence in a patient of more than one 
independent prognostic factor cannot be easily established. This is a pity, as the 
possibility for the clinician of tailoring a prognostic profile for each patient taking into 
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account the role of independent survival predictors simultaneously present would be 
clinically relevant both to plan follow-up and to communicate the personal risk to the 
patient him/herself. 
 
During the last two decades, a tree-building technique has been slowly entering the 
literature. It is the so-called Classification and Regression Tree (CART) analysis 
(Breiman, 1984). This is an automatic method that splits data by means of     a binary 
recursive process creating a ‘tree’ of groups with different profiles according to the 
analysed outcome, for example, the risk of death. Although this approach 
automatically produces data easy to be interpreted by clinicians, it does not seem to 
be very popular yet. 
 
The aim of the present study was to compare malignant melanoma survival 
information from both Cox and CART approaches in a multicentric population-based 
Italian data set. 
 
Materials and methods 
In the present study, invasive CM incident in the period 1996–2001 in the area of the 
Tuscany Cancer Registry (RTT) and of the Reggio Emilia Cancer Registry (RECR) were 
included. 
 
Both RTT and RECR are located in central Italy and are included in the Italian Network 
of Cancer Registries (AIRT, www.registri-tumori.it). Further details on their 
organisation and data management are available for RTT at 
http://www.cspoweb.it/rtt.asp and for RECR at 
http://www.ausl.re.it/Home/DocumentViewer.aspx?ID = 773&-TIPODOC = IAP. 
Overall, 1403 malignant melanoma were analysed (1110 from RTT and 293 from 
RECR). 
Follow-up has been carried out up to 31 December 2003 or death, whichever comes 
first. The mean follow-up time was 4.2 years, ranging from 0 to 8 years (median follow-
up, 4.0 years). 
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The CART analysis was used to identify different prognostic groups. This is an 
automatic method that build up a ‘tree’ by means of a binary recursive partitioning of 
data. Full data are evaluated for all the possible binary splits. It means that the method 
evaluates the possibility of splitting each variable into two groups if there is a 
statistically significant difference according to the analysed outcome (e.g. risk of 
death). The process repeats building up a tree until all groups are unsplittable 
(Breiman, 1984). 
 
The variables included in the CART analysis were as follows: sex (males, females), 5-
year age classes, registry (RTT, RECR), Breslow’s thickness (continuous), Clark level (2–
5, missing), site (head and neck, trunk, upper arm, lower arm, not specified), 
morphology (superficial spreading – SSM, nodular, others, not otherwise specified). 
We chose not to analyse separately lentigo maligna melanoma owing to their small 
number, n= 31). 
Information on lymph node involvement was not available. 
 
CART uses the martingale residuals of a Cox model to calculate (approximate) w2 
values for all the possible cut points on all the CART covariates. The significant value 
for cut point definition was 0.05. The minimum size of the group was defined as 30 
participants. 
Once CART had identified different groups, Kaplan and Meier survival curves were 
computed and compared by means of log-rank test (Mante 1966). Only statistically 
significant groups were considered for the definition of the final groups of patients 
with significantly different risks of dying. 
 
Moreover, we analysed the prognostic role of the same variables also in a more 
conventional approach by means of the Cox conditional hazard model. Within each 
variable, the statistical significance of the difference between values has been 
evaluated; the original variable definition has been modified according to the 
comparison, in particular the site has been recoded as head and neck, other specified, 
not specified. 
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The variables that showed a significant effect in the univariable analysis were included 
in a multivariable Cox proportional hazard model to evaluate their independent effect. 
By means of a step-forward approach, the effect of each variable in improving the fit 
of the model was evaluated with the likelihood ratio test. 
The product-limit estimate according to Kaplan and Meier was used for computing 
overall and variable- specific observed survival probabilities (Kaplan, 1958). 
The analysis has been performed by Stata 8 (www.stata.com). 
 
Results 
The analysis was based on 1403 patients with newly diagnosed, incident CM; during 
the follow-up (mean time, 50.5 months) 343 of these patients died. 
 
The overall observed survival was 93.1% at 1-year, 82.7% at 3-year and 74.7% at 5-
year period. 
 
In the CART analysis, 1154 patients with complete information for sex, age, Breslow’s 
thickness, Clark’s levels, registry, sub-site and morphology were included and all those 
variables were evaluated. The main relevant split involved Breslow’s thickness 
identifying lesions thinner and thicker than 2.25 mm. The second split of the 
regression tree involved age classes. The third split was based on sex, and again on 
Breslow's thickness, as the fourth one (Fig. 11 [n.1 in the original numeration]). 
 
The CART analysis identified 10 prognostic groups according to Breslow's thickness, 
sex and age. For each of these groups, Kaplan and Meier survival curves were 
computed and compared by means of log-rank test. When there was no statistical 
difference in survival between groups, they were summed. The result produced six 
groups of patients with significantly different risks of dying (Fig. 12 [n.2 in the original 
numeration]). 
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Figure 11 (n.1 in the original numeration): Classification And Regression Trees with the 
following variables: sex, registry, sub-site, age, Breslow, Clark and morphology. Split if 
(adjusted) P < 0.05. RHR, relative hazard ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 (n. 2 in the original numeration): Kaplan–Meier survival rates of the six 
prognostic groups defined by Classification And Regression Trees analysis (groups 
definition is given in Table 12). 
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In Table 12 (n.2 in the original numeration), the CART results are used to show a 
straightforward way to define these six prognostic groups according to Breslow, age 
class and sex. The best prognostic group (5-year observed survival, 98.1%) included 
male and female patients with Breslow's thickness less than 0.94 mm and aged 19–44 
years. The same thickness but an older age (50–69 years) was associated with a 
statistically significant different prognosis (5-year observed survival 92.8%). The 
prognosis was good (85.9% at 5 years) for both men and women, with Breslow's 
thickness between 0.93 and 2.24 mm and age 10–64 years or for females with 
thickness less than 2.25 mm. The next group (5-year survival, 63.5%) included men 
aged 65–74 years with Breslow < 2.25 mm and both men and women aged 15–69 
years with Breslow >= 2.25 mm. The prognosis was poor (5-year survival, 53.5%) for 
men with Breslow thickness < 2.25 mm and age 70 + years and for women with 
Breslow thickness 2.25–4.99 mm and age 70 + years. The group with the worst 
prognosis (5-year survival, 17.1%) included participants of 70 or more years of age, 
women with Breslow >= 5.00 mm, or men with Breslow >= 2.25 mm. 
 
Table 12 (n.2 in the original numeration): Malignant melanoma, 1996–2001. 
Prognostic groups according to Classification And Regression Trees analysis. Each 
group is defined according to the characteristics of the included patients, for example, 
male and female patients with Breslow lower than 0.94 mm, 19–49 years old belong 
to the group with excellent prognosis. 
 
  Prognostic factors 5-year 
observed 
survival 
Group of 
prognosis 
N. Breslow 
mm 
Age 
years 
Sex % 
Excellent 273 <0.94 19-49 F/M 98.1 
Very good 189 <0.94 50-64 F/M 92.8 
Good 318 0.93-2.24 
<2.25 
10-64 F/M 
F 
85.9 
Medium 209 <2.25 
>=2.25 
65-74 
15-69 
M 
F/M 
63.5 
Poor 72 <2.25 
2.25-4.99 
75 
70+ 
M 
F 
53.5 
Very poor 93 >=5.00 
>=2.25 
70+ 
70+ 
F 
M 
17.1 
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Data on traditional survival analysis based on univariate approach followed by 
multivariate Cox regression models are shown in Table 13 (n. 3 in the original 
numeration). The survival was significantly higher among women than among men, 
among younger patients (< 60 years) than among older ones, for melanoma with 
Breslow thickness less than 1 mm than for >= 1 mm, for smaller Clark’s levels, for 
specified subsites (or not-specified ones) than for head and neck and for superficial 
spreading melanoma than for not specified ones. No statistically significant differences 
were evidenced between the two registries. 
 
Discussion 
The population-based series of CM analysed in this study resulted perfectly in line with 
that expected – according to the literature – in terms of overall 5-year survival (75%) 
and significance of major variables of risk of death. Indeed, the conventional Cox 
hazard analysis showed that Breslow thickness, sex, Clark level, morphology and age 
resulted in independent prognostic variables (Leiter, 2004; Garbe, 1995). 
 
In this study, a CART analysis of survival was performed in order to easily investigate 
what happens when more than one independent prognostic variables are present in 
a patient. CART analysis enables clinicians in identifying subgroup of risk – 
characterised by the simultaneous presence of more than one variable – that differ 
significantly among them in terms of survival. Indeed, by means of this approach, the 
identification of different subgroups of risk is possible, with easier risk communication 
and, eventually, a more patient-tailored follow-up strategy. 
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Table 13 (n.3 in the original numeration): Malignant melanoma. Crude and adjusted 
risk of dying (hazard ratio - HR) for several prognostic variables with corresponding 
95% confidence intervals (95% CI). The multivariate model includes sex, age, Breslow's 
thickness, Clark's level and morphology subtype. n.o.s., not otherwise modified. 
 
Variable N. Crude 
HR 
95%CI Adjusted 
HR 
95% CI 
Sex      
Woman 762 1  1  
Men 644 1.40 1.14-1.73 1.30 1.05-1.61 
Age (annual)      
<60 784 1  1  
60+ 622 3.73 2.95-4.70 2.92 2.30-3.71 
Registry      
Firenze 1113 1 0.73-1.24   
Reggio Emilia 293 0.96    
Breslow (mm)      
<1 631 1  1  
>=1 524 3.93 2.95-5.23 1.97 1.27-3.07 
Missing 251 5.39 3.95-7.37 1.76 0.96-3.23 
Clark      
2 396 1  1  
3 361 1.60 1.06-2.41 1.09 0.67-1.76 
4 337 4.04 2.79-5.84 1.45 0.84-2.51 
5 48 11.08 6.85-17.9 2.89 1.51-5.53 
Missing 264 5.72 3.95-8.29 1.79 0.93-3.45 
Site      
Head&neck 136 1  1  
Other specified 1085 0.43 0.32-0.57   
Other unspecified 135 0.91 0.63-1.32   
Morphology      
SSM 903 1  1  
Nodular 133 3.72 2.76-5.03 1.59 1.14-2.22 
N.o.s. 225 4.14 3.21-5.33 2.23 1.61-3.08 
Other 142 2.07 1.44-2.97 1.19 0.81-1.73 
 
 
In the present study, the CART analysis constructed a pruned tree of 10 groups. 
Breslow thickness defined the first and the third split (Leiter, 2004; Garbe, 2002). 
Moreover, the cut-point automatically identified by the software in the third split (0.94 
mm) almost overlapped the well-accepted limit of 1 mm used to separate thin from 
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thick melanomas. The original 10 groups were reduced, according to Kaplan and Meier 
comparisons, into six homogeneous groups with statistically significant different risks 
of dying. The attribution of a patient to the corresponding group seems very simple 
and it is based on the age, sex and Breslow. Using this method, it is possible to define 
the prognosis of a patient in a qualitative (from excellent to very poor) and 
quantitative (from 98.1 to 17.1% survival at 5 years) way. For example, facing a patient 
with a melanoma thinner than 0.94 mm, the prognosis significantly changes according 
to age with better 5-year survival (98.1%) if the patient is younger than 44 years than 
that expected if older than 50 (92.8%, P < 0.01). It is interesting that the effect of sex 
as independent prognostic factor seems to act for some subgroup, only when 
balanced with the effect of major predictors of risk as Breslow thickness and age. 
Indeed, the sex was not able to significantly modify the risk of dying facing the 
subgroups at better prognosis (defined in this study excellent and very good (5-year 
observed survival, more than 92%); on the contrary, sex was statistically relevant 
facing the other groups at less favourable prognosis. 
 
The results from the present study may be influenced by the number of cases included 
and by the underline tumours characteristics; however, the three prognostic variables 
identified in the present study were the same as that in a study including 11 688 
German patients (Leiter, 2004). 
 
The use of the results from Cox analysis seems not so easy. In fact, Cox model produces 
for each variable coefficients (b) that show the relationship between the specific value 
of the variable and the outcome. The overall risk should take into account all the 
computed coefficients, according to the following formula: ex- p(coefficient [e.g. sex] 
+ coefficient [e.g. age] + coefficient [e.g. Breslow] + coefficient [e.g. Clark] + etc.) in 
comparison with all the variables in the reference categories. 
 
Although the CART approach has more closeness to the clinical reasoning process than 
regression models, it is not as common as expected. The main reason for the low 
dissemination of CART seems to have been just the low diffusion itself that had 
hampered both the growth of statistical interest and knowledge on it and therefore 
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the availability of specific procedures within more diffused software packages. 
Although it has been criticised (Marshall, 2001), its application has also been 
suggested (Lemon, 2003), and the method has been developed over time (Friedman, 
2003), also to overcome the limits of traditional models (Xu, 2002). As regards the 
latter point, one of the advantages of CART analysis is just to be a nonparametric 
method that works with quantitative and qualitative data without any assumptions on 
their distributions (Lewis, 2000). 
 
The present method has several appeals for clinicians: its automatic process, the easily 
interpretable results and the growing availability of software packages (Lewis, 2000). 
The number of papers that use this method to evaluate cancer prognosis is growing, 
and this will stimulate discussion and knowledge on this possibly very useful clinical 
tool. 
In conclusion, the present study contributes to demonstrate the possible usefulness, 
in addition to traditional approach, of the CART analysis for defining the risk profile of 
a melanoma patient in a clinical set. 
 
References: The original references of the paper have been included in the general list 
of the thesis. 
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6.1.1. Comment 
 
The general idea behind my thesis is that CR's data has to be of good quality and as 
informative as possible. Only in this way, can it be useful to the largest number of 
possible stakeholders.  
Cancer patients and clinicians are among the principle stakeholders. The previous 
paper (Paper 5) addresses the aspect of prognosis and compares two ways in which 
to communicate the outcome. Therefore, the topic is communication (how to give a 
prognosis) between oncologists and cancer patients. 
 
Getting cancer patients to fully comprehend their prognosis is still an on-going 
problem (Cartwright, 2014). For example, 39% out of a sample of metastatic breast 
cancer patients were unaware of their real prognosis (Shin, 2016). In a study carried 
out in Japan, involving two samples of patients and radiation oncologists, more than 
half of the patients reported that they had not discussed, as they would have liked to, 
their life expectancy. In general, there was little agreement between patients and 
clinicians as to whether the prognosis had been discussed (Mackenzie, 2018). It is also 
complex and difficult for oncologists and patients to reach an agreement. In a recent 
paper, which addresses this topic concerning head and neck cancer patients, the 
Authors (Dronkers, 2018) prepared guidelines about sharing prognostic information. 
They suggested, among other things, 'to assure that the information given in the 
prognosis is as accurate and as specific as possible to the individual patient and to use 
the information in a 'digestible way ' (Dronkers, 2018).  
 
Moreover, variables related to the patient may influence their understanding. For 
example, the capacity of breast cancer patients to understand their disease and 
treatment has been seen as highly correlated to them having received higher 
education, daily Internet access and being in paid employment. These factors gained 
the highest scores on disease prognosis knowledge (Berger, 2018). However, in 
general, patients’ knowledge of their disease increases during the course of their 
treatment (Berger, 2018; Engqvist Boman, 2017). 
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The National Cancer Institute in the US, which has a website set up for patients, 
includes a section on the ‘Questions to Ask Your Doctor about Your Diagnosis’. One of 
the questions listed is: “What are my chances of survival?” 
(https://www.cancer.gov/about-cancer/diagnosis-staging/questions). 
The possessive adjective 'my' helps to clarify why a method like CART analysis would 
be appealing to both clinicians and patients. CART is capable of theoretically answering 
this question (giving a prognosis to those patients who share the same personal and 
cancer characteristics). 
 
The use of the Cox model is widespread. However, the interpretation of the hazard 
ratio (HR) produced by such a model may not be straightforward to clinicians. HRs are 
commonly interpreted as relative risks. The reading may cause a misinterpretation of 
the clinical relevance of the treatment effect (Case, 2002; Trinquart, 2016). ‘The mean 
limited survival time’ (Pak, 2017; Trinquart, 2016) has been proposed as an alternative; 
it offers intuitive, clinically meaningful interpretation (Pak, 2017). 
 
As regards to CART and nomograms, a comparison of the capability of predicting 
prostate cancer-related outcomes, revealed a better predictive performance of the 
nomogram. Moreover, the Authors stated that CART (and other tested methods) rely 
on methodologically sound and valid alternatives (Chun, 2007). 
In the field of urology nomograms and CART have been considered the best aids in 
decision making out of those available (Shariat, 2009).  
Nevertheless, the CART analysis has been applied to identify the predictive variables 
to be included in a nomogram (Makkouk, 2017). 
 
One of the substantial criticisms raised against CART is the choice of the variables 
which relies on a mathematical algorithm which maximises the model’s discriminant 
ability (Shariat, 2009). 
However, this is not the application I propose.  
On the contrary, once the prognostic (or predictive) variables are identified, the CART 
could be applied to split patients into homogenous groups.  
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After the publication of Paper 5 (in 2006), the use of CART analysis has been 
documented many times in scientific literature to address different clinical outcomes. 
Some examples are illustrated below. 
CART analysis has been applied: 
- to measure the prognostic effect of lymph node dissection (in particular more than 
ten lymph nodes) in women with corpus uterine cancer (Abu-Rustum, 2008); 
- to stratify risk groups for pulmonary complications after lung resection, in resected 
lung cancer patients (Kim, 2012); 
- to distinguish low-risk sub-groups in melanoma stage III patients for which adjuvant 
therapy may not be warranted (Egger, 2013); 
- to evaluate which clinicopathologic factors (age, stage, tumour subtype, grade, 
myometrial invasion, total lymph nodes removed, and para-aortic lymph node) 
influenced overall survival (OS) in endometrial cancer (Barlin, 2013); 
- to identify different prognostic groups with different molecular subtypes of ovarian 
cancer (Lu, 2016); 
- to investigate the risk factors for bone-only metastasis in advanced breast cancer 
patients (Diessner, 2016); 
- to find optimal cut-offs points for prognostic variables identified by Cox model in a 
cohort of myeloid leukaemia patients in blast phase (Jain, 2017);  
- to identify three risk levels which could be incorporated into the TNM staging system 
for nasopharyngeal cancer patients (Yuan, 2017); 
- to classify patients with surgically resectable micropapillary bladder cancer in three 
risk groups (low, high, highest) under continuous observation and disease-free 
(Fernández, 2017); 
- to develop a prognostic transcriptome molecular staging model for oesophageal 
squamous cell carcinoma in China (Guo, 2018); 
- to develop a polygenic approach (genes, their regulators, and DNA repair genes) to 
identify various polymorphic variants in determining lung cancer susceptibility 
(Bhardawaj, 2018); 
- to identify the predictors of treatment-related (eribulin) toxicity in advanced soft 
tissue sarcoma of Japanese patients (Kobayashi, 2019); 
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- to develop an algorithm that has achieved high accuracy in being able to identify 
breast cancer recurrences using available administrative data in a universal health 
system in Canada, (Xu, 2019). 
 
However, although there is much scientific literature based on the CART application, I 
was unable to find anyone who could compare whether the prognosis was 
understandable to the cancer patients, using the different statistical approaches. 
 
Therefore, a formal study comparing the understandability of HRs (from Cox) and 
patient groupings, (from CART) should be planned and analysed with qualitative 
methods (Cartwright, 2014). Hence, if the CART application should prove more 
effective in informing patients than other approaches, it could open the road for its 
widespread clinical application.  
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7. Evaluation of cancer care 
 
The previous papers (Paper 1-5) display some of the indexes produced by registries 
and their use.  
Among the purposes of registries’ data, there is also the evaluation of the quality of 
the diagnostic and therapeutic pathways and their agreement with clinical guidelines 
(Jensen&Storm, 1991). The sources of information of CRs represent many of the 
‘contacts’ of patients with the health systems: e.g., screening participation, out-
patient visit, biopsy, hospitalisation, surgery, bio-marker testing, prescriptions, 
chemotherapy, radiotherapy, palliative care. Moreover, the number of sources has 
increased over time, thanks to the digitalisation of the health systems.  
 
Therefore, CRs can describe the patients care throughout the pathway from the date 
of diagnosis until death. 
 
The population-based point of view of a registry allows it to measure real-world care 
and effectiveness, appropriateness, accessibility and equity in treatments (Spitale, 
2017; Malin, 2006; Schneider, 2004). 
 
Appropriateness remains a relevant topic due to the documented overuse of 
unnecessary health services and sometimes can be unsustainable for single patients 
and healthcare systems (Grilli, 2018). 
 
Sustainability of cancer care is a general and recognised concern in the light of the 
simultaneous increase in the number of cases and cost of care. Therefore, the 
evaluation of quality of care can also be helpful to address such issue (Campbell, 2000). 
Moreover, considering the long-time necessary to accomplish the full registration 
process (Zanetti, 2015), short term deliverables should also be considered. 
Cancer-specific indexes focusing on diagnosis and/or treatment could represent the 
ideal target for such type of short-term deliverables. 
Clinicians, policymakers and cancer patients could all be interested in a measure of 
the quality of diagnosis and care at the population level. 
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The analysis of the distribution of cancer-specific treatments in different area hospitals 
and services and the comparison between volumes and outcomes of activity can 
identify too low volumes of clinical or surgical care inconsistent with a similar offer in 
the same healthcare system with an elevated level of experience and capability 
(Amato, 2017). Proper management is even more challenging for rare cancers for 
which the need for, and effectiveness of specific networks are underlined (Gatta, 
2017; Nicolai, 2018). 
 
Registries have to collaborate with clinicians and policymakers in the evaluation and 
improvement of quality of care (Jochems, 2017; Spitale, 2017). 
The quality of the whole clinical path should be evaluated, including, for example, 
palliative care in terminally ill patients (Ziegler, 2018). 
 
Many registries are presently working on this topic (e.g., Spitale, 2017; Andreano, 
2016; Andreano, 2018; Sacerdote, 2016; Vrijens, 2018; Vlayen, 2012; Stordeur, 2012) 
contributing to increasing knowledge on the quality and accessibility of the best 
possible care in the real-world setting. 
 
The next paper (6) presents a pioneer experience - at least in Italy - which started 
assessing the feasibility of an evaluation of quality of care based on indexes 
computable based on registry and health records for the most frequent cancer sites 
(Caldarella, 2012). 
 
The usefulness of CR’s data manifests measuring and evaluating clinical care of 
melanoma at the population-level based on indicators. To measure and highlight, with 
high-quality indexes, points of weakness contributes to circumscribe the areas 
(services, procedures) that need to be improved to offer a better quality of care to 
patients. Therefore, the stakeholders of this activity of CRs are several: policymakers, 
clinicians, patients and citizens. 
 
  
  128 
7.1. Paper 6 
The paper has been published in Melanoma Res. 2013; 23: 283-9 with the following 
title: 
 
"Indicators of the standard of care for melanoma: Tuscany data".  
 
Authors Crocetti Ea, Caldarella Aa, Massi Db, Sacchettini Ca, Amunni Ga,d, Borgognoni 
Lc. 
Affiliation: a) Clinical and Descriptive Epidemiology Unit and b Melanoma Early 
Diagnosis Service, Institute for Cancer Study and Prevention ISPO, Florence, Italy, b) 
University of Florence, Florence, Italy, c) Plastic and Reconstructive Surgery Unit, 
Regional Melanoma Referral Centre, S.M. Annunziata Hospital, d) Tumour Institute of 
Tuscany (ITT), Florence, Italy 
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Abstract 
Formal indicators for the evaluation of the quality of melanoma care are needed. We 
identified 13 process indicators, which encompassed early diagnosis, pathology 
reporting and surgical treatment. We evaluated the adherence to these indicators 
using a population-based series on incident skin melanomas (only primary 
melanomas) for the year 2004 (687 cases) and for the first semester of 2008 (539 
cases). We compared the indicators for the 2 years. The melanoma incidence 
increased between 2004 and 2008. There were statistically significant increases in the 
percentage of thin (<= 1 mm) melanomas (from 50.7 to 61.3%) and in the number of 
pathology reports that mentioned ulceration (from 61.4 to 84.6%) and margin statuses 
(from 76.8 to 84.3%). The percentage of patients staged by sentinel lymph node biopsy 
was stable (63%) and was higher for patients younger than 75 years of age (74%). The 
number of nodes almost invariably exceeded the proposed site-specific cutoff 
reference, and, in 2008, the number of nodes removed was always reported for 
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lymphadenectomy. From 2004 to 2008, surgical and pathological waiting times 
increased. Collection and analysis of these indicators would enable continuous 
evaluation of the quality of melanoma care in Tuscany and provide sources for a 
comparative study between Italy and abroad. 
 
Introduction 
The incidence of skin melanoma has greatly increased in Italy during recent years 
(Airtum, 2009), as in many other western countries. In Tuscany (central Italy), cancer 
care is coordinated by the Tumour Institute of Tuscany (ITT), a network-based Institute 
that organises and supervises public health services in the community with the aim of 
providing optimised cancer treatment. The ITT also conducts studies on tumours 
(http://www.ittumori.it). In particular, in 2007, it published clinical recommendations 
to standardise diagnostic and therapeutic pathways for skin melanoma for specialists 
and hospitals throughout the region. On the basis of the ITT’s recommendations, the 
standard and effective treatment for cutaneous melanoma is now surgery-based (ITT, 
2007). As most skin melanomas are diagnosed early (when, in most cases, the lesion 
is thin) (Crocetti, 2010), complete pathological examination and timely surgery 
represent the best option for the majority of patients. To reduce variability in cancer 
care procedures and improve the general quality of care, the ITT works on the basis of 
indicators. Specific indicators for breast, lung, colorectal and ovarian cancer care are 
available (Caldarella, 2012). 
 
The role of indicators in evaluating clinical care is increasing (Mainz, 2003; Mainz, 
2009). However, to our knowledge, in Italy, there are no formal indicators for care 
quality for melanoma. In the USA, the four measures available in the National Quality 
Measures Clearinghouse address only a few points in the clinical course (diagnosis, 
imaging and follow-up, http://www.qualitymeasures.ahrq.gov/), although further 
indicators, mainly for surgical treatment, have recently been evaluated (Bilimoria, 
2009). 
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This paper aims at evaluating the clinical care of melanoma in Tuscany through formal 
indicators and gauges whether ITT recommendations have succeeded in instituting 
and improving standardised patterns of care 
 
Materials and methods 
Setting and study population 
We first evaluated primary skin melanoma cases occurring in Tuscany between 2004 
and 2008, excluding melanomas with unknown primary sites. We retrieved melanoma 
incidence data for 2004 from the archive of the Tuscan Regional Cancer Registry 
(RTRT), a population-based cancer registry that collects data from several information 
sources, including hospital discharge notes, pathology reports, and death certificates 
(Paci, 2007). The RTRT was, however, not active in the Tuscan province of Arezzo in 
2004, accounting for 330123 out of 3566071 Tuscan inhabitants. 
 
We identified melanoma cases occurring in 2008 from the regional pathology archive 
(http://web.rete.toscana.it/attinew/?LO=00000001a6b7c8d9000000030000003400
003f7a397d5a0f0000000000012b8000000000000000000000000000000000000000
000000000000000000000000000000000000000000&MItypeObj=application/pdf), 
which includes all pathology reports, positive or uncertain, for cancers, as defined by 
SNOMED (vers. 3) morphology codes M-8**** and M-9****. We also collated the 
incidence of the term ‘melanoma’ in each pathology report from the first semester of 
2008 (from January to June). We included individuals residing in Tuscany and 
restricted our interest to those with primary melanomas, making sure that the 
individuals had no pathology reports or hospital discharge notes, nor had they 
undergone any outpatient treatment for melanoma in previous years. When 
melanoma-related reports were not available (neither in the RTRT nor in the regional 
pathology archive system), as was the case with a few individuals, we searched 
through the reports in the regional pathology departments. In total, we analysed 687 
melanomas from 2004 (161, 23.4% in situ) and 539 from the first semester of 2008 
(143, 26.5% in situ). For each patient, we collected and detailed information on 
pathology characteristics, diagnostic methods, staging and type and dates of surgery. 
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THE LIST OF INDICATORS 
Working groups within the ITT studied specific cancers in depth, in order to better 
define and exchange experiences on specific topics and to make better clinical 
recommendations. The melanoma working group is a multidisciplinary panel of 
individuals and institutions, each belonging to the regional cancer network, including 
experts in melanoma (dermatologists, pathologists, surgeons, oncologists and 
epidemiologists), academic institutions and community hospitals. In 2007, the ITT 
published a set of recommendations on the diagnosis and treatment of melanoma 
based on the investigations of the melanoma working group, whose components 
agreed upon a consensus procedure based on scientific literature and on their 
experience (ITT, 2007). 
 
The ITT Melanoma Working Group (see Acknowledgements) identified a preliminary 
set of indicators by analysing scientific guidelines on melanoma diagnosis and 
treatment, literature reviews (Lilford, 2007; Garbe, 2010; Garbe, 2012; Marsden, 
2010; AIOM, 2013; Coit, 2009; Dummer, 2011; Dummer, 2012; Morton, 2006; Aitken, 
2006; Carli, 2003; Carli, 2001; Schiffner, 2003; Wagner, 2000; Lens, 2008; Garbe, 2007; 
Erickson, 2008; Blazer, 2007; Riker, 2006; Lavie, 2007; Eddy, 2003; Wright, 2011; 
Mocellin, 2011; Sladden, 2009; Lens, 2007; Haigh, 2003; Borgognoni, 2004; Amersi, 
2007; Sondak, 2007; Cook, 2003; Cook, 2008; Chakera, 2009; Lens, 2002; Greene, 
2002) and panel discussions. A necessary condition while selecting the indicator was 
that only data from the Cancer Registry could be used, so that a homogeneous analysis 
could be carried out and objective results valid for the whole of Tuscany could be 
obtained. After meetings, discussions and email exchanges, the Group selected 13 
indicators. The chosen indicators measured the appropriateness of the clinical care 
procedure on the basis of ITT recommendations (ITT, 2007) and encompassed the 
diagnosis, pathology reporting and surgical treatment of melanoma care. 
 
STATISTICAL ANALYSIS 
We calculated percentages and medians for quality measures using the w2-test or 
median test to compare values between the years. The results were reported at a 
regional level but were also available at subregional levels for local use. 
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Results 
Table 14 (n.1 in the original numeration), presents the selected quality indicators. 
Table 15 (n.2 in the original numeration), compares the average regional values of 
each quality indicator for 2004 and 2008. 
 
1. Percentage of incident cases <= 1 mm 
The thickness of a melanoma is one of the most relevant prognostic factors. The ITT 
and other recommendations state that a pathology report must specify the thickness. 
The number of new melanoma cases increased from 2004 to 2008, the standardised 
incidences being 14.1 and 18.4 per 100000, respectively. Almost all the pathology 
reports recorded information on Breslow’s thickness (97.5% in 2004, 513/526 and 
98.0% in 2008, 388/396). The percentage of thin (<= 1 mm) melanomas increased over 
time from 50.7 to 61.3% (P = 0.001). Moreover, there was a significant percentage of 
in situ melanomas: 23.9% (161 out of 674 invasive and in situ melanomas) in 2004 and 
26.9% (143/531) in 2008. 
 
2. Percentage of pathology reports on incident invasive melanomas mentioning 
ulceration (present or absent) 
Ulceration has been included in the staging process since 2002 (Greene, 2002). The 
ITT recommendations state that pathology reports must specify ulceration (ITT, 2007). 
The percentage of relevant pathology reports mentioning ulceration statuses (present 
or absent) increased over time from 61.4% (404/526) in 2004 to 84.6% (334/396) in 
2008 (P<0.001). This increase concerned both thin (from53.1 to 82.5%, P < 0.001) and 
thick melanomas (from 70.4 to 88.0%, P < 0.001). 
Ulceration was present in a decreasing percentage of reports over time – 34.4% in 
2004 (111/323) and 25.7% in 2008 (86/335) (P = 0.005). 
 
3. Percentage of pathology reports on excised incident invasive melanomas with 
margin statuses (positive or negative). 
The margin status confirms the completeness of melanoma excision. The ITT 
recommendations state that pathology reports must specify the margin status (ITT 
  133 
2007). The percentage of the margin status (whether positive or negative) mentioned 
in the pathology reports increased significantly, from 76.8% (404/526) in 2004 to 
84.6% (334/396) in 2008 (P = 0.005). On stratifying for thin and thick melanomas, an 
almost similar statistically significant increase was observed (thin 79.1 vs. 85.4%, P = 
0.064; thick 74.3 vs.82.7%, P = 0.052). 
In 2008, 92% of the excisions had negative margins. Among the 24 cases with positive 
margins, 15 (62.5%) dealt with large melanomas of the face and acral sites, for which 
an incisional biopsy was planned. 
 
Table 14 (n.1 in the original numeration):  Quality indicators of skin melanoma care 
and areas of interest (SLB, sentinel lymph node biopsy). 
 
 Area Main indicators 
1 Early diagnosis Percentage of incident cases<=1mm 
2 Pathology reporting Percentage of pathology reports on incident invasive 
melanomas with ulceration mentioned 
(present/absent) 
3 Pathology reporting Percentage of pathology reports on excised incident 
invasive melanomas with the margin status 
(positive/negative) 
4 Surgery Percentage of patients staged by SLB 
5 Surgery Percentage of patients staged by SLB <75 years of age 
6 Surgery-Pathology Percentage of patients with positive sentinel nodes 
7 Pathology reporting Percentage of lymphadenectomies with the number 
of removed lymph nodes reported 
8 Surgery-Pathology Percentage of cervical lymphadenectomies with >15 
nodes removed 
9 Surgery-Pathology Percentage of axillary lymphadenectomies with >10 
nodes removed 
10 Surgery-Pathology Percentage of inguinal lymphadenectomies with >5 
nodes removed 
11 Time for pathology Waiting time between the first surgery and the 
pathology report (time for pathology of diagnosis; 
days, median) 
12 Time for surgery Waiting time between the diagnostic pathology 
report and the second surgery (enlargement/SLB, 
time for surgery; days, median) 
13 Time for overall 
surgical treatment 
in positive SLB 
Waiting time between the first melanoma diagnosis 
and the final lymphadenectomy in patients with a 
positive SLB (days, median) 
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Table 15 (n. 2 in the original numeration): Average regional value of the quality 
indicators of skin melanoma care for 2004 and 2008, probability of equality according 
to testing (X2, rank sum). 
 
 Main indicators Regional  
average 
2004 
Regional 
average 
2008 
p 
1 Percentage of incident cases<=1mm 50.7 61.3 0.001 
2 Percentage of pathology reports on incident 
invasive melanomas with ulceration 
mentioned (present/absent) 
61.4 84.6 <0.001 
3 Percentage of pathology reports on excised 
incident invasive melanomas with the margin 
status (positive/negative) 
76.8 84.3 0.005 
4 Percentage of patients staged by SLB 63.6 63.3 0.95 
5 Percentage of patients staged by SLB <75 
years of age 
73.9 74.3 0.95 
6 Percentage of patients with positive sentinel 
nodes 
26.1 26.3 0.97 
7 Percentage of lymphadenectomies with the 
number of removed lymph nodes reported 
98.2 100 0.51 
8 Percentage of cervical lymphadenectomies 
with >15 nodes removed 
100 100 1 
9 Percentage of axillary lymphadenectomies 
with >10 nodes removed 
85.7 66.7 0.20 
10 Percentage of inguinal lymphadenectomies 
with >5 nodes removed 
100 100 1 
11 Waiting time between the first surgery and 
the pathology report (time for pathology of 
diagnosis; days, median) 
9 13 <0.001 
12 Waiting time between the diagnostic 
pathology report and the second surgery 
(enlargement/SLB, time for surgery; days, 
median) 
23 26 0.084 
13 Waiting time between the first melanoma 
diagnosis and the final lymphadenectomy in 
patients with a positive SLB (days, median) 
72 82.5 0.71 
 
 
4. Percentage of patients staged by sentinel lymph node biopsy 
Sentinel node biopsy (SLB) enables melanoma pathological staging. The sentinel node 
(SN) status is a major prognostic factor. The ITT recommendations state that SLB has 
to be performed when the thickness is at least 1 mm, in cases of ulceration or when 
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the Clark level is at least IV (ITT 2007). The percentages of SLB were similar in 2004 
and 2008 – 63.6% (161/253) and 63.3% (95/150), respectively. 
 
5. Percentage of cases with sentinel lymph node biopsy in patients < 75 years old 
SLB is a technique under-utilised in elderly patients (Cormier, 2005). As it is more 
invasive than excision, it may sometimes not be indicated in older patients because of 
the presence of comorbidities. Moreover, most SLB trials did not include patients 
above 75 years of age (Morton, 2006; McMasters, 2004; Reintgen, 2004). Among the 
total number of patients who underwent SLB, the majority were less than 75 years of 
age – 73.9% in 2004 (139/188) and 74.3% in 2008 (75/101). 
 
6. Percentage of patients with a positive sentinel node  
The SN status is a major prognostic factor; therefore, node/s should be correctly 
removed and pathologically examined (ITT, 2007). Around one-quarter of SLBs were 
positive both in 2004 [26.1% (42/161)] and in 2008 [26.3% (25/95)]. 
 
7. Percentage of lymphadenectomies with the number of nodes reported 
The ITT recommendations state that the pathological report must specify the number 
of nodes removed after lymphadenectomy (ITT, 2007). The number of nodes with 
metastases is a basic point for staging (Greene, 2002). The number of nodes was 
mentioned in almost all the relevant pathology reports in both years. The number of 
the nodes removed in cases of complete node dissection was also reported in almost 
all the cases, both in 2004, 98.2% (54/55) and in 2008, 100% (24/24). 
Indicators 8, 9 and 10 concern the number of lymph nodes removed during 
lymphadenectomy. The number of lymph nodes removed by lymphadenectomy could 
be considered a measure of the quality of surgical care. 
 
8. Percentage of cervical lymphadenectomies with >15 lymph nodes removed 
In cervical lymphadenectomy, a cut-off value of 15 lymph nodes has been adopted 
(Bilimoria 2008). The number of nodes removed exceeded the cut-off value in all cases 
in both years. In 2008 the median number of excised nodes was 24.5. 
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9. Percentage of axillary lymphadenectomies with >10 lymph nodes removed 
In axillary lymphadenectomy, a cut-off value of 10 lymph nodes has been adopted 
(Bilimoria, 2008). The number of nodes removed exceeded the cut-off value in 85.7% 
of cases in 2004 (24/28) and in 66.7% (6/9) cases in 2008. In 2008, the median number 
of excised nodes was 16. 
 
10. Percentage of inguinal lymphadenectomies with >5 lymph nodes removed 
In inguinal lymphadenectomy, a cut-off value of 5 lymph nodes has been adopted 
(Bilimoria, 2008). The number of nodes removed exceeded the cut-off value for all 
patients in both years. In 2008, the median number of excised nodes was 14. 
 
Indicators 11, 12 and 13 concern the waiting time. 
 
11. Waiting time between the first surgery and the corresponding pathology report 
The time between the removal of a suspected skin lesion and the pathological 
diagnosis of melanoma may influence the timeliness of the necessary subsequent 
actions (enlargement, SLB, etc.). The median diagnostic time was 9 days in 2004 and 
13 days in 2008 (P < 0.001). On analysing thin and thick melanomas separately, the 
median time increased for thin melanomas (from 9 to 14 days, P < 0.001) and was 
stable for thick ones (from 10 to 11, P = 0.509). 
 
12. Waiting time between the diagnostic pathology report and second surgery 
(enlargement/sentinel node biopsy)  
The ITT recommendations (ITT, 2007) suggest performing enlargement or SLB within 
3 months from the biopsy. The median time was 23 days in 2004 and 26 days in 2008 
(P = 0.084). There were no differences with regard to Breslow’s thickness. 
 
13. Waiting time between the first melanoma diagnosis and final lymphadenectomy 
in patients with positive sentinel node (time for overall treatment in sentinel node 
positive patients). 
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The total waiting time for the surgical treatment of a melanoma patient is the time 
from the first biopsy to the report of the lymphadenectomy (in case of a positive SN). 
It was reported to be 72 days in 2004 and 82.5 days in 2008 (P = 0.71). 
 
 
Discussion 
This study provides a comprehensive population-based evaluation of the diagnostic 
and surgical treatment of melanoma in the central Italian region of Tuscany. Our 
proposed indicators are based on local cancer registry data and the official regional 
pathology databases. The method of computation of the indicators enables us to 
compare different years or geographical/administrative areas when the same 
information systems are available. The population-based setting theoretically provides 
unbiased information and shows average measures for clinical care in the population. 
In Tuscany, a multilevel strategy for early diagnosis of skin melanoma has been in use 
since the 1990s. The strategy includes specific initiatives for raising awareness in the 
population, namely, distribution of information packs for skin self-examination, 
organising training courses for general practitioners (GP) and setting up skin units 
across the region. In addition, the multi-disciplinary ITT Melanoma Working Group has 
developed specific clinical recommendations to optimise the clinical course 
throughout the region (ITT, 2007). 
 
A hypothetical and optimal clinical course for skin melanoma should start when an 
individual discovers a changing skin lesion, the GP confirms the need for further 
evaluation, the skin clinic dermatologist performs the excisional biopsy and the 
pathologist reports the diagnosis, specifying all the main prognostic factors that 
address the subsequent appropriate surgery. Therefore, the aim of the ITT Melanoma 
Working Group in identifying possible melanoma indicators was to find parameters 
useful in evaluating the diagnostic phase, the completeness of the pathological 
reporting and the surgical treatment of the melanoma. The indicators analysed in the 
present study were selected by the ITT Melanoma Working Group on the basis of data 
available in the Cancer Registry in order to have unbiased, homogeneous and 
comparable information. On the basis of the above requirements, the ITT Melanoma 
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Working Group analysed scientific guidelines on melanoma diagnosis and treatment 
and performed literature reviews (Garbe, 2010; Garbe, 2012; Marsden, 2010; AIOM, 
2013; Coit, 2009; Dummer, 2011; Dummer, 2012; Morton, 2006; Aitken, 2006; Carli, 
2003; Carli, 2001, Schiffner, 2003; Wagner, 2000; Lens, 2008; Garbe, 2007; Erickson, 
2008; Blazer, 2007; Riker, 2006; Lavie, 2007; Eddy, 2003; Wright, 2011; Mocellin, 
2011; Sladden, 2009; Lens, 2007; Haigh, 2003; Borgognoni, 2004; Amersi, 2007; 
Sondak, 2007; Cook, 2003; Cook, 2008; Chakera, 2009; Lens, 2002) and panel 
discussions with the purpose of identifying possible indicators of an early diagnosis 
and appropriate melanoma treatment. After discussions, meetings, reports and email 
exchanges, the Melanoma Working Group selected 13 indicators on the basis of the 
Cancer Registry data (Table 14 [n.1 in the original numeration]). All measures were 
process indicators that are among the most suitable management tools for measuring 
quality (Lilford, 2007). 
 
During the analysed period, there was a strong increase in melanoma diagnosis, in 
both the standardised and crude rates. As they are based on the number of cases, 
crude rates show the real workload of a healthcare system in terms of the need for 
diagnosis and treatment. This is the rate that must be taken into account when 2 years 
are compared. The increased incidence was mainly driven by the growing percentage 
of thin melanomas (<= 1 mm), which in 2008 was 61.3% of all newly diagnosed invasive 
melanomas. This indicator attests to the efficacy of early diagnosis in the region, as a 
consequence of increased awareness in the population, the role of the GP and of the 
activity of the dermatologists in skin clinics (with the support of dermoscopy). In the 
area of the present study, a randomised clinical trial confirmed the usefulness of 
dermoscopy in improving melanoma diagnosis and reducing the number of pigmented 
skin lesions excised for diagnostic verification (Carli, 2004). The possible use of 
dermoscopy in the diagnosis of pigmented skin lesions is included in the ITT melanoma 
recommendations (ITT, 2007; Carli, 2001; Carli, 2004). 
 
Mortality for melanoma is still increasing in Tuscany (Chellini, 2007). No effective 
treatments for advanced melanomas were available in Italy at the time of the study. 
Encouraging results from new molecular drugs have emerged only recently 
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(Eggermont,2010; Hodi 2010; Chapman, 2011). Therefore, early diagnosis and 
appropriate surgical treatment are the primary recourse for the healthcare system. 
However, an increase in diagnostic drift and instances of reclassification of previous 
severely atypical dysplastic nevi as melanoma has been found (Frangos, 2012). The 
increased diagnoses of thin but not deadly melanomas (Crocetti, 2010) have a positive 
significance, although the possible role of over-diagnosis of indolent pigmented 
lesions should also be considered (Welch, 2010). 
 
Melanoma prognosis is strictly dependent on characteristics that may be evaluated 
only by a pathologist, and, for this reason, there are indicators that address the 
completeness of the pathology reports. The quantity of information available in the 
pathology reports has increased over time. In 2008, almost all reports included 
Breslow’s thickness (98%), around 85% included the presence or absence of 
ulceration, 84% included the margin status for excised melanomas and all reports 
included the number of nodes in patients of lymphadenectomy. The latter results 
were as good as those recently documented in the USA (Bilimoria, 2009). 
 
As regards the weaknesses of this study, for the patients diagnosed in 2008, we used 
only the information from pathology reports. Therefore, few cases may have been lost 
and the estimates may be slightly overestimated. 
 
Moreover, not all the relevant prognostic factors were analysed; for example, the 
number of mitoses was not included. However, the analysed data refer to 2004 and 
2008, and it was only in 2009 that AJCC melanoma staging (Blach, 2009) included the 
number of mitoses as an important prognostic factor. For this reason, recent 
melanoma guidelines, such as those in the UK (Marsden, 2010), include the mitotic 
count among the requirements for a pathological report, and this parameter will be 
included in the updated ITT recommendations for melanoma that are to be published. 
They will also be included on future indicator analyses. 
 
About two-thirds of eligible patients had SLB. The percentage for patients younger 
than 75 years (74%) shows that this procedure was performed mainly on non elderly 
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patients. Presumably, the presence of comorbidity in patients older than 75 years 
influenced the decision of the surgeon for SLB. Once performed, an SLN biopsy 
showed approximately the same rate of positivity in 2004 as that in 2008 – about 26%. 
The mean regional figure of 26% in Tuscany is higher than the percentage of 16% 
reported in the Multicenter Selective Lymphadenectomy Trial I (Morton, 2006) and 
the 19.9% reported in an Italian Multicentre Study (Testori, 2009), indicating 
appropriate surgical and pathological approaches. Pathology reports always specify 
the number of lymph nodes removed during lymphadenectomy in the entire region. 
The cutoff values obtained by Bilimoira in a recent work on melanoma indicators in 
the USA (Bilimoria, 2009) were adopted to evaluate the quality of the surgical 
procedures in stage III patients. Moreover, the same cutoff values made it possible to 
compare the results between the two studies. The number of nodes removed from 
sites in the cervical and inguinal regions always exceeded the levels of 15 and 5 nodes, 
respectively. As regards the axillar region, two-thirds of patients had 10 or more nodes 
removed in the first semester of 2008. However, this number is based on just nine 
patients. The values registered in Tuscany are higher than those reported in Bilimoira’s 
study (Bilimoria, 2009). Moreover, it has been reported in a previous American study 
that less than 50% of patients with positive SLB in the USA underwent complete node 
dissection (Bilimoria, 2008), whereas the percentage in Tuscany was 63%. 
 
A crucial aspect for any public healthcare system, for both patients and healthcare 
policy makers, is the waiting time. Three indicators addressed waiting times in the 
diagnostic and surgical course of melanoma. The median time for receiving the report 
for a skin lesion suspected to be a melanoma was 13 days in 2008. The length of this 
period depended on the pathologist, his/her workload, and the availability of 
resources. It increased from 2004 by 44%; however, the crude incidence rate (number 
of melanomas) increased during the same period by about 33% and, therefore, the 
longer waiting time for melanoma diagnosis resulted mainly from the increased 
number of patients awaiting diagnosis. The waiting time after a pathology diagnosis 
depended on the surgeons’ workload and resources. The waiting time, for wider 
excision or SLB, increased by 13% (median from 23 to 26 days) during the 
aforementioned period (during which there was an increase in melanoma incidence). 
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In particular, there was an increase not only in the number of thin melanomas but also 
in the number of cases with a thickness greater than 1 mm (an increase of 4%). The 
total surgery-related waiting time, commencing with the positive SLB report and 
ending with lymphadenectomy, increased by about 15% (from 72 days in 2004 to 82.5 
days in 2008). The implementation of a modified EORTC protocol in Tuscany as the 
standard procedure for extensive pathological handling of SLB (Cook, 2001) 
presumably had an impact from 2004 to 2008, lengthening the time of reporting. 
 
Conclusion 
In this study, we analysed a set of 13 quality indicators for evaluation of the diagnosis, 
surgical treatment and pathological definition of melanoma. These indicators, 
evaluated using a population-based dataset in Tuscany, showed an increase in the 
number of thin melanomas (a mark of early diagnosis), an improvement in the 
completeness of the pathology reports, and good surgical management. Some of the 
latter improvements may be related to the development of ITT recommendations for 
melanomas for the regional healthcare system in 2007, a product of the regional 
multidisciplinary Melanoma Group. These as well as other indicators, such as the 
mitotic rate (Balch, 2009; Thompson, 2011), should be monitored to identify the 
potential improvements and shortcomings in melanoma care. 
 
References: The original references of the paper have been included in the general list 
of the thesis. 
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7.1.1. Comment 
 
The previous paper (Paper 6) exemplifies a practical application of the data from a 
cancer registry (CR), and more generally, the CR’s staff’s technical competence in 
managing data. The information from a CR, as well as the information selected from 
the pathological reports, have been used to compare some quality indexes in the 
diagnosis and treatment of MM in the Tuscan region. 
MMs almost always have a microscopic verification. All quality indexes were measured 
in MMs with microscopic confirmation (e.g., cases with biopsy, surgery). The use of 
pathological reports was made possible by the availability of digitalised information 
and the expertise of the CR staff diligently data mining these reports (Crocetti, 2005). 
This last point made it possible to select skin melanoma, both in situ and invasive, 
Breslow’s thickness, and information on the involvement of lymph nodes. 
 
In this way, the CR was useful for the entire scientific community involved in MM care, 
offering a reliable and comparable population-based data set and the ability to analyse 
it. 
 
The CR has entered the real-world as a useful and valid partner, collaborating with 
dermatologists, pathologists, surgeons, and policymakers, to measure the quality of 
care in the early stages of MM. 
With the help of CRs, the diagnosis and course of cancer treatment could improve, 
and therefore modify the information given by patients during their contact with 
healthcare services. That same information would then be used by the CRs to produce 
still better, high quality and insightful information at the disposition of the scientific 
community, which furthermore, could verify the quality of MM care.  
 
It is a virtuous circle that the CRs must exploit to show their concrete and constructive 
role in the healthcare system. 
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8. Discussion 
 
8.1. Introduction 
 
The field of research exemplified in the six papers presented in this thesis focusses on 
the process followed by registries in the transformation of raw data into information 
applicable in the real world.  
 
This procedure identifies three crucial and inter-related areas: quality, 
informativeness, and usefulness of data.  
 
The sequence of these six papers illustrates a possible fruitful path that registries have 
to consider to become a bringer of knowledge in cancer epidemiology and care. 
Although each issue represents a specific and independent topic, which may apply to 
various subjects, a correct and fruitful activity of registries must necessarily consider 
such aspects jointly. In Figure 13 the leitmotiv of the research presented in this thesis, 
which deals with cancer registration as a whole, from raw data to concreate messages 
to guarantee quality, informativeness and usefulness of data, is exemplified. 
 
The present thesis summarises how an application of this research in the real-world 
context contributed to improving the role of population-based cancer registries as 
valuable tools for the development of knowledge on cancer. The topics covered by the 
six papers presented here concern not only cancer epidemiology but also public health 
organisation and clinical and translational research. 
 
This thesis may be helpful to those who want to understand how powerful registries 
maybe if only their potential is exploited to serve all the possible stakeholders in the 
community. Registries collect and provide data on all malignant tumours arising in a 
specific population (Shanmugaratnam, 1991). These data can be useful in different 
contexts and for different stakeholders (e.g., clinicians, patients, public health 
operators, policymakers).  
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Figure 13: Exemplification of the cancer registry' data path presented in this thesis. 
 
 
Moreover, it offers a structured set of effective methods and tools for those who work 
in this field and are willing to improve their registry’s capability to be effectively used 
by different stakeholders.  
 
Most of the papers presented here ground on skin melanoma. For two of them, which 
address generally applicable methods in cancer epidemiology, unpublished analyses 
have been added in which these methods have been applied explicitly to skin 
melanoma.  
 
8.2. Quality of data 
 
The evaluation of data quality is a prerequisite for any data and methodology which 
strives to provide scientific evidence. In the introduction, the available methods to 
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evaluate the different dimensions of registry data quality (validity, comparability, 
completeness and timeliness) have been presented. They have been used for many 
years and are widely appreciated. 
 
In general terms, they are based on simple computations providing numbers. Based 
on such evaluations, registries may be attributed various degrees of quality, as 
exemplified by the North American Association of Central Cancer Registries using 
specific criteria to identify two positive certification levels: gold and silver 
(https://www.naaccr.org/certification-criteria/).  
 
Regrettably, the evaluation of quality indicators is not always explicit and reproducible 
because of the lack of standard cut-offs. Notwithstanding, registrars attribute to a 
specific range of values of the analysed indexes the meaning of good quality when 
considered high enough, e.g., ..."93% were morphologically verified"... (Leinonen, 
2017), or "The proportion of microscopically-verified cases increased from 73.6% in 
2002 to 82.3% in 2012" (Ryzhov, 2018). Similarly, when they were low enough, e.g., 
"The proportion of cancers with uncertain or ill-defined primary site and the 
proportion of death-certificate-only registrations were both low at 1.9% and 2.6%" 
(Leinonen, 2017), or  "...with death-certificate-only (DCO) proportions stable at around 
0.1% and unknown stage recorded in 9.6% of male and 7.5% of female solid 
tumours..." (Ryzhov, 2018). 
 
Although the quality evaluation is a complex process based on the joint interpretation 
of several parameters, the lack of unique and shared cut-offs for indexes may hamper 
the reproducibility and consequently, the interpretation of the literature.  
 
For example, when comparing the data selection in a study on childhood leukaemia of 
the Concord-2 project (Bonaventure, 2017) with an International incidence of 
childhood cancer study (Steliarova, 2017), the criteria for case-series selection did not 
seem to match. In both situations, the thresholds adopted for acceptance for the 
numerous checks performed in the quality assessment process were unmade explicit 
(Crocetti, 2017b). 
  146 
 
Therefore, although the quality of data is crucial for registries and many methods to 
evaluate it are available, overall agreed rules with specific cut-offs are lacking, and ad 
hoc interpretation cannot be ruled out. 
 
Paper 1 represents one of the possible approaches to overcome the limitation caused 
by subjectivity in data quality estimation and proposes an entirely innovative method 
for quality assessment that could enrich the traditional toolkit by introducing an 
objective evaluation.  
 
The method presents the application of a mathematical law, Newcomb-Benford law 
(N-B) (Newcomb, 1881; Benford, 1938) describing the frequency distribution 
(probability function) of the first digits (from 1 to 9, being 0 not considered) of real 
numbers. In the series of numbers which abide by N-B law, the frequency distribution 
has a robust positive skewness, with 1 being the first digit more than 30% of times. 
 
Paper 1 evaluated for the first time whether cancer incidence rates abided by this law.  
To document it, a vast data set of 146,590 incidence rates was randomly sampled from 
the dataset used for CI5-X, and the 1-digit distribution was evaluated showing a 
positive skewness (0.84) with mean higher than the median (as expected by the 
theoretical N-B distribution) and with ratios between 1st and 9th digits and 1st and 
2nd digits corresponding to the theory. 
In the second part of paper 1, once incidence rates were considered among those 
numbers abiding by the law, N-B distribution was checked in each of the 43 registries 
which had been previously analysed jointly. 
 
To evaluate the abidance to N-B law, I presented the plotting of observed and 
theoretical frequencies and a set of five tests. An internal evaluation compared those 
registries whose data were more or less coherent with N-B. Results of each test were 
ordered to identify the most extreme values (the decile with the most unsatisfactory 
results). One of the registries had all the results of the applied tests in the worst decile. 
This result had a very low probability of occurring by chance. However, this outcome 
  147 
is relative to the internal comparison in the analysed data set. All the registries had 
passed the CI5-X data checks, which assessed their quality.  
 
The value of this paper is to have documented that cancer incidence rates abide by 
Newcomb-Benford law. Consequently, the first digit distribution of cancer incidence 
rates can be compared with the theoretical N-B one.  
 
N-B can be quickly evaluated as it is based on the comparison of the observed 
frequency of the first nine digits of incidence rates with the theoretical ones. 
Observing a graphical plot of the two distributions may provide sufficient hints about 
rough anomalies. A more formal evaluation is made possible by specific commands 
included in many commercial (e.g. Stata, SAS) and open source (R) statistical software. 
 
Traditional quality indicators (e.g., mortality/incidence ratio, DCO or 
Other&Unspecified sites) may vary widely among registries of accepted quality (e.g., 
CI5-XI for 'All sites but non-melanoma skin cancer' http://ci5.iarc.fr/CI5-
XI/Pages/Indices_sel.aspx). Therefore, a comprehensive evaluation of data may be 
useful for preliminary screening and to address further thorough analysis. 
 
N-B check could represent the first step in the process of data quality assessment. A 
violation of such distribution may suggest questionable data requesting a 
comprehensive and strict evaluation of traditional quality indexes.  
 
The additional value of the paper is its demonstration that in the methodology on 
registry quality evaluation, there are still opportunities for innovation and 
improvement. Moreover, the continuous development of digitalisation has provided 
a growing number of datasets that are increasingly used by registries. N-B can equally 
be applied to them, once abidance of data is confirmed, for a preliminary evaluation 
of their global correspondence to what expected and early detection of surprising 
results. Some examples were already present in the paper by Benford. Benford found 
the first digit of the sizes of 3,259 populations in USA abided this law. Therefore, 
registries, which use populations (sex-, age-, time- or area-specific) as denominators 
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for computing rates, can apply Benford’s law to examine them (Benford, 1938). 
Moreover, newly published applications such as those which evaluate waiting lists 
(Pinilla, 2018) or death counts (Daniels, 2017) may be useful for registries. There is a 
growing interest in the application of N-B law in the scientific environment 
(Hüllermann, 2017; Karathik, 2016; Lee, 2019) and it has been suggested for many 
fields of medicine and community health (Pollach, 2016). 
 
8.3. A new index to improve informativeness 
 
Once the quality of a dataset is considered checked and confirmed, it may be used for 
analysis. Traditionally registries have described incidence in a defined population 
showing, in tables and figures, overall cases and rates with cross-tabulations for a few 
variables: e.g., cancer topography, age, sex or place of residence. The previous is the 
usual way to describe the frequency of cancer in a specific area (Jensen, 1991).  
The interest in the comparison of incidence in different areas or different periods in 
the same area has also made it necessary to consider the possible effect of age on 
incidence and the different age distributions in the populations under comparison, 
leading to age-standardisation, with both direct and indirect methods (Boyle, 1991).  
 
Therefore, the publication of frequencies and crude rates meets local needs, and age-
standardised rates (usually computed with the direct method) allow for comparisons 
over time and/or with other registries. 
 
This way of presenting incidence has remained almost the same in the last decades 
(Jensen, 1991). For example, the frequency of cases, with crude and age-adjusted 
rates (Segi, 1960) has been chosen to summarise and compare incidence for cancer 
types within and between registries participating in CI5-XI (http://ci5.iarc.fr/CI5-
XI/Pages/summary_table_site_sel.aspx). This information is complete and unbiased, 
and it provides handy data allowing for reliable comparisons. 
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However, in descriptive international studies incidence in a vast country with national 
coverage may be summarised with the same index used for a small national or even 
regional registry. 
 
Paper 2 presents an entirely new application which could enrich the traditional 
presentation of ASR by adding a measure of internal variability. It does not request 
new variables since it is based on available data. 
 
It may be applied to those registries which have incidence information also for sub-
areas (e.g., regions in a country, provinces in a region). When only global ASR is 
provided, the proposed index should be handy to show further information 
straightforwardly. 
 
This index is computed as the ratio between the difference among the highest and 
lowest sub-area specific rates ASR (r), and the overall one (R), r/R. The index is 
expressed as a percentage. It shows how much the maximum difference in the sub-
areas is (between the highest and the lowest ASRs) respect the overall ASR (in 
percentage points). The smaller the index (0% when incidence is the same in all the 
sub-areas), the smaller the heterogeneity of incidence in the sub-areas represented 
by the summary ASR. Conversely, the higher the index is, the more significant the 
heterogeneity.  
 
In paper 2 this index has been tested in the data available from the Nordic countries 
(NORCAN). NORCAN provides data from three decreasing geographical dimensions: 
supra-national (all Nordic countries), national (individual Nordic countries), and 
regional. The overlapping of 95% confidence intervals has been used for comparisons 
between ASRs. The application of the proposed index has quantified in a 
comprehensible way how much an incidence ASR may be more or less representative 
of the incidence ASRs in sub-areas.  
 
As an empirical assessment, when r/R value is <10-15% it may be considered 
representative of homogeneous sub-areas. In fact, at the most, ASR incidence in one 
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of the sub-areas is 10-15% higher or lower than the other most extreme value. On the 
contrary, when r/R is >30%, the dispersion of incidence across sub-areal ASRs might 
not be negligible (at least one of the ASRs is 15% smaller and another 15% larger than 
the average summary). 
This simple index would help users understand how much a summary incidence ASR 
significantly represents the incidence in underlying sub-areas, showing a measure of 
the amount of variability in incidence in the area. 
 
The index has also been applied to incidence rates in the USA in 2014 for all cancers 
(except skin epitheliomas) available at U.S. Cancer Statistics Working Group 
(www.cdc.gov/uscs) for the USA overall, for four geographical regions, for two or more 
sub-regional areas, for 51 States and five metropolitan areas. The 95% confidence 
intervals of sub-areal ASRs did not always overlap with that of the broader area of 
which they were part. In this setting, the r/R index also confirmed its use in providing 
a measure of the amount of underlining variability in incidence related to a summary 
ASR (Crocetti 2017a).  
 
In the example presented in paper 2, the index was applied to countries of a somewhat 
different dimension and more homogeneous regions (except for Iceland). The 
variability in incidence may also be related to the dimension of the sub-areas 
considered and may increase when they are small. This topic may be a problem when 
the index is computed for more registries based on sub-areas of different dimensions. 
In this case, the value of the index may not only show the amount of heterogeneity 
but also the presence of different geographical granularity, with at least one of them 
with a value far from the summary ASR. 
 
The index may be used as a measure of macro-area variability in incidence for a 
specific registry and different registries when sub-areas have almost the same 
magnitude in the size of the resident population (and level of incidence). 
 
The addition of a measure of variability would considerably improve the use of the 
index. 
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The main assets of the method are simplicity of computation, the fact that it grounds 
on already available measures and its ease of interpretation. The simplicity of 
computation and interpretation have been preferred to more formal statistics (e.g., 
analysis of variance, extreme quotient) (Gumbel and Kerry, 1950; Fisher, 1921) to 
make such approach suitable for all the people working in registries or for those who 
use registry data and who may not have a background in statistics. 
  
Such index has already received some appreciation. In fact, the method was presented 
in recent scientific meetings of cancer registries where it was used to compare internal 
variability in registries located in countries where a language derived from Latin is 
spoken (Contiero, 2018), in some registries participating in a European project 
(Martos, 2018) and to discuss the effect of the choice of different standard 
populations (Rashid, 2018). 
 
The r/R index could complement ASR and standard error when incidence is presented. 
In this way three kinds of information would be provided: a comparable level of 
incidence in a specific area (ASR), the precision of such estimate (standard error) and 
a simple measure of heterogeneity in incidence in macro sub-areas (r/R index). If 
grounded on reliable data, this information is essential. 
 
This index of heterogeneity could be extensively applied in those International 
collaboration initiatives, which include dozens or hundreds of registries. For example, 
in CI5 many countries have national coverage. Their incidence is presented as a 
national average only.  In case also regional estimates would be available although not 
published, the computation of the r/R index would provide additional information on 
the homogeneity/heterogeneity of incidence within the country. 
 
Moreover, the same approach used here for incidence could be exploited and applied 
to prevalence or survival (e.g. Eurocare, Concord) or other epidemiological metrics. 
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The proposals for new methods presented in papers 1 and 2, address quality 
evaluation and data visualisation. The next examples take a step forward and show 
how registry's data potentiality may be exploited to increase their informativeness, 
interest and usefulness. 
 
8.4. Which variables to analyse? 
 
The information that a registry traditionally collects is somewhat limited (e.g., cancer 
topography, morphology, sex, date of incidence, basis of diagnosis and age) and based 
on the requests of big International projects (for example CI5, Concord, Eurocare).  
 
Adding any other variable implies a certain amount of extra time and resources as well 
as additional validity, completeness and comparability evaluations, which may request 
specific methods. Moreover, this implies an increased workload which does not 
improve overall timeliness. 
 
Therefore, while the critical information provided by the registries fulfils big 
consortia’s necessities, it is scarcely fascinating for other stakeholders (e.g., 
oncologists). 
Further, big projects involving registries from different countries and even continents, 
need to find out the minimum data set, which allows the majority of registries to 
participate.  
Besides, increase the workload by coding more or more detailed variables may 
jeopardise the compliance with big projects’ deadlines.  
 
It is a recursive process that limits the possible use of registries. 
 
One of the bottlenecks of the registration procedure is the manual handling of 
traditional and new data. Registries should exploit the implementation of software for 
data-mining from sources for the preliminary harvest of information, involving 
personnel only at the second level of revision (Crocetti, 2005). 
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In conclusion, registries data specific for cancer topography, morphology, and a few 
other demographic variables are appealing for those who want to compare incidence 
or survival in the world but have raised limited interest among clinicians, including 
those working in the same area of the registry. 
 
The risk for registries is to produce high-quality data with no value outside their self-
referential circle. 
The use of data should not be independent of the concept of quality of registry data 
applied until now. On the contrary, it should urge those who work in the registries’ 
world to reconsider it.  
 
If high-quality data are not used outside the limited world of registries these complete, 
valid and comparable datasets (on average timeliness is not an asset for registries) 
(Zanetti, 2015) are not recognised as valuable and appreciated by many others who 
should use such data. 
Since registries use clinical data, clinicians should be expected to be partners in the 
analysis and interpretation of registry data. Regrettably, this is frequently not the case. 
In fact, in a comprehensive evaluation performed in 2009-2013, the majority of 
registries (65%-75%) declared they were not active in the range of cancer research 
areas but just provided incidence and survival data to others for analysis (Coebergh, 
2015). 
 
However, only if registries increase their capability to bridge the gap with the clinical 
world by providing data valuable for the clinical interpretation of epidemiological 
patterns, will they become an active part of their health system.  
Unfortunately, in most cases, these surveillance systems are isolated and do not 
collaborate with all those for whom data would be available. Therefore, the 
collaboration with all the possible stakeholders is among the future challenges 
recommended to cancer registries (Zanetti, 2018). 
 
Paper 3 provides an example of a fruitful collaboration between epidemiologists and 
clinicians (in this particular case, dermatologists). Such collaboration arose from the 
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mutual interest in understanding and integrating two professionalisms: the values of 
population-based reliable information and the relevance of some clinical variables for 
patients and clinicians.  
 
In this experience, dermatologists extended their interests outside their own 
department/hospital, and epidemiologists entered into the real world.  
 
In this study, which is the first on this specific topic published in Italy, the method of 
cancer registration and established clinical practices have interacted effectively. 
The process has implied an exhaustive use of one of the official sources of information 
for registries: the pathology report. The diagnosis of skin melanoma, although 
suspected by visual inspection or enhanced by dermoscopy examination, requires a 
microscopic confirmation by the pathologist. Pathologists provide three essential sorts 
of information which steer the further therapy of skin melanoma: invasiveness, its 
extent in millimetres and morphology. 
 
This information, included in the registries, has made epidemiological analysis more 
effective in the interpretation of skin melanoma clinical patterns. Although the 
increase over time of in situ and thin lesions may be related to an increased awareness 
of skin moles and a grown bioptic aggressiveness of dermatologists raising the concern 
of over-diagnosis, the concomitant increase of ASR of thick (and deadly) melanoma 
has confirmed a real epidemic in central Italy. 
 
Some sub-site analysis of melanoma onset and type of morphology of melanoma and 
patients’ age and sex have enriched the information provided to dermatologists and 
improved their interpretation of clinical patterns and identifying groups at risk. 
 
The same approach has recently been applied to evaluate the trend of skin melanoma 
in Europe, based on the datasets of 18 registries (Sacchetto, 2018) confirming, after 
eight years from the publication of paper 3, the appropriateness of the variables and 
methods used.   
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However, much work is still necessary. A recent study aimed at evaluating stage-
specific survival differences in Europe for seven selected cancers showed that 
between 15% to 22% of registries did not possess the information on stage (the range 
among European regions and cancer sites was 8-28%) (Minicozzi, 2018). In the same 
project stage evaluation in 15 solid cancers in Europe confirmed that stage was often 
incorrectly assigned or missing, especially among older people. Such results spoke out 
for the need for improving data collection and coding (Minicozzi, 2017). 
 
Therefore, also, a quantitative aspect should belong to the quality of data.  
High-quality data should imply a varied and rich offer of those variables relevant in 
defining and describing the diagnosis, treatment and prognosis of patients (Zanetti, 
2018). More high-quality clinical variables are essential to root registries in the health 
system and to appoint them ‘agents of change’ as it has been recently hoped for their 
future (Zanetti, 2018). 
 
8.5. The application of a wider variety of statistical methods could help the 
exploitation of data informativeness 
 
The collection and analysis of data by registries represent a continuous process 
providing substantial and reliable information: clear identification of prevalent cases 
(challenging to be detected especially at the beginning of the registration activity), 
precise evaluation of the timeliness of reaching completeness (especially relevant for 
more recent years of incidence) and the identification of multiple primary cancers in 
the same person. Moreover, the availability of high-quality data for an extended 
period allows reliable time trend analysis. 
 
Time trend evaluation in cancer incidence represents an invaluable addition to the 
information on incidence level; any difference over time or among groups of people 
may suggest possible inputs for analytic studies.  
 
The analysis of changes in incidence levels over time represents a fundamental tool 
for community health. By monitoring such indicators one can evaluate the effects of 
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health programmes (e.g., awareness-raising campaigns on skin mole changes), the 
introduction of novel therapies or new diagnostic instruments (e.g., dermoscopy) as 
well as changes in lifestyles and environmental exposures (e.g., recreational sun 
exposure). Furthermore, time trends allow documenting the effectiveness of 
prevention measures at the population level. 
 
In paper 4, we applied an age-period-cohort model which showed that the best model 
fitting the analysed melanoma incidence data included age and drift. Such drift (linear 
temporal effect) showed that in every 5-years or cohort analysed there was an 
increase of incidence by about 37% in each 5-year age-group. This paper was the first 
one in Italy to show that melanoma incidence was increasing in all the age groups in 
different periods and age-specific incidence rates increased in all the analysed cohorts, 
including the youngest. 
 
Paper 4 presented the analysis of clinically relevant indicators in which registry data is 
not limited to a mere counting of cancer cases. 
 
The role of CRs not only is to provide high-quality data but also to make this data 
utilized at best by as many stakeholders as possible. Reliable data must be used, 
involving all possible methodological approaches. In paper 4 the knowledge of 
melanoma clinics and epidemiology indicated that over the latter decades cultural 
change which caused an increase in recreational exposure to UV and the increase in 
early diagnosis has acted more as a period than as a cohort effect. Moreover, the 
availability of a high-quality series of data can constitute a basis for reliable projection 
for more recent periods. In fact, in the same paper, we used the high-quality data 
collected in the Tuscan registry from 1987 to 2001 to estimate the expected burden 
of newly diagnosed melanomas in 2002-2006. To be specific, we adopted the non-
linear model proposed by Dyba et al., (Dyba, 1997), including the effect of age and 
age-specific temporal trends. 
 
Also, the economic burden related to diagnosis and treatment of specific cancers can 
be calculated based on observed data and projected in the future to estimate the 
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amount of the necessary investment which has to be planned to fulfil resources 
adequate to the expected burden. For example, this evaluation has been performed 
in the US, applied to colorectal cancer. Moreover, costs had detailed for three 
different periods of the clinical care: diagnosis and first treatment continues phase of 
diseases and last year of life (Yabroff, 2007). 
 
In conclusion, not only does trend analysis provide further insights on the crucial 
determinants of changes, but if based on high-quality data, it can be used to predict 
future burdens. Reliable future projections enable to monitor the effectiveness of 
preventive programmes and to determine future needs. For example, recently 
published estimates for the UK have drawn attention to the need to contrast smoking 
(women), alcohol, overweight and obesity, HPV and hepatitis infections to dampen 
the growth of those cancers which demonstrate an increasing tendency (Smittenaar, 
2016). Similar conclusions came from Canada based on projections made available for 
tailoring resources and services’ planning on the on-going demographic changes and 
to the increase of specific cancers. Besides, such projections suggest prevention as a 
useful tool to control the future burden (Xie, 2015). 
 
The production of short-terms predictions should be extensively exploited by 
registries also to fill the timeliness gap between clinical events and availability of 
incidence estimates and move high-quality data series into recent years. 
 
8.6. Communication of data contents 
 
The knowledge in medicine evolves when the experience acquired on an individual 
patient extends to a similar group. This process also applies to survival for which 
population-based registries provide for clinicians, citizens and patients average 
measures at population-level for specific cancer, in specific sex or age-group or stage 
or even in more detailed aspects. 
 
However, every day, any oncologist visits patients with specific genetic/phenotypic 
personal disease who want to know details about their prognosis. 
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If that patient was a man, middle-aged, ex-smoker and with regionally diffused cancer, 
the answer of the oncologist, based on the most updated information collected from 
high quality research published in peer-reviewed scientific journals, could be 4.3 times 
worse than for a women, younger than 30 years, who has never been a smoker and is 
affected by the same cancer but confined to the site of onset. 
 
The previous example shows how the hazard risk is typically presented, applying the 
worldwide appreciated and adopted the Cox model (Cox, 1972). 
The answer would be correct, evidence-based, but presumably meaningless for that 
patient who would leave the oncologist's office more confused than informed. 
The output of a Cox model is reliable when the necessary assumptions are respected, 
but interpretation is complicated, even for health-care personnel. 
 
Paper 5 dealt with this topic which links methodology and communication, comparing 
the prognostic effect of several variables with both Cox model and Classification and 
regression trees (CART) analysis in a high-quality registry series of incident skin 
melanoma. 
CART possesses several advantages, starting from its being essentially nonparametric, 
and therefore requiring no assumptions about the underlying distribution of the data 
to analyse (Lemon, 2003 and 2012; Kraemer, 1992). 
 
Moreover, in my opinion, the friendly outcome remains the most relevant asset, 
considering the need to comprehend and communicate in a comprehensible way 
information concerning the life expectancy of patients. 
 
Patients are one of the most important and engaged stakeholder groups with whom 
registries have to collaborate. The relationship and communication between doctors 
and patients remarkably changed in the last decades. In fact, over time, the right of 
patients to be informed and the duty of doctors to inform them have been affirmed 
(Buckmann 1996). Patients and doctors have become responsible for shared 
accountability for trustworthy information (Schain, 1980).  
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Moreover, cancer patients' associations are advocating the right of patients to be 
involved in any decision which affects their lives (Souliotis, 2018). “No decision about 
me, without me” is the norm in many countries and hopefully all the others will follow 
suit. 
Registries have to respond to patients' questions, and many collaborations are still 
going on to fulfil this task. For example, the network of Italian registries has provided 
a measure of time to cure for cancer patients (Dal Maso, 2014). 
 
Paper 5 moved my research on making registry data more informative and useful for 
all possible stakeholders interested in survival by improving the way to measure and 
communicate the prognosis.  
 
According to my knowledge, this type of analysis (CART) was the first-ever made in 
Italy on this topic. It involved two high-quality registries. 
CART analysis proved able to identify homogenous groups of patients with the same 
levels of the variables analysed who had a defined observed survival. In this manner, 
patients can receive information on their specific average prognoses as absolute 
values that do not require complex computations.  
 
Unfortunately, despite the greater straightforwardness of CART in comparison with 
Cox, CART is not widely used. A search for the terms "Classification and regression tree 
analysis" AND "Cancer" done on 17th May 2018 in Pub Med identified only 97 papers. 
Conversely, search for "Cox" AND "Cancer" highlighted 47,402 papers. Something 
hampers a more general introduction of CART analysis in the scientific community. 
 
Statistically, by constructing subgroups directly on the covariates, the CART algorithm 
satisfies the objective of finding both independent prognostic factors and prognostic 
subgroups. Apart from some computational weakness (Marshall, 2001; 
Venkatasubramaniam, 2017), this methodology has several advantages, and its 
application suggested (Lemon, 2003). In contrast to traditional regression methods 
(e.g., Cox proportional hazard regression) which compute a prognostic index as a 
weighted average of the covariates, CART constructs groups based on logical 
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combinations of patient’s characteristics. The results of the Cox proportional hazard 
model may be challenging to implement into clinical practice. Although the Cox model 
enables to predict the survival probability associated with a specific variable, it is 
always challenging to interpret or predict a patient’s cumulative risk for a given set of 
prognostic factors. In daily medical practice, patients habitually have many prognostic 
factors, especially when there are interactions involved (Chang, 2012).  
 
Hence, providing a useful and informative risk group definition for practical use is a 
tough task.  
 
There are several examples in literature on the uses of CART analysis for risk 
assessment at the bedside (Abu-Rustum, 2008; Barlin, 2013; Diessner, 2016; Egger, 
2013; Fernández, 2017; Hess, 1999; Kim, 2012; Kobayashi, 209; Jain, 2017; Lamborn, 
2004; Langendijk, 2005; Lu, 2016; Xu, 2019; Yuan, 2017).  
On the other hand, CART analysis raised criticisms for being inherently unstable 
(Rokach & Maimon, 2007; Protopopoff, 2009; Su, 2011). Minor changes in data can 
drastically alter a tree’s appearance and its interpretation if the tree is unmanaged 
with caution.  When a split changes, all subsequent splits change, too. Therefore, each 
optimal partition depends on the path already taken through the tree (Crichton, 
1997).  
Moreover, also the objections stated by Marshall (Marshall, 2001) are correct, but 
they apply exclusively in a blinded situation in which no previous scientific evidence is 
available.  
 
In conclusion, results of paper 5 let suppose CART as a method capable of summarising 
evidence on the prognosis in a way which may be easily understood by both clinicians 
and patients. However, such an impression has to be tested and quantified in proper 
studies.  
The need for a clear comprehension of cancer prognosis has also been addressed 
using nomograms. For example, SEER has developed a prognostic nomogram for 
prostate and colorectal cancer based on tumour characteristics, age, stage, gender 
and comorbidity (Feuer, 2014). The nomogram provides information on the chance of 
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dying of cancer and other causes, complementing the traditional survival information 
(Feuer, 2014). The use of nomograms goes in the direction of providing information 
on individualised prognosis and of helping clinicians to select the adequate treatment 
for a specific patient (Caulfield, 2018). 
A more extensive use of CART in prognosis communication still requires further 
analysis which hopefully will be addressed in the future research on registries 
progression (Zanetti, 2018). 
Moreover, also the information flow from registry to oncologists and patients has to 
be further evaluated to understand how, where, and with whom registry may best act 
to improve the comprehensibility of produced prognostic indexes. 
 
The role of paper 5 was not to belittle Cox's model and its undisputed capability to 
handle uncertainty in survival estimates but to emphasize the still unmet need of an 
explicit, straightforward and comprehensible communication of epidemiological 
measures to not statisticians.  
 
The scientific community cannot ignore this assignment. 
Otherwise, high-quality data, correctly analysed and full of informativeness, would 
turn out to be useless when they cannot be adequately comprehended.  
 
This issue belongs to the broader topic of communication in oncology. It is incredibly 
complex and implies ethical, cultural and legal issues (Gordon, 2003). The 
communication of risk - e.g., prognosis - is even more complicated, as it presupposes 
uncertainty (Spiegelhalter, 2011). However, recommendations are becoming available 
(Freeman, 2017). 
 
Registries could engage patients and oncologists also in this topic by jointly planning 
and performing studies aimed at evaluating the comprehensibility of the prognostic 
message provided by different survival measurement methods. In therapies, patients’ 
preferences are more and more carefully considered. Therefore, also the 
comprehensibility of prognostic statistics based on different tools should be formally 
compared and evaluated by users. 
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Approaching the last of the papers presented in this thesis, it is worth recalling that 
the activity of a registry starts from clinical (and administrative) data. The research 
presented here tries to link the production of data to the improvement and extension 
of their use, closing the circle with epidemiological data aimed at improving cancer 
care. 
 
8.7. Cancer registry: a proactive part of the health system 
 
In previous papers (Paper 1-5), the quality of the registry's data has been highlighted, 
as well as traditional and innovative tools to assess it. Quality is a prerequisite for any 
epidemiological evaluation, necessary to guarantee reliable inferential estimates. 
 
The second discussed issue underlines that data not only have to be of excellent 
quality but they, also, have to bear a relevant, informative message.  
 
Finally, in paper 6, also the last leading theme is presented jointly with the previous 
two: the usefulness of registry data.  
 
Therefore, all three themes coexist in this paper, completing the circle. 
 
Paper n. 6 deals with skin melanoma with recommendations for evaluating patterns 
of diagnosis and care. In Tuscan regional recommendations are evaluated here based 
on 13 quality indicators. 
 
The paper involved not only the registry but also a large working group of the Tuscan 
regional oncological institute made up of all the experts from disparate professional 
fields in skin melanoma knowledge and care (dermatologists, pathologists, surgeons, 
oncologists and epidemiologists), academic institutions and community hospitals. 
 
In paper 6 the registry entered the real world with full recognition and appreciation 
by clinicians and policymakers. It provided a fruitful contribution on evaluation of 
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population-based sources of information and in the production of objective and 
reproducible indicators of care.  
 
The process started from questions on melanoma care, raised by clinicians and 
policymakers, aimed at evaluating the level of compliance of services to specific 
recommendations ('usefulness'). The registry defined and produced appropriate 
valuable indexes ('informativeness') based on population-based high-quality data 
('quality'). 
 
Thanks to this multi-professional activity, expected and observed procedures and 
treatments for skin melanoma were compared at the regional level, and reliable 
information was provided to correct weaknesses. 
 
Registries should become more actively involved in the evaluation of quality of care, 
and national and international registry associations should agree on standardised 
cancer-specific indexes, aligned with their periodic updates. The availability of 
common and comparable indexes would make useful comparisons possible. 
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9. Conclusion 
 
The six scientific papers presented in this thesis by Prior Published Work aimed at 
exemplifying how CRs have contributed, and how their contribution could increase, in 
the field of cancer epidemiology and the use of data for a more appropriate and 
effective allocation of resources. 
 
The CRs data represents not only the output of a complex process but also the result 
of technical and strategic decisions. All these steps are inter-related.  
 
In the present thesis, I describe how my research has considered this process as a 
whole, a continuum in which any factor of novelty (new methods, new uses, new 
users) positively affects the following ones.  
 
Registries activity represents a circular process that starts from clinical data and ends 
with epidemiological indexes useful to improve the related care.   
 
The research activity reported in the six presented papers concerned the full process.  
 
Different types of data feed registries. These data are checked, condensed, integrated, 
evaluated and at the end used for producing other data in the form of epidemiological 
indexes to apply by different users for various purposes.  
The informativeness of such indexes, based on high-quality data, has to be 
continuously reconsidered and customised to stakeholders to improve their 
understandability and usefulness for users with different skills. 
If registry data are underused, the money the community pays for supporting such 
activity is partly wasted. The larger the number of users, the higher the registry's 
usefulness for the community and the efficiency of resource investment. 
 
High-quality data, if customised to the objectives and professions of different readers 
are more clearly understood, perhaps appreciated and hopefully used.  
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The process of quality evaluation has probably still rooms for improvement. The 
application of Newcomb-Benford law shows that the topic is still open to innovation, 
using approaches appropriate to the 'big data’s epoch’.  
 
However, the concept of quality should not be confined to data but expanded to 
marketability and use of the information. If high-quality data are not appealing and 
remain unused, they represent merely a waste of public resources typically limited.  
 
Registries should not work merely for epidemiologists and registrars. This self-
referential process distances even more registries from the real world.  
Quality is just the starting point of a process that must continue until data are 
appropriately used as much as possible by all potential stakeholders.  
Therefore, those who produce registries data and are aware of their value have to 
bridge the gap and engage stakeholders.  
 
The summary information traditionally provided by registries (age-standardised 
incident rates) may be made more informative for all types of readers, including a 
measure of internal variability whenever this is possible. The r/R index represents an 
innovative and straightforward change which is objectively useful to improve 
informativeness.  
 
Registries must move closer to clinicians and patients to gain their collaboration. For 
this reason, registries have to include as much clinical data as possible to make 
epidemiological indexes interesting for clinicians and useful for patients and 
policymakers as well. The on-going digitalisation of health systems databases and the 
development of methods for data-mining (Crocetti, 2005) make this possible. 
Registries have to consider the current paths made available by technology. 
 
Collaboration with clinicians joins epidemiological and biostatistical expertise of 
registries with the real clinical world.  
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The experience of registries in data analysis should be exploited as much as possible 
using the potentiality of methodology, for example, to improve the timeliness of 
registries. Time trends exemplify how registries data could be employed to generate 
predictions, i.e., identify the future impact of the disease and the expected demand 
on health services. Such projections are quite relevant for policymakers when they 
plan health care strategies.  
 
Patients should expect registries to provide relevant and reliable information. The 
example comparing Cox and CART analysis reinforces a point in between 
informativeness and usefulness. Registrars could involve both stakeholders (patients 
and oncologists) in the attempt of measuring the effective comprehensibility of the 
two methods and gather evidence for future decisions. 
The scientific community should debate about the balance between statistical 
robustness and comprehensibility of statistics.  
 
The duty to demonstrate the immense value of registry data concerns registrars and 
cannot be the responsibility of readers.  
Registries data must accomplish their role of monitoring tools for the health system 
and the whole population, ensuring the correspondence between clinical 
recommendations and current clinical practice. Registries are surveillance services 
embedded within health systems, and data produced by the same systems feed them. 
Therefore, they are in a privileged position for evaluating the quality of cancer care, 
highlighting critical challenges and proposing advice for their improvements. 
Future health policies need evidence on the clinical points of strength and weakness, 
based on reliable data.  
 
The data input to registries is the footprints left by cancer patients in the databases of 
the health systems during their diagnostic and therapeutic experience. Data produced 
by registries must return to patients in the form of reliable evidence contributing to 
the development of the knowledge of cancer and improvement of the quality of 
cancer care.  
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Therefore, cancer registration may be imagined as a circular process that starts and 
ends with data, both of which represent the real experience of patients.  
 
The primary aims of this research have represented the improvement of quality and 
usefulness of registry data using skin melanoma as a common thread. However, the 
leading concepts of the thesis apply to registration as a whole, that means that they 
may be extended to any tumour. 
This thesis addresses some relevant aspects, but others have been partly or left aside. 
For example, among the former, the need to evaluate the quality of primary sources. 
Examples of not addressed topics may be the right of citizens and patients to be more 
informed about the role of environmental (e.g. UV), recreational (e.g. tanning beds) 
and professional (e.g. outdoor workers) exposure, as other relevant topics, e.g., rules 
and problems with coding, extent of the use of algorithms for automatic decisions, 
have been left in the background. 
 
However, I hope that the general message that the maximum potential of registry data 
must be recognised, used and exploited has been clearly stated. 
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10. Recommendations 
 
The topics discussed in the present thesis may be summarised in the form of some 
recommendations which could contribute to improving the role of registries in the 
short term: 
 
- Traditional methods for quality of data evaluation are well established and reliable. 
However, a formal process of quality assessment with clear cut-offs for each 
indicator is still lacking. International registries associations are expected to agree 
on guidelines on such topics. Moreover, possible violations of Newcomb-Benford 
law could be included in the process of data quality assessment with the 
recommendation for registrars to devote particular attention to traditional indexes 
in case of anomalies. Also, the traditional sources of information (e.g., hospital 
admission forms, pathology reports) and any other digital data which feed the 
process of registry should be tested, first for abidance and then for violation of such 
law. 
 
- The proposed index of internal heterogeneity (r/R) could be routinely added in 
International projects which include dozens or even hundreds of registries, as well 
as in local publications. This index would help readers to understand how far the 
summary index - in the example for incidence - represents sub-areas of each 
registry. Further applications of the same approach could also be investigated and 
applied for other measures (e.g., survival, prevalence) for which identical question 
(Internal homogeneity or heterogeneity?) may still be open. 
 
Each registry individually and networks of registries and scientific societies as well 
should strengthen the collaboration with clinicians, to join forces (and 
competences) to provide the most useful cancer-specific analysis. Therefore, each 
cancer registry has to make available data on those variables which currently 
address diagnosis and treatment. 
 
  169 
- Lack of timeliness is one of the critical points of weakness of registries, and the weak 
interest in data may partly be due to this. Short-term projections could bridge the 
gap and provide, e.g., policymakers, with reliable estimates of the burden of cancer, 
necessary for health policy planning. 
 
- The maximisation of the value and utility of the data could be ensured: 
- A more extensive involvement of stakeholders in planning the agenda of a 
registry is vital. 
- Cancer registries should establish active and continuous collaborations with 
patients. Cancer patients may be extremely supporting, lobbying the need for 
registries. Registrars should plan with them some patient-centred research (e.g., 
infertility, late effect of treatments, economic effects of cancer, time to cure). 
Communication of the risk may be one of the issues for which registrars could 
test and propose technical alternatives to mainstream approaches. 
-  Healthy people have to be also part of the planning of a registry's activity. There 
are specific topics: e.g. environmental pollution, local specific exposures, for 
which a registry is expected to provide reliable population-based evidence. 
 
- Collaboration with cancer patients, clinicians and policymakers will exploit the role 
of registries within the health system to monitor the appropriateness of provided 
care and focus on local weakness. 
 
- The last recommendation is to remind the innovative paradigm proposed in the 
present work: the interrelationship between data production, data analysis and 
data dissemination/interpretation. These represent phases of a continuous process 
and any improvement in each step affects all the others. 
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11. Future research 
 
The future research on cancer registration (and subsequently on cancer epidemiology) 
will be conditioned and inspired by the ongoing technological development, which will 
increasingly affect the availability of information and machines’ capability of managing 
it. 
 
- In this manner, it will be possible to exploit automation in almost all phases of 
cancer registration: collection of sources of information, data selection, linkages, 
identification of possible cases, variables' collection, coding, quality evaluation and 
production of epidemiological measures. Systems for data-mining (e.g., automated 
data extraction and classification, artificial-intelligence-assisted procedures for data 
recording) could be exploited to gather more information from digitalised sources. 
In each specific assessment cost/effectiveness should be compared between 
manual extraction and automated procedure, considering timeliness, accuracy, 
reproducibility and resources availability. The involvement of artificial intelligence 
is supposed to increase in the next future, but this will be a gradual process. This 
change would move human resources from data collection and coding to their 
quality evaluation, shortening the time for information harvesting and valorising 
professionalism. Automation may offer unprecedented opportunities for more 
value-added work, shortening the time of production and expanding the 
deliverables. 
 
This new scenario will require a radical rethinking of well-established principles. On 
the other hand, it will offer an opportunity to extend the capability of registries to 
produce more information, for more stakeholders, in a shorter time. 
 
Presumably, the concept of quality of data is one of the paradigms that registrars will 
have to reconsider. 
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Until now, the quality of data is evaluated at the end of the full registration process. 
Once quality is considered excellent enough, data analysis is performed, for any 
possible purpose. Presently we consider quality in absolute terms. 
 
This type of approach contributes to the lack of timeliness of registry data. Indeed, 
data are unused at all until the full registration process is accomplished. The side effect 
is that even high-quality data on clinical events that had occurred several years before 
may not raise the interest of policymakers, patients or clinicians.  
 
With more automation in the registration process, we could think of diverse types of 
data with a different timing and a diverse quality.  
 
The latter could be called - paraphrasing Zygmunt Bauman (Bauman, 2000) - a liquid 
quality. 
A high quality, appropriate for producing reliable information for a specific aim, but 
possibly different from the high quality necessary for another purpose. 
 
The quality of data has a cost. It requests resources and time. Why should a public 
health system pay for the highest possible quality for data which may appear out-of-
date for some of the possible purposes when published and are not valuable and 
useful for clinicians and patients? 
 
Future research should adopt the quality for specific purposes. The general aim will be 
to employ data with the best necessary quality for reliably answering specific 
questions. 
For example, a study involving an automatic extraction of data from hospital 
admissions produced an equal number of incident breast cancers as the traditional 
cancer registration (Ferretti, 2009). However, the cases were not the same. Therefore, 
the quality of the information produced with this simplified approach was perfect for 
estimating the burden, but not enough for identifying the people. At that time, the 
authors of the paper, including myself, gave more relevance to the negative result, 
reinforcing their belief on the conventional approach to registration (Ferretti, 2009). 
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Regrettably, this delayed the opportunity for registries to directly provide - with 
sufficient quality – information on the burden before the full cohort of patients had 
been carefully identified. However, research on decisional algorithms is going on and 
their capability to correctly identified patients improves thanks to the availability of a 
gold standard (registry) (Rasmussen, 2018; Wu, 2018; Goldsbury, 2017; Kemp, 2013). 
Therefore, their development has to be carefully monitored to utilize them when a 
registry is unavailable (Goldsbury, 2017; Kemp, 2013) but also to consider their 
implementation in the registry’s process. 
 
Registries have to respond to changing demands trying to use as much as possible the 
potentiality offered by automation. At the same moment, they have to enhance their 
professionalism on data, on their quality and interpretation. These precious 
competencies have to complement the expected speed from automation in a good 
collaboration.   
Conversely, there is the risk that registries will be replaced by other systems capable 
of producing a flow of information at a remarkable pace, but without reliable expertise 
on the knowledge and interpretation of its content. 
 
Registrars have both the interest and the responsibility of steering this technological 
change.  
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Oral presentation, 21st May 2009 
 
Diverging figures for thin and thick skin melanoma. 
 
GRELL 2009. XXXIV Group for cancer registration and epidemiology in Latin language 
countries. 20-22 May 2009, Lugano, Switzerland. 
 
Emanuele Crocetti, Carlotta Buzzoni, Antonella Corbinelli, Francesco Giusti, Teresa 
Intrieri, Gianfranco Manneschi, Liuba Nemcova, Claudio Sacchettini, Alessandras 
Chiarugi, Paolo Nardini, Eugenio Paci 
 
Tuscany Cancer Registry, Clinical and descriptive epidemiology unit and *Unit for early 
diagnosis of melanoma, ISPO, Florence, Italy 
 
Objective 
Breslow’s thickness is the most relevant prognostic factor for skin melanoma. Most of 
thick melanomas are of nodular type. Early diagnosis aims at detecting melanoma 
when it is thin and it can be successfully removed with very good prognosis. This study 
focuses on the evaluation of melanoma incidence trends according to thickness and 
morphology. 
Methods 
We analysed data from the Tuscany Cancer Registry for four subsequent 5-year 
periods from 1985 to 2004. The following morphology were analysed (ICD-0 3 
morphology code): superficial spreading (8743), on lentigo (8742), nodular (8721), 
other types, not otherwise specified (8720). Thickness was categorized as follows: thin 
(0.01-0.99 mm), intermediate (1.00-1.99 mm), thick (2+mm). 
Results 
The incidence of skin melanoma has markedly increased over time. The number of 
newly diagnosed skin melanoma has particularly increased (+57%) from 1985-89 (n. 
442) to 2000-04 (n. 1020). The proportion of thin melanoma has grown from 18.6% to 
45.5%, while the proportion of thick ones has decreased from 28.1 to 20.5. Also, 
intermediate melanoma has decreased from 17.9 to 12.9, by the same amount of the 
cases who were lacking information on Breslow’s thickness (from 35.5 to 21.1%). The 
main cause of the growth of incidence lies in the growth of superficial spreading 
melanoma. In the meantime, the median thickness went from 1.7 mm to 0.8 mm. The 
thinning of the median thickness for SSM went from 1.20 mm to 0.68 mm. Among 
thick melanoma (>=2 mm) from 1985-1989 to 2000-2004 there were no statistically 
significant changes, neither of the mean thickness (from 4.2 mm to 4.9 mm) nor of 
that median (from 3.3 to 3.7 mm).In the most recent period (2000-2004), nodular 
melanomas represent 6.2% of all the cases but 24.5% of the thick ones. During the 
analysed period there was no statistically significant change in the median thickness 
for nodular melanomas. 
Conclusions 
The overall decrease of the mean thickness at diagnosis for skin melanomas observed 
in central Italy from mid-80ths to mid 2000ths was due to the diagnosis of a number 
of increasingly thinning melanomas. On the other hand, thick melanomas – most of 
them of nodular type - did not show any evident sign of modification regardless of the 
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time of diagnosis. Nodular melanomas did show stable incidence over time and their 
median thickness did not change. This type of deadly melanoma, more than others, is 
the target for future prevention actions. 
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Oral presentation, 5th May 2016 
 
A possible contribution to the quality evaluation of cancer registry data may come 
from the Benford's mathematical law 
 
Grell - Group for cancer registration and epidemiology in Latin language countries. 4 - 
6 May 2016, Albi, France 
https://docs.wixstatic.com/ugd/6510a0_e79879a68cd44b4093c6ca71c48dacac.pdf 
 
Emanuele Crocetti, Giorgia Randi, Tadek Dyba, Raquel Carvalho, Francesco Giusti, 
Carmen Martos, Roisin Rooney, Manola Bettio 
 
European Commission, DG Joint Research Centre (JRC), Institute for Health and 
Consumer Protection, Public Health Policy Support Unit 
 
Objectives  
According to the Benford's law, the distribution of the occurrences of the first digit 
(FSD) in many large collections of numbers is not uniform. We evaluated, in a sample 
of GRELL cancer registries, whether incidence rates followed Bedford's law, as a 
possible contribution in their quality check process. 
Materials and methods 
Data from six European population-based cancer registries from GRELL countries 
(Belgium, France, Spain, Italy, Portugal and Switzerland) were retrieved from the 
Cancer Incidence in 5 Continents-X website. Crude incidence rates were computed for 
the main cancer groups. The distribution of FSD of incidence rates was computed for 
the six registries altogether, and separately by registry and sex. The adherence of the 
observed FSD frequency distributions to the Benford's law was evaluated both 
graphically and through several statistical tests. 
Results 
All the FSD distributions of incidence rates were positively skewed, as expected for 
those following Benford's law. The ratios between the frequency of the first and the 
second digit ranged around Benford's expected value (1.7), as that between the first 
and the ninth (6.6). The coefficient of correlation was overall high but not always as 
expected, ranging from 0.82 to 0.99. Also the distance measures from the observed 
and the expected FSD distribution, although generally small, showed slightly higher 
values for some registries. 
Discussion and conclusions 
The quality evaluation of cancer data is complex and implies assessing several different 
dimensions. The FSD distribution of incidence rates, in this GRELL setting, appeared to 
adhere to the Benford's law. The analyzed data had already been checked and 
approved for publication in Cancer Incidence in 5 Continents-X. However, some minor 
deviations from the Benford's distribution may still suggest possible revision or 
integration of the applied criteria for data validation. 
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Poster, 7-10 June 2016 
 
Can We Apply Benford’s Law To Check Quality Of Cancer Incidence Data? 
 
IARC 50 years Global cancer. Occurrence, causes and avenues to prevention. 7-10 June 
2016, Lyon, France. 
http://www.iarc-
conference2016.com/index.php?onglet=21&idUser=&emailUser=&acces=&recherch
e=crocetti 
 
Emanuele Crocetti, Giorgia Randi, Tadeusz Dyba, Raquel Carvalho, Francesco Giusti, 
Carmen Martos, Roisin Rooney, Lydia Voti, Manola Bettio 
 
European Commission, DG Joint Research Centre, Institute for Health and Consumer 
Protection, Public Health Policy Support Unit, Ispra (VA), Italy 
 
Purpose 
Benford's law states that the distribution of the occurrence of the first significant digit 
(FSD) of a number, in many large collections of numbers, is not uniform. The aim of 
this study was to evaluate whether population-based cancer incidence rates follow 
Benford's law and if this can be used in their data quality checking process. 
Methods 
Detailed databases from six population-based cancer registries (from Africa, North and 
South America, Asia, Europa and Oceania) were retrieved from the Cancer Incidence 
in 5 Continents-X website. These datasets consisted of 244 combinations of 
topography and morphological groups, 18 age groups and two sexes. The distribution 
of FSD was evaluated for the whole dataset, plus for some subgroups as cancer 
registries, cancer types and sexes. Several statistics, including Pearson's coefficient of 
correlation, distance measures and specific tests, were applied to check for 
consistency between calculated FSD frequency distribution and the theoretical 
Benford's one. 
Results 
The distribution of FSD, calcutated for each combination, consistently showed mean 
values greater than the medians and were positively skewed. For the whole dataset 
(22,180 observations), and for single cancer registries (from 1,546 to 6,296 
observations), the coefficient of correlation was high, ranging from 0.918 to 0.997. 
Also the distance measures were very low. Very similar results were obtained for 
major cancer sites, and sexes. The need for statistical tests, not influenced by sample 
size, was confirmed. 
Conclusions 
The data analyzed in this study had already been checked and approved for publication 
in Cancer Incidence in 5 Continents-X. Therefore, their quality was expected to be 
good. This study demonstrated that cancer incidence rates follow Benford's law. This 
suggests using the adherence to Benford's law of the FSD distribution of incidence 
rates as a quick tool in their quality evaluation, in order to identify possible deviations 
for further investigations. 
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Oral presentation, 6th October 2016 
 
Cancer incidence rates and Benford’s law: a useful liaison 
 
ENCR Scientific Meeting and General Assembly. Joining forces for better cancer 
registration in Europe 5-7 October 2016, Baveno, Italy 
http://publications.jrc.ec.europa.eu/repository/bitstream/JRC102769/encr%202016
%20conference%20book%20%28print%29%20%28secured%29_2.pdf 
 
Emanuele Crocetti, Giorgia Randi, Raquel Carvalho, Tadeusz Dyba, Francesco Giusti, 
Carmen Martos, Roisin Rooney, Lydia Voti, Manola Bettio 
 
European Commission, DG Joint Research Centre, Ispra, Italy 
 
Background and Introduction 
In 1938 Benford described an odd distribution of the first significant digit (FSD) in many 
numerical collections: the probability to have 1 as FSD is 30.1 % then it slightly and 
consistently lowers up to 9 which is least frequent FSD. This pattern is already used to 
identify possible violations in numerical data (e.g. in accounting). We evaluated 
whether population-based cancer incidence rates follow Benford’s law (BL), to detect 
possible violations during data quality assessment of cancer registry (CR) data. 
Materials and Methods 
We randomly sampled from CI5C-X web site the detailed databases of two population-
based CRs 
for each of the following regions: Africa, north 
and south America, Asia, Europe and Oceania. The distribution of the FSD of crude 
incidence rates was evaluated for each separate registry, and for all of them together 
in a single dataset. The observed FSD distribution was plotted against the Benford 
theo- retical one, and the following statistics were computed: Person’s r, distances’ 
measures, and Chi2/n to check if the data are well-modelled by BL. A summary index 
was also computed (the lowest the index, the best the fitting). 
Results 
The distributions of FSD of crude incidence rates (overall on 40493 observations) 
showed a mean greater than the median and a positive skewness, typical of Benford-
like distributions. In fact, it fitted almost perfectly Benford distribution (r = 0.997; 
m=0.01; d*=0.02; Chi2/n=0.05). Individual selected CRs (from 779 to 5 376 
observations) had generally very good fitting; however, one registry had all the four 
statistics in the worst duo-decile (p=0.00005). 
Conclusions 
Crude cancer incidence rates adhere to BL. This suggests using BL as a quick, easy and 
objective screening tool for assessing CR data quality. The CR with the worst 
adherence to BL had a warning also in CI5C-X. We propose to use the BL as a screening 
tool in cancer data quality evaluation, identifying anomalies worthy of further 
inspection.  
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Poster, 5-7 October 2016 
 
Cancer registries should additionally provide information on cancer incidence 
geographical variability 
 
ENCR Scientific Meeting and General Assembly. Joining forces for better cancer 
registration in Europe 5-7 October 2016, Baveno, Italy. 
http://publications.jrc.ec.europa.eu/repository/bitstream/JRC102769/encr%202016
%20conference%20book%20%28print%29%20%28secured%29_2.pdf 
 
Emanuele Crocetti, Giorgia Randi, Raquel Carvalho, Tadeusz Dyba, Francesco Giusti, 
Carmen Martos, Roisin Rooney, Lydia Voti, Manola Bettio 
 
European Commission, DG Joint Research Centre, Ispra, Italy 
 
Background and Introduction 
The frequency of cancer in a defined population and in a certain period is reported by 
cancer reg- istries (CR) as a rate, age-standardised to allow for reliable comparisons. 
This is the standard statistic computed by all CRs independent of the size of the 
population at risk. The measure of variability provided – standard error – refers to the 
precision of the estimator and does not reflect the heterogeneity in cancer incidence 
within the area. Some national CRs are publishing incidence rates at a lower geo- 
graphical level providing thus more insight into intra-CR incidence variability. 
Materials and Methods 
We retrieved from Nordcan (http://www-dep.iarc. fr/NORDCAN) the European age-
standardised incidence rates (ASR) for Denmark and Finland in 2013, at national level 
as well as for five regions in each country, for all sites excluding non-melanoma skin 
cancer, for men. Differences between and within countries were evaluated. 
Results 
The national ASR for Denmark was 479.4, and for Finland 422.2 per 100000 py. The 
standard errors, 3.68 and 3.46, were negligible due to a big number of incident cases 
considered, 17 582 and 15 517 respec- tively. ASRs for the Danish regions ranked from 
458.7 in Zealand to 495.9 in Southern Denmark (range: 37.2). As regards Finland, 
regional ASRs varied between 362.1 in Turku to 490.4 in Tampere, with a range of 
128.3. Significant differences were observed both between and within countries. 
Conclusions 
Although both Danish and Finnish ASRs are cor- rect, the analysed example 
demonstrates that the national ASR may reflect more (Denmark) or less accurately 
(Finland) the incidence of cancer in the different regions of a country. When 
heterogeneity is present regional rates are more informative than the national ones. 
The unavailability of a unique population-unit for sub-areas makes comparisons 
difficult. However, CR should start to deal with the need to provide information on 
internal cancer incidence variability as well as just incidence.  
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Poster, 19-21 October 2016 
 
No hints on geographical heterogeneity of cancer incidence in cancer registry rates.  
 
The 38th Annual IARC Conference Marrakech (Morocco) 19 - 21 October 2016  
http://www.iacr.com.fr/images/AnnualMeetings_Abstracts/20161012_IARC_WEB-
Abstracts-Marrakesh_V8.pdf 
 
Francesco Giusti, Emanuele Crocetti, Giorgia Randi, Raquel Negrao Carvalho, Tadeusz 
Dyba, Carmen Martos,  Roisin Rooney, Lydia Voti, Manola Bettio 
 
Joint Research Centre / European Commission, Ispra (VA), Italy 
 
Background 
As a standard practice worldwide, cancer registries (CRs) express the frequency of 
cancer in a defined population and in a certain period as a rate, independently of the 
size of the population at risk. However, this single measure may not describe the 
variability of incidence within a country. In fact, the only measure of variability 
provided – the standard error - refers to the precision of the estimator. 
Methods 
We retrieved from the CDC website 
(https://nccd.cdc.gov/uscs/) age-adjusted (US 2000) incidence rates (ASR) and 95 
confidence intervals (CI) for all cancer sites combined, for the period 2008-12, in the 
whole United States (US). We compared them across sub-geographical areas (4), 
regions, states (50) and a few cities, using the overlap between CI of ASR. 
Results 
The overall US ASR, for men and women together, was 462.0 cases per 100.000 
person/year (95 CI 461.6-462.3). The national rate was lower (95 CI did not overlap) 
than the ASRs in Northeast and Midwest and higher (95 CI did not overlap) than in 
South and West regions. 26 states had incidence rates higher, 18 lower and six states 
within the variability of the national average rate. Additionally, within states, the 
overall ASR did not reflect accurately single cities (e.g. California and sub-areas) 
Conclusions 
In this exploratory analysis, the US ASRs are used to demonstrate how a national (or 
supranational) ASR may not reflect incidence of subareas. Although we did not 
statistically quantify this variability major differences appeared between and within 
regions, states and cities. When heterogeneity is present among regions, regional 
rates are more informative than the single national one. CRs should then start 
providing information on internal cancer incidence variability as well as on incidence 
level. 
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Poster, 19-21 October 2016 
 
Cancer incidence rates are numbers which must abide by mathematical laws.  
 
The 38th Annual IARC Conference Marrakech (Morocco) 19 - 21 October 2016 
http://www.iacr.com.fr/images/AnnualMeetings_Abstracts/20161012_IARC_WEB-
Abstracts-Marrakesh_V8.pdf 
 
Giorgia Randi, Emanuele Crocetti, Raquel Negrao Carvalho, Tadeusz Dyba, Francesco 
Giusti, Carmen Martos, Roisin Rooney, Lydia Voti, Manola Bettio 
 
Joint Research Centre / European Commission, Ispra (VA), Italy 
 
Background 
Some numerical series abide by Benford's law (BL). BL describes the distribution of the 
first significant digit (FSD) of these numbers, which is unexpectedly skewed towards 
small figures. Violations of BL are already considered evidences in trials for frauds in 
accounting. We evaluated whether population-based cancer incidence rates follow BL, 
to use possible violations during the quality assessment of cancer registry (CR) data. 
Methods 
We randomly sampled from CI5C-X website the detailed databases of two population-
based CRs for each of the following regions: Africa, north and south America, Asia, 
Europe and Oceania. The distribution of the FSD of crude incidence rates was 
evaluated for each registry separately, as well as for all of them together in a single 
dataset. The observed FSD distribution was plotted against the Benford theoretical 
one, and the following statistics were computed: Person's r, distances' measures, and 
Chi2/n to check if the data were fitting Benford's distribution. A summary index was 
also computed (the lower the index the best the fitting). 
Results 
The distributions of FSD of crude incidence rates (overall on 40493 observations) 
showed a mean greater than the median and a positive skewness, typical of Benford-
like distributions. In fact, FSD of rates fitted almost perfectly BL (r=0.997; m=0.01; 
d*=0.02; Chi2/n = 0.05). Single CRs (having from 779 up to 5376 observations) had 
generally very good fitting; however, one registry had all the four statistics in the worst 
decile (p=0.00005). 
Conclusions 
Crude cancer incidence rates adhere to BL. BL is very simple, quick and easy to be 
understood and computed. Moreover, it does not rely on subjective opinion or 
personal professional expertise of any reviewer. Therefore, we propose to add the use 
of BL, as an objective screening tool in cancer data quality assessment, to identify 
anomalies worthy of further inspection. 
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Oral presentation, 25th May 2017 
 
Incidence rates and intra-area variability. 
 
Grell - Group for cancer epidemiology and registration in Latin language countries. 
Ascension Reunion, 24-26 May 2017, Brussels 
 
Emanuele Crocetti, Francesco Giusti, Giorgia Randi, Tadeusz Dyba, Carmen Martos, 
Manola Bettio  
 
European Commission, Directorate General Joint Research Centre, Directorate F – 
Health, Consumers and Reference Materials, Health in Society Unit Via E. Fermi, 2749. 
21027 Ispra (VA), Italy 
 
Objectives.  
Usually the new cases of cancer diagnoses within a specific area are reported in the 
form of incidence rate. The standard error (SE) of the rate expresses the precision of 
the estimator. Incidence rates in themselves do not provide any information on the 
variability in a geographical comparison among different areas. The objective of this 
study is the evaluation of this issue, and related suggestion for a measure reflecting 
correctly this variation.  
Methods.  
We retrieved from Nordcan (www-dep.iarc.fr/NORDCAN) the age standardised 
incidence rates (ASR, European population) and 95% confidence intervals (CI) for all 
cancer sites but non-melanoma skin cancers, in 2014, among men. We compared, 
looking at 95% CI overlaps, the overall ASR for Nordic Countries with each country-
level ASRs, and the latter with the Regional ASRs. We tested as a summary measure to 
report on variation the ratio (r) between ASRs for sub-areas and the overall ASR (R) of 
the area, r/R.  
Results.  
The overall ASR for Nordic Countries is 453.1 cases for 100.000 inhabitants (SE 1.6); 
95% CI of this rate are above those of Faroe Islands (251.0; 28.8), Finland (404.5; 3.4), 
Iceland (387.2; 14.8) and Sweden (428.5; 2.6) and below those of Denmark (504.4; 
3.7) and Norway (509.9; 4.1). This heterogeneity becomes evident when looking at the 
r/R value of 46%, meaning that the range between ASRs of single Countries is 46% of 
the overall ASR. The same pattern applies for the comparison within Countries, where 
the r/R is small in Iceland (r/R 10%), Denmark and Norway (14%), and wider in Finland 
(32%) and Sweden (38%).  
Conclusions.  
This exploratory analysis confirms that the overall ASR for a well-defined area may not 
reflect correctly the variation occurring among the different sub-areas. The adoption 
of the proposed r/R ratio in addition to the traditional ASTs would help to underline 
such heterogeneity. 
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Appendix 2: Sub-analysis originally not included in the presented papers (‘data not 
shown’). 
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Addendum to paper n. 1 
 
Sub-analysis by sex.  
Comparison of expected (Benford’s law) distribution of first significant digits with 
observed ones by sex. 
Sex: men (n. 70,722 observations) 
 
Table 16: Incidence rates for men: comparison of the observed and expected 
percentage distribution of each first significant digit. 
First digit Observed Expected 
1 31.4 30.1 
2 17.54 16.61 
3 12.52 12.49 
4 9.6 9.6 
5 7.7 7.9 
6 6.3 7.7 
7 5.8 5.8 
8 4.7 5.1 
9 4.7 4.6 
   
Mean 3.4 3.4 
 
Pearson correlation coefficients (r) = 0.999 
Maximum distance in absolute terms between expected and observed frequencies for 
each of the nine digits (m) = 0.01267 B2/n: B2 divided by the sample size = 117.2 
the normalised Euclidean distance between the two distributions divided by the 
maximum possible distance (d*) = 0.0143 
Z statistic (z) = 0.82 
 
Sex: women (n. 75,868 observations). 
 
Table 17: Incidence rates for women: comparison of the observed and expected 
percentage distribution of each first significant digit. 
First digit Observed Expected 
1 31.6 30.1 
2 17.7 16.61 
3 12.1 12.49 
4 9.2 9.6 
5 8.1 7.9 
6 6.0 7.7 
7 5.8 5.8 
8 4.8 5.1 
9 4.8 4.6 
   
Mean 3.4 3.4 
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Pearson correlation coefficients (r) = 0.999 
Maximum distance in absolute terms between expected and observed frequencies for 
each of the nine digits (m) = 0.01461 B2/n: B2 divided by the sample size = 117.2 
the normalised Euclidean distance between the two distributions divided by the 
maximum possible distance (d*) = 0.0174 
Z statistic (z) = 1.22 
 
 
Sub-analysis by registries.  
Comparison of the expected (Benford’s law) mean (3.44) and median (3) of first 
significant digits distribution with the observed values by registries. 
The expected (Benford’s law) values are: 3.44 for the mean and 3 for the median.  
 
Table 18: Distribution of first significant digits by registries: observed mean and 
median. 
Registry Mean Median 
1 3.5 3 
2 3.5 3 
3 3.5 3 
4 3.4 3 
5 2.8 2 
6 3.7 3 
7 3.5 3 
8 3.7 3 
9 3.5 3 
10 3.6 3 
11 3.2 2 
12 3.4 2 
13 3.1 2 
14 3.4 3 
15 3.6 3 
16 3.1 2 
17 3.3 3 
18 3.3 2 
19 3.4 2 
20 3.1 2 
21 3.4 3 
22 3.2 2 
23 2.9 2 
24 3.3 2 
25 2.9 2 
26 3.5 2 
27 3.6 3 
28 4.2 3 
29 3.5 3 
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30 3.6 3 
31 3.4 2 
32 3.6 3 
33 3.2 2 
34 3.7 3 
35 3.2 2 
36 3.6 3 
37 3.0 2 
38 3.2 2 
39 3.5 3 
40 3.5 3 
41 3.3 2 
42 3.2 2 
43 3.2 2 
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Addendum to paper n. 2 
 
Table 19: Country layers, number of incident  cases of 'all sites excluding non-
melanoma skin cancer', in men, in 2012, resident population, European age-
standardised incidence rates (ASR), standard error (SE) of the ASR, lower (LCI) and 
upper (UCI) 95% confidence intervals and R/R (Range/Rate : Range is the absolute 
difference in ASRs between the greatest and lowest ASR for areas in the lower layer; 
Rate is the ASR) Data from Nordcan (http://www-dep.iarc.fr/NORDCAN). 
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Nordic countries 76,603 452.6 1.67 449.3 455.9 152.9 0.34 
  Denmark 18,819 522.6 3.87 515.0 530.2 52.5 0.10 
   North Jutland 2,107 523.3 11.68 500.4 546.2     
   Central Jutland 3,887 483.4 7.85 468.0 498.8     
   Southern 4,200 521 8.12 505.1 536.9     
   The capital 5,300 535.9 7.44 521.3 550.5     
   Zealand 3,294 521 9.46 502.5 539.5     
  Faroe Islands 112 373.2 35.62 303.4 443.0     
  Finland 14,865 415.1 3.47 408.3 421.9 61.9 0.15 
   Helsinki 4,638 431.1 6.4 418.6 443.6     
   Kuopio 2,227 363.7 7.95 348.1 379.3     
   Oulu 1,935 386.2 8.96 368.6 403.8     
   Tampere 3,277 425.6 7.6 410.7 440.5     
   Turku 2,778 445.1 8.68 428.1 462.1     
  Greenland 94 380.9 41.62 299.3 462.5     
  Iceland 755 440.1 16.24 408.3 471.9 1.5 0.00 
   Reykjavik-Reykjanes 504 441.6 19.9 402.6 480.6     
   Outside the capital 251 437.1 28.14 381.9 492.3     
  Norway 15,634 526.1 4.26 517.8 534.4 64.8 0.12 
   Central 2,233 517.2 11.13 495.4 539.0     
   Northern 1,470 479.9 12.69 455.0 504.8     
   South-Eastern 8,743 530.6 5.74 519.3 541.9     
   Western 3,188 544.7 9.74 525.6 563.8     
  Sweden 26,530 404.8 2.56 399.8 409.8 64.7 0.16 
   Northern 2,528 376 7.8 360.7 391.3     
   Stockholm-Gotland 5,284 420.1 5.84 408.7 431.5     
   Southern 5,217 436.3 6.25 424.1 448.6     
   South-Eastern 3,109 422.5 7.98 406.9 438.1     
   Uppsala-Örebro 5,515 371.6 5.22 361.4 381.8     
   Western 4,877 402.9 5.95 391.2 414.6     
        
  
  226 
Addendum to paper n. 3 
 
 
Table 20: Time trends of median thickness for skin melanoma thick >=3 and >=4 mm. 
Thickness 1985-1989 1990-1994 1995-1999 2000-2004 
>=3mm 4.0 4.5 4.5 4.68 
>=4 mm 5.1 6.0 5.35 5.8 
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Appendix N. 3: List of the six published papers discussed in the thesis. 
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Variability of cancer risk within an area: time to complement
the incidence rate
Emanuele Crocetti, Francesco Giusti, Carmen Martos, Giorgia Randi,
Tadeusz Dyba and Manola Bettio
The aim of this study was to show that age-adjusted cancer
incidence rates for an area may not be representative of the
incidence in subareas. We propose a simple measure to show
the amount of geographical variability. European age-
standardized incidence rates (ASRs) for ‘all sites excluding
nonmelanoma skin cancer’, for men, in 2014, for Nordic
countries as a whole, for each country (Denmark, Faroe Islands,
Finland, Greenland, Iceland, Sweden and Norway) and for their
regions, were retrieved from the Nordcan with corresponding
standard errors SEs. We compared the ASR for Nordic
countries versus single country and single country versus
specific regions. The overlapping of 95% confidence intervals
was used for ASRs comparisons. As a measure of variability,
we computed the range between the highest and the lowest
ASR within an area and the ratio between this range and the
ASR of the overall area, r/R= (range/ASR)×100. The 95%
confidence interval of the ASR for Nordic countries as a whole
did not overlap those of the majority of the single countries; in
fact, the r/R – which provides a clue for the amount of
underlying geographical variability – was rather large (57.1%).
Within countries, the variability was negligible in
Iceland (r/R=9.6%), whereas the highest value was found in
Sweden (37.1%). The ASR does not provide any information on
underlying geographical variability. Therefore, its
interpretation could be misleading. When data for subareas are
available, the r/R, which is simple to compute and to
understand, should be added to the ASR for providing
more truthful information. European Journal of Cancer
Prevention 26:442–446 Copyright © 2017 The Author(s).
Published by Wolters Kluwer Health, Inc.
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Introduction
As a standard practice worldwide, population-based cancer
registries (CRs) express the occurrence of cancer in a
defined population in a certain period as the ratio between
the newly diagnosed cancers and the at-risk resident
population. This ratio is called the crude incidence rate
(Boyle and Parkin, 1991). Cancer incidence increases with
the ageing of the population. Therefore, incidence rates are
strongly dependent on the age structure of the underneath
population. Consequently, rates are computed using a
standard age structure as a reference (age-standardized rate,
ASR) to enable reliable comparisons across time and
countries (Boyle and Parkin, 1991). Crude rates and ASRs
are the standard indicators reported by all CRs indepen-
dent of the size of the population at risk. These statistics
are usually complemented by a measure of precision, the
standard error (SE) of the rate and/or the 95% confidence
intervals (CIs).
An incidence rate expresses the summary probability of
developing cancer in the area covered by the CR. It
provides no clues on the homogeneity or the hetero-
geneity of incidence rates across subareas.
To gain more insight into this topic and to explore the
possible variability in ASRs among subareas of CRs, we
analysed the data of the Association of the Nordic Cancer
Registries, which makes data available in the Nordcan
project (Engholm et al., 2016).
Methods
We retrieved from the Nordcan the European ASRs for
‘all sites excluding nonmelanoma skin cancer’, for men,
in 2014.
ASRs are available for three geographical layers as pre-
sented in Table 1: (a) Nordic countries as a whole; (b)
single country: Denmark, Faroe Islands, Finland,
Greenland, Iceland, Sweden, Norway; and (c) regions: five
in Denmark: North Jutland, Central Jutland, Southern
Denmark, The Capital and Zealand region; five in Finland:
Helsinki, Kuopio, Oulu, Tampere and Turku region; two
in Iceland: Reykjavik-Reykjanes and Outside The Capital;
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six in Sweden: Northern, Stockholm–Gotland, Southern,
South-Eastern, Uppsala-Örebro and Western region; and
four in Norway: Central, Northern, South-Eastern and
Western region.
The overall male resident population in Nordic countries
in 2014 was 13 075 123. Residents in single countries and
regions are shown in Table 1.
ASRs express the number of new cases diagnosed among
100 000 men in 2014 according to the observed age-
specific rates and the age-groups of the European stan-
dard population.
We also retrieved from Nordcan the SE of the ASRs and
we computed the 95% CIs according to the method of
the binomial approximation (Boyle and Parkin, 1991)
(Table 1).
We evaluated whether two rates were different inspect-
ing the overlap between specific 95% CI (Schenker and
Gentleman, 2001). The precision of the age-specific rates
that concur in the calculation of ASR increases when the
number of cases in this group increases. This applies to
each age group and thus to ASR as the whole entity. The
overall numbers observed yearly in the analysed series
(Table 1) were, with the exception of Faroe Islands and
Greenland, in the order of several hundreds or even
thousands. SEs of the ASR are greater when the numbers
on which they are based are small.
We compared the ASR at each geographical level with
the level underneath: Nordic countries versus Denmark,
Faroe Islands, Finland, Greenland, Iceland, Sweden,
Norway and single country versus specific regions.
Moreover, we computed the absolute difference (range)
between the highest and the lowest ASR within a nested
layer (the range between countries for Nordic countries
and between regions for a specific country). Then we
calculated the percent ratio between this range and the
ASR of the level above interpreted as a summary value of
the subareas (for Nordic countries or a single country,
respectively), r/R= (range/ASR)× 100.
The r/R provides a measure of the variability across the
available ASRs of the nested level for which the ASR
represents the summary measure. The smaller the r/R
(minimum 0%), the lower the variability across
subarea ASRs.
Results
In Fig. 1, the ASRs for Nordic countries as a whole, for
single countries and for country-specific regions, are
shown with the corresponding 95% CI. The ASRs for
countries appear to be scattered in the picture. In fact,
Table 1 Data from Nordcan (http://www-dep.iarc.fr/NORDCAN): country layers, country/region name, number of incident cases of ‘all sites
excluding nonmelanoma skin cancer’, in men, in 2014, resident population, European age-standardized incidence rates, SE of the ASR, lower
and upper 95% confidence intervals and r/R
Layer Area N Resident population ASR (European) SE LCI UCI r/R (%)
1 Nordic countries 79 441 1 307 5123 453.1 1.6 449.9 456.3 57.1
2 Denmark 19 031 2 799 895 504.4 3.7 497.1 511.7 14.4
3 North Jutland 2004 292 697 474.8 10.9 453.4 496.2
3 Central Jutland 4165 639 192 496.5 7.8 481.2 511.8
3 Southern 4230 600 667 493.0 7.8 477.7 508.3
3 The Capital 5245 860 818 507.1 7.1 493.2 521.0
3 Zealand 3387 406 521 547.5 9.7 528.4 566.6
2 Faroe Islands 78 25 039 251.0 28.8 194.6 307.4
2 Finland 15 142 2 686 119 404.5 3.4 397.9 411.1 31.9
3 Helsinki 4849 922 582 427.2 6.2 415.0 439.4
3 Kuopio 2194 403 920 345.5 7.7 330.5 360.5
3 Oulu 1970 372 534 382.2 8.8 364.9 399.5
3 Tampere 3811 545 749 474.6 7.9 459.1 490.1
3 Turku 2303 441 350 348.5 7.5 333.7 363.3
2 Greenland 99 29 742 384.1 40.6 304.5 463.7
2 Iceland 694 164 257 387.2 14.8 358.1 416.3 9.6
3 Reykjavik 481 115 443 401.2 18.5 365.0 437.4
3 Outside 213 48 818 364.1 25.4 314.3 413.9
2 Norway 15 865 2 581 421 509.9 4.1 501.9 517.9 13.9
3 Central 2362 357476 526.9 11.0 505.3 548.5
3 Northern 1489 242 918 468.8 12.4 444.6 493.0
3 South-Eastern 8685 1 433 445 502.9 5.5 492.2 513.6
3 Western 3329 547 582 539.8 9.4 521.3 558.3
2 Sweden 28709 4 843 303 428.5 2.6 423.4 433.6 37.8
3 Northern 2521 444 391 364.5 7.6 349.6 379.4
3 Stockholm-Gotland 6735 1 111 680 526.3 6.5 513.6 539.0
3 Southern 5375 872 866 438.1 6.2 425.9 450.3
3 South-Eastern 3130 510 943 415.8 7.7 400.6 431.0
3 Uppsala-Örebro 5852 1 002 193 385.8 5.3 375.5 396.1
3 Western 5096 901 258 407.1 5.9 395.6 418.6
The smaller the r/R the lower the variability across subareas ASRs.
range/Rate% (r/R): range is the absolute difference in ASRs between the greatest and the lowest ASR of subareas in the lower layer; rate is the ASR.
ASR, age-standardized incidence rate; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval.
Cancer incidence heterogeneity Crocetti et al. 443
the ASR for Nordic countries (453.1) is compatible with
the Greenland's one only (384.1) because of the wide
range of variability of the latter, because of the small
number of cases on which it is based and the resulting
imprecision in its computation (wide 95% CI). In con-
trast, Denmark (504.4) and Norway (509.9) showed
greater ASRs that the Nordic countries one and Faroe
Islands (251.0), Finland (404.5), Iceland (387.2) and
Sweden (428.5) have lower values than the supranational
summary ASR (Fig. 1).
In Table 1, for each area (Nordic countries, country and
region), the number of cancer cases for ‘all sites excluding
nonmelanoma skin cancer’, for men, in 2014 and the
resident population are reported together with the ASR,
the SE and the 95% CI.
The inverse relationship between number of observed
cases and the SE is evident. In fact, SE is only 1.6 (cases
per 100 000 men in 2014) for Nordic countries (on the
basis of 79 441 analysed cases), whereas it is 40.6 for
Greenland (99 cases).
In Table 1, the r/R is also reported for geographical level
1 (Nordic countries vs. countries) and 2 (single countries
vs. regions).
When the ASR of Nordic countries is evaluated together
with the r/R, the value of r/R= 57.1% provides a clear
hint of a huge intercountries variability in ASRs, clearly
shown in Fig. 1. In fact, this r/R means that the range
between the lowest and the highest country-specific ASR
is almost 60% of the Nordic country ASR.
Also within single countries, the overall ASR may not
represent the regional ASRs and the amount of internal
variability (Fig. 1) is well described by r/R (Table 1).
The smallest r/R value (9.6%) was observed in Iceland,
where the small numbers of observed cases led to a non-
negligible uncertainty in the regional estimates whose
wide 95% CI overlapped the national one. A minor
amount of variability (r/R= 13.9%) was present in
Norway, where the Northern region (ASR= 468.8) had a
lower value and the Western region (539.8) had a higher
ASR than the summary one. Almost the same r/R was
present in Denmark (14.4%), where North Jutland
(474.8) showed an ASR lower than the national value and
Zealand (547.5) showed a greater one. Finland showed a
greater inter-regional variability (31.9%), with Kuopio
(345.5) and Turku (348.5) below and Helsinki (427.2)
and Tampere (474.6) above the national mean. Finally,
the slightly higher internal variability was found in
Sweden (RR= 37.8%) where three regions, Northern
Fig. 1
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European age-adjusted incidence rates for ‘all sites excluding nonmelanoma skin cancer’, for men, in 2014, for Nordic countries, single countries and
regions. From Nordcan (http://www-dep.iarc.fr/NORDCAN).
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(364.5), Uppsala-Örebo (385.8) and Western (407.1),
were below the national ASR and Stockholm–Gotland
(526.3) higher than the country one.
Conclusion
This epidemiological exercise underlines that ASRs,
which clearly provide the level of cancer incidence in a
specific area and time for geographical and time com-
parisons, do not provide any information on possible
internal variability. In fact, the SE, which usually
accompanies ASR, refers only to the precision of the
estimate and does not reflect the possible heterogeneity
in cancer incidence in the area.
Therefore, the ASR of a CR, although correct from the
computational point of view, and informative for geo-
graphical and time comparisons, could represent the
incidence level only in some subareas or even in none.
If a CR also provides ASR for subareas, r/R is not
necessary because the information on possible geo-
graphical heterogeneity is available. In contrast, if a CR
only publishes a summary ASR, as happens for many CRs
in Cancer incidence in five continents (Ferlay et al.,
2014), which is the most well-known and authoritative
publication in the field, r/R is invaluable to have a clear
impression of the variability behind the ASR.
When incidence data are available for different geo-
graphical layers, it is possible to add to the ASR a sum-
mary measure about the underlying variability. The
Nordic countries dataset provided the invaluable chance
of evaluating three subgeographical levels: supranational,
national and regional.
We propose to compute the range between the highest
and the lowest underlying ASRs to divide it by the ASR
(r/R) and to express the result as a percentage.
The index r/R has been chosen among other more formal
statistics (e.g. extreme quotient) (Gumbel and Keeney,
1950) because it only relies on ASRs and provides a direct
measure of the effect of internal heterogeneity (range
between maximum and minimum ASR in subareas) on
the overall summary ASR.
In our example, on the basis of long-standing high-
quality Nordic countries incidence data (Ferlay et al.,
2014), the r/R for the Nordic countries was quite high
(57.1%), suggesting that the national ASRs could vary
notably. In fact, the overall ASR for Nordic countries did
not correspond with any of the national ASRs, out of
Greenland’s one (Fig. 1).
Also at a national level, when regional estimates are
available, it is possible to add to the national ASR the r/R
based on regional ASRs to express how well the national
ASR represents the regional ones. In the dataset ana-
lysed, we showed that country ASR may reflect more
(Iceland, Denmark and Norway) or less accurately
(Finland and Sweden) the incidence of cancer in the
different regions within a country.
The comparison between ASRs using the 95% CI over-
lap is simple and intuitive (Schenker and Gentleman,
2001) and showed major differences in ASRs between
and within areas.
This study was based only on one incidence year. To
check the reliability of r/R, we repeated the exercise also
for the year 2012. The r/R in 2012 were similar to that in
2014 (data not shown) for almost all the countries, with the
exception of Sweden, for which r/R showed in 2012 a
smaller heterogeneity (r/R=16.6%) than in 2014 (37.8%).
The reason for this strong change was the change in the
incidence ASR in the Stockholm–Gotland region from
2012 (420.5 cases/100 000) to 2014 (526.3). This change
was the effect of a study on prostate cancer carried out in
the county between 2012 and 2014 (Grönberg et al., 2015).
The ASR for all causes except skin and prostate cancer
were 268.3 and 266.7, respectively. This example confirms
that r/R reflects the true variability within an area.
Heterogeneity was identified among countries (areas
between around 25 000 and 4 800 000 resident men) and
among regions of several hundred thousand inhabitants,
except for Iceland, where the population is smaller than in
any of the other countries with regional information available.
It is possible to identify slight differences in cancer
incidence between two geographical areas if the number
of cases (population) is huge. Then, the ASRs are precise
and the 95% CI is narrow. Thus, it is easier to detect a
slight difference between two large (populated) regions
than between two small ones. For example, between the
ASRs of Kuopio and Oulu (highly populated), there is the
same difference as that between the two Icelandic
regions (poorly populated), but only the first two do not
have overlapping CIs.
In general, the unavailability of a unique population-unit
for subareas (countries, regions, provinces, counties, etc.)
makes comparisons across areas difficult.
With the increase in the number of subareas, the varia-
bility among them is expected to increase and conse-
quently the r/R. The aim of r/R is exactly to offer
summary and straightforward information on possible
outliers. In case r/R is small (∼ < 10–15%) it is immedi-
ately clear that all the ASR for each of the subareas are
concentrated in a quite narrow range and if it is large
(>30%) it underlines that at least one of them is rather
different from the overall ASR.
The r/R is a measure intended as a macro indicator of major
heterogeneity among quite large subareas (e.g. regions in a
country). For small areas and cluster analysis, other meth-
ods have to be chosen (Colonna and Sauleau, 2013).
CRs should start to provide also general information on
internal cancer incidence geographical variability in
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addition to standardised incidence rates. This would
make the information more complete and clear for
readers, avoiding misinterpretations. When incidence for
subareas is available, r/R, which is very simple to com-
pute, could be presented together with the general ASR
as a first attempt to raise the issue.
The interpretation of incidence ASR requires the com-
bined reading of ASR, SE and r/R: the ASR shows the
level of incidence, the SE shows the precision of the ASR
and r/R shows the amount of internal geographic varia-
bility. The r/R will be smaller if the ASR for subareas are
quite similar to each other (more or less precisely esti-
mated) or greater if they are rather different. This is the
original and useful contribution provided by the r/R.
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The thickness of melanomas has decreased in central Italy,
but only for thin melanomas, while thick melanomas are as
thick as in the past
Emanuele Crocettia, Adele Caldarellaa, Alessandra Chiarugib, Paolo Nardinib
and Marco Zappaa
The objective of this study was to evaluate the time trend
of melanoma thickness in a population-based case series.
All invasive (n=2862) and in-situ (n=605) cutaneous
melanoma incident cases diagnosed in 1985–2004 were
retrieved from the Tuscany Cancer Registry, central Italy.
Standardized (European population) incidence rates
were computed for four periods: 1985–1989, 1990–1994,
1995–1999, 2000–2004, and for Breslow thickness classes
(r1, 1.01–2.00, > 2mm). The annual percent change
(APC) of the standardized rates was computed. Thickness
was evaluated on the basis of sex, age, morphology type,
site and period of time. Median thickness was evaluated
by means of a nonparametric K-sample test. The incidence
rate of melanoma rose significantly for both invasive
(APC= +5.1%) and in-situ lesions (APC= +11.1). The
sex distribution of patients with invasive melanoma did
not change over time (mean male/female ratio 0.95).
The mean age at diagnosis did not change (57.2 years;
SD=17.2 years). From 1985–1989 to 2000–2004 the
median value of thickness decreased from 1.68 to 0.8mm
(P<0.001). Within the Breslow categories the median value
of thickness decreased significantly for thin melanomas
(r1mm) but not for intermediate (1.01–2.00) or for
thick melanomas (>2mm). Among the most common
melanoma types, the median thickness decreased for
superficial spreading melanomas but not for nodular
melanomas. Over time, the incidence of melanoma has
increased notably and the median thickness has
decreased. However, median thickness has decreased
only among thin melanomas, whereas it has not changed
for thick melanomas, most of which are of the nodular
type. Melanoma Res 20:422–426 !c 2010 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
Melanoma Research 2010, 20:422–426
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Introduction
The incidence of melanoma has increased notably over
the last decades in all western countries [1,2] including
Italy [3]. A major cause for this increase has been early
diagnosis. In addition, most of the diagnosed lesions are
now in-situ [4] or thin melanomas [5–7], especially of
the superficial spreading melanoma type (SSM) [1,8];
therefore, their prognosis is very good.
In contrast, the incidence of thick melanomas has not
decreased [4,7,9–11] nor increased [1].
Thickness is the most relevant prognostic factor. More-
over, a large proportion of thick melanomas is of the nodular
type [11–13]. Against the background of stable or even
rising rates for thick melanomas, melanoma mortality has
not significantly decreased [1].
In recent years, health-care professionals have focused
on how to cope with thick deadly melanomas, but the
problem is still unsolved [14].
The aim of this paper is to evaluate the incidence trend
of cutaneous melanomas with special reference to thick-
ness in an Italian population-based case series.
Materials and methods
We retrieved all the invasive (n=2862) and in-situ
(n=605) cutaneous melanoma incident cases diagnosed
in 1985–2004 from the archives of the Tuscany Cancer
Registry (RTT). RTT is a population-based cancer registry
active in the provinces of Florence and Prato (approxi-
mately 1 161 000 residents in the 2001 census), central
Italy [15].
We arranged Breslow thickness in three classes, thin
(r 1mm), intermediate (1.01–2.00), and thick (>2mm),
as indicated by Balch et al. [16]. As for thick tumours, we
also analysed thick (Z 3 orZ 4mm) lesions.
We used the median to measure thickness because of the
skewness of its distribution.
Thickness categories were evaluated according to the
following variables:
(1) Sex.
(2) Age (0–49,Z 50).
(3) Morphological type (the International Classifica-
tion of Diseases for Oncology morphology codes):
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SSM(ICDO-M=8743), nodular melanoma (NM;
ICDO-M=8741), lentigo maligna melanoma
(LMM, ICDO-M=8742), not otherwise specified
(NOS, ICDO-M=8720), ‘other types’ (ICDO-M=
8722, 8730, 8740, 8744, 8770, 8771, 8772).
(4) Site: head and neck, trunk, upper limb, lower limb,
others and unspecified.
(5) Period of time: 1985–1989, 1990–1994, 1995–1999,
2000–2004.
Statistical methods
Incidence rates were age-standardized through the direct
method using the European standard population.
We computed the annual percent change (APC) of the
standardized rates using the weighted least squares
method, on the basis of single incidence year. We per-
formed the above-mentioned computations by means of
the SEER*Stat 6.3.6 software (www.seer.cancer.gov/seerstat).
We compared proportions by means of the w2 test, or the
Fisher’s exact test, when we expected less than five
observations.
As regards the median, we used the Stata command
‘median’ that performs a nonparametric K-sample test that
evaluates the null hypothesis that those samples were
drawn from populations with the same median (www.
stata.com). In the case of two samples, the w2 statistic test
is calculated with and without a continuity correction.
Results
From 1985 to 2004, 3467 patients residing in the RTT
area had a diagnosis of malignant melanoma (2862 invasive
and 605 in situ). The standardized incidence rate of
invasive malignant melanoma rose from 6.4 per 100 000 in
1985–1989 to 13.6 in 2000–2004, with a mean annual
pace of + 5.0% [95% confidence intervals (CIs), + 4.0/
+ 8.2], Table 1. The growth of incidence was statistically
significant for both men (APC= +5.3, 95% CI, + 4.2/
+ 6.5) and women (APC= +4.9, 95% CI, + 3.5/+ 6.3).
In the analysed period, the sex ratio was stable, with
a slight predominance of women. The median age at
diagnosis did not change over time, being 58.1 years
(range 21.2–100.6 years).
With regard to invasive melanomas, a statistically signi-
ficant growing incidence was detected for thin (APC=
+9.5; 95% CI, + 7.1/+ 11.9), for intermediate (APC=
+3.1; 95% CI,+ 1.1/+ 5.2) and for thick melanomas
(APC= +2.1; 95% CI, + 0.4/+ 3.7), and it was almost
statistically significant for those melanomas without the
information on Breslow thickness (APC= +1.9; 95% CI,
– 0.3/+ 4.1; Table 1.
Six hundred and five in-situ melanomas were diagnosed
with a statistically significant growing trend (APC= +11.1;
95% CI, +8.1/+14.3); standardized incidence rates for
in-situ melanomas rose from 0.8 per 100 000 in 1985–1989
to 4.0 in 2000–2004. The incidence trend for in-situ
melanomas was statistically significant for both men
(APC=+12.7; 95% CI, +8.7/+16.9) and women (APC=
+9.4; 95% CI, +6.1/+12.8). In-situ invasive melanomas
did not show any statistically significant change, either in
sex ratio (percentage of women 54.1) or in the median age
at diagnosis (57.8 years).
The mean age at diagnosis for in-situ melanomas was lower
than for invasive melanomas (55.5 vs. 57.2 years; P=0.02).
However, among invasive melanomas (r 1mm) the mean
age at diagnosis (52.7 years) was lower than for in-situ
Table 1 Tuscany Cancer Registry: invasive melanoma, absolute numbers, proportion of females, standardized (European population)
incidence rates, annual percent change of standardised rates
1985–1989 1990–1994 1995–1999 2000–2004 n/p
Invasive melanoma, n 442 565 835 1020 2862
% females 54.5 54.0 55.3 50.2 P=0.13
Incidence rate 6.4 8.0 11.4 13.6 P<0.01 for APC
Breslow thickness
>0 to r1mm, n (%) 92 (20.8) 182 (32.2) 375 (44.9) 476 (46.7) 1125
Incidence rate 1.4 2.7 5.5 6.7 P<0.001 for APC
1.01–2.00mm, n (%) 76 (17.2) 93 (16.5) 112 (13.4) 129 (12.8) 410
Incidence rate 1.1 1.3 1.5 1.9 P=0.006 for APC
>2mm, n (%) 117 (26.5) 134 (23.7) 153 (18.3) 200 (19.6) 604
Incidence rate 1.6 1.8 1.8 2.2 P=0.016 for APC
Unknown, n (%) 157 (35.5) 156 (27.6) 194 (23.4) 215 (21.0) 723
Incidence rate 2.2 2.2 2.5 2.8 P=0.07 for APC
In-situ melanoma, n 55 72 182 296 605
% females 61.8 63.9 52.2 51.4 P=0.15
Incidence rate 0.8 1.0 2.7 4.0 P<0.01 for APC
Morphology type
SSM 2.9 4.5 7.3 9.0 <0.001 for APC
NM 0.8 0.8 0.8 0.8 0.96 for APC
LM 0.2 0.2 0.2 0.2 0.14 for APC
Other 0.3 0.3 0.4 0.4 0.15 for APC
N.o.s. 2.2 2.2 2.7 3.2 0.006 for APC
Annual percent change of standardized rates (APC) are computed on single years of diagnosis. Probability (P) for APC to be equal to 0 or for the probability that each
sample has the same proportion of observations.
LM, lentigo melanoma; N.o.s., not otherwise specified; NM, nodular melanoma; SSM, superficial spreading melanoma.
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melanomas (P=0.001), whereas the mean age of 60.2
years for melanomas (>1mm) was higher than for both
in-situ melanomas (P<0.001) and those with a thickness
of 1mm or less (P=0.001).
According to types of morphology, the increasing inci-
dence trend was statistically significant for SSMs (n=
1655, APC= +7.0; 95% CI, +5.2/+8.8) and for the
group ‘other types’ (n=155, APC= +6.7%; 95% CI,
+ 2.6/+ 11.0), whereas for NMs (n=238), LMM
(n=79) and for NOS melanomas (n=775), the trends
did not reach any statistical significance.
From 1985–1989 to 2000–2004 the median value of
thickness, for invasive melanomas, decreased from 1.68
to 0.8mm (P<0.001). The median thickness decreased
statistically significantly for both men (from 2.1 to
0.8mm) and women (from 1.3 to 0.75mm) Fig. 1.
The decrease over time in median thickness was not
present in all Breslow categories. In fact, the median
value of thickness decreased statistically significantly
for thin melanomas (r 1mm) but not for intermediate
(1.01–2.00mm) or thick melanomas (>2mm) Table 2.
Median thickness did not decrease among thick melano-
mas in other Breslow categories either (Z 3mm,Z 4mm;
data not shown).
The decrease in median thickness was statistically
significant only for SSM (from 1.20 to 0.68mm) and for
other types (from 2.75 to 1.10), whereas it did not reach
statistical significance for the other morphological types
of melanoma (Table 2). In the most recent period (2000–
2004), SSM represented the largest proportion of melano-
mas (62.6%; 639/1020), followed by melanomas NOS
(17.5%; n=179), the group ‘other’ (10.7%; n=109),
nodular melanomas, (6.2%; n=62) and LMMs (2.9%;
n=30). Among the 208 thick melanomas diagnosed in
2000–2004, 45.7% were SSM and 24.5% of nodular type.
With regard to age, the increase in incidence was present and
statistically significant for both younger (0–49 years) men
(APC= +5.0, 95% CI, +2.7; +7.2) and women (APC=
+6.2, 95% CI, +4.0; +8.5) and for older (50+years) men
(APC= +5.6, 95% CI, +4.1; +7.0) and women (APC=
+3.5, 95% CI, +2.2; +4.8).
With regard to skin sub-sites, by age group and sex
(Table 3), melanomas of the head and neck did not show
any statistically significant change either in incidence or
in Breslow thickness in both sexes and age groups. The
incidence of melanoma of the trunk increased significantly
in both sexes and age groups, and the median thickness
showed a statistically significant change towards a decrease,
with the exception of younger women. The incidence of
melanomas of the upper limbs increased in all age groups
and both sexes, whereas their median thickness decreased
statistically significantly only among younger subjects.
With regard to melanomas of the lower limbs, there was a
significant increase in incidence and a statistically sig-
nificant decrease in median thickness among women. The
group of melanomas of NOS sites increased over time,
whereas their median thickness was stable.
Discussion
The increasing incidence of invasive melanomas observed
from 1985 to 2004 in central Italy was mainly supported
by increasingly thinner lesions, especially of the SSM
type. Therefore, the overall median thickness of mela-
nomas has decreased over time, being in recent years
0.8mm. This result was supported by the decrease in
the median thickness of thinner melanomas (r 1mm;
0.5mm during 2000–2004). However, the shift in
thickness observed for thin melanomas does not affect
thick melanomas, which in Italy are now as thick as they
Fig. 1
0
0.5
1
1.5
2
2.5
3
3.5
19
85
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
Median Breslow (Men) Median Breslow (Women)
Th
ic
kn
es
s 
(m
m
)
Tuscany Cancer Registry. Invasive melanoma: median Breslow
thickness for men and women by calendar years.
Table 2 Tuscany Cancer Registry
1985–
1989
1990–
1994
1995–
1999
2000–
2004 P
Overall 1.68 1.2 0.8 0.8 <0.001
Males 2.1 1.3 0.8 0.8 <0.001
Females 1.3 1.15 0.8 0.75 <0.001
Breslow’s thickness
r 1mm 0.66 0.57 0.55 0.50 0.001
1.01–2.00mm 1.50 1.45 1.40 1.30 0.239
>2mm 3.4 3.5 3.7 3.8 0.418
Morphology type
SSM 1.20 0.85 0.70 0.68 <0.001
NM 3.33 3.39 3.30 4.00 0.517
LM 1.80 0.81 0.67 0.79 0.398
Other 2.75 3.20 1.10 1.10 0.003
N.o.s. 2.25 2.35 1.79 1.80 0.675
Invasive melanoma: median thickness by period of diagnosis for males and
females, for Breslow’s thickness categories, for morphology type (LM, lentigo
melanoma; N.o.s., not otherwise specified; NM, nodular melanoma; SSM,
superficial spreading melanoma) and for site. P shows the probability that the
medians in different groups are medians of samples drawn from the same
population.
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were in the past. In fact, the median thickness of inter-
mediate (1.01–2.00mm) and thick melanomas (> 2mm)
did not decrease over the analysed period.
Moreover, although the proportion of intermediate and
thick melanomas has reduced over time, their incidence
rates show a statistically significant increasing trend [1].
In addition, their absolute number has increased [7,14].
In agreement with the literature, we observed a strong
increasing trend for in-situ melanomas in central Italy [4],
and almost half of the invasive melanomas are now thin.
Such lesions have a very good prognosis, in so much as the
UK recently proposed a change in guideline recommen-
dations for those less than 0.5 thick, suggesting less
frequent follow-up [17]. The mean age at diagnosis was
lower for r 1mm melanomas than from in-situ melano-
mas. This would indicate that in-situ melanomas are not a
precursor lesion of melanoma, but have a different
pathway than invasive melanomas.
As observed in other reports, we did not detect any decrease
in the thickness of NMs at diagnosis [7]. We documented
that in this population-based series a significant percentage
(24.5%) of thick melanomas are NMs, reaching around 30%
when melanomas NOS are excluded [16].
There was an increase in incidence for all skin sites, with
the exception of head and neck, for which the rates were
stable over time. The trends for skin sites were similar for
younger (0–49 years) and older (50+ years) patients of
both sexes. A statistically significant change (decrease) in
median thickness was present for melanomas of the trunk
in men and older women, for upper limbs only in younger
patients, and for lower limbs only in women.
The epidemiology of melanoma is further divided into
different groups of lesions [18]. A first group includes
those melanomas easily detectable by enhanced early
diagnosis, increasingly thinner, mainly of a SSM type,
with a very good prognosis and presumably with some
amount of over-diagnosis [19]. There is a second group of
melanomas, more aggressive, thick at diagnosis, and often
of a nodular type [20]. The relationship between these
two types of lesions is still unknown. Therefore, it is
crucial to investigate further the biological history of
thick melanomas.
Table 3 Tuscany Cancer Registry
Males Females
r 49 years 50+ years All ages r49 years 50+ years All ages
Head and neck
Number 32 132 164 28 125 153
APC 1985–2004
95% CI
– 2.3
( – 5.8; + 1.4)
+ 1.6
( – 1.6; + 4.9)
+0.4
( – 2.6; + 3.5)
– 1.9
( – 5.3; + 1.7)
+0.3
( – 3.5; + 4.3)
– 0.3
( – 3.8; +3.4)
Thickness 2000–2004 0.55 2.7 2.3 0.7 1.19 0.9
P thickness change
1985–2004
0.10 0.64 0.41 0.54 0.20 0.17
Trunk
Number 179 472 651 200 184 384
APC 1985–2004
95% CI
+4.7
( +1.3; + 8.2)
+ 4.8
( + 2.7; +7.1)
+4.8
( +2.9; + 6.7)
+6.9
( + 3.1; + 10.8)
+4.5
( + 1.1; +8.1)
+ 6.1
( + 2.8; +9.5)
Thickness 2000–2004 0.86 0.7 0.8 0.7 0.7 0.7
P thickness change
1985–2004
0.005 <0.001 <0.001 0.69 0.01 0.02
Upper limb
Number 54 102 156 79 128 207
APC 1985–2004
95% CI
+4.5
( +0.9; + 8.3)
+7.5
( +4.0; + 11.2)
+ 7.6
( +4.7; + 10.5)
+5.7
( + 1.2; + 10.4)
+5.1
( + 1.8; +8.7)
+ 5.3
( + 2.7; + 8.0
Thickness 2000–2004 0.64 0.85 0.65 0.6 0.9 0.68
P thickness change
1985–2004
0.054 0.20 0.03 0.07 0.60 0.12
Lower limb
Number 71 132 203 204 423 627
APC 1985–2004
95% CI
+8.3
( +3.8; + 13.0)
+ 4.4
( +0.6; + 8.3)
+5.3
( +2.5; + 8.1)
+4.3
( + 1.2; +7.5)
+1.8
(0; + 3.6)
+ 3.0
( + 1.1; +4.9)
Thickness 2000–2004 0.8 1.8 1.1 0.71 1.3 1.1
P thickness change
1985–2004
0.10 0.40 0.09 0.06 0.04 0.08
N.o.s
Number 58 110 168 56 93 149
APC 1985–2004
95% CI
+7.4
( +2.0; + 13.0)
+ 8.9
( +3.7; + 14.3)
+ 7.9
( +3.9; + 12.1)
+12.2
( + 3.8; + 21.6)
+11.1
( + 5.4; + 17.2)
+ 14.2
( +7.6; + 21.1)
Thickness 2000–2004 0.53 0.5 0.5 0.52 0.72 0.52
P thickness change
1985–2004
0.51 0.23 0.16 0.47 0.68 0.56
Melanoma, number of cases according to sex, age (0–49, 50+ years and all ages), annual percent change (APC) of standardized incidence rates 1985–2004 with
corresponding 95% Confidence Intervals (95% CI), median thickness during 2000–2004, probability (P) that the median thicknesses for the periods 1985–1989,
1990–1994, 1995–1999 and 2000–2004 belong to populations with the same medians according to a non parametric K sample test.
N.o.s., not otherwise specified.
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Melanoma incidence in central Italy will go on increasing
also in the near future: A registry-based, age–period–cohort
analysis
Emanuele Crocettia, Paolo Carlib and Guido Miccinesia
The aim of the study was to evaluate malignant melanoma
incident trends in central Italy by means of an age–period–
cohort approach. A total of 1977 malignant melanoma
(15–84 years) incidents in the area of the Tuscany Cancer
Registry between 1987 and 2001 were analysed. Poisson
regression has been used to estimate age, cohort and
period effect. A nonlinear regression model was used to
estimate the expected number of new cases in the period
2002–2006. Incidence rates increased in all age, period and
cohort groups. The model that best fitted the data included
age and ‘drift’. The linear effect (‘drift’) showed, in each age
group, an increase of the risk of malignant melanoma
diagnosis of about 36.6% every 5 years of period or cohort.
For the period 2002–2006, 1112 new cases were predicted
with a standardized rate (age 15–84 years) of 19.2!
100.000. In the Tuscany Cancer Registry area, no clues for
malignant melanoma incidence rates levelling off were
documented. Growing rates and number of malignant
melanoma are expected in the near future. European
Journal of Cancer Prevention 16:50–54 !c 2007 Lippincott
Williams & Wilkins.
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Introduction
Malignant melanoma (MM) incidence has increased over
the last decades in almost all Western countries (Lens
and Dawes, 2004). In central Italy also incidence trends
showed a significant increasing trend in both men and
women (Crocetti and Carli, 2003). More recently,
levelling of or even decreasing trends in incidence have
been identified among young participants in Denmark, in
the Netherlands, in Switzerland and in the United
Kingdom (De Vries et al., 2003). A decrease in incidence
among young cohorts indicates that there will be a future
overall decline in rates as soon as these participants
contribute to older age groups.
The aim of the present paper was to explore incidence
trends for cutaneous MM in central Italy focusing on the
age, period and cohort effect.
Materials and methods
Incidence data were retrieved from the Tuscany Cancer
Registry (RTT), a population-based cancer registry active
in the provinces of Florence and Prato (about 1 160 000
residents in the 2001 census), central Italy, since 1985.
The description of the criteria for collection, and
registration followed by the Registry, has been presented
elsewhere (Paci et al., 2002).
During 1987–2001, 2071 incident cutaneous melanomas
were registered in the RTT; in the present analysis, we
selected age range 15–84 years and 1977 incident cases
were included.
Number of cases and person-years were aggregated in
5-year age groups (from 15–19 to 80–84 years), 5-year
periods (1987–1991, 1992–1996, 1997–2001). Five-year
cohorts of birth were computed according to age and
period. In the figure, cohorts are labelled according to the
central year of the cohort of birth.
The incidence rates were standardized using direct
method with the European standard population as the
reference.
Poisson regression has been used to estimate age, cohort
and period effect. We may consider cohort effects as
influences that affect rates in a specified generation or
birth cohort throughout life, whereas period effects affect
rates equally across all age groups at a specified period
(Clayton and Schifflers, 1987a). When there is a regular
temporal trend, which cannot be ascribed to either period
or cohort influences, it is called ‘drift’. Only when we
observe irregular or sudden changes, we can ascribe the
observed temporal trend to either period or cohort
influences. The goodness-of-fit of different models was
assessed by the deviance. The closer the deviance with
the degree of freedom, the better the fit of the model.
Differences between deviances allowed us to compare
0959-8278 !c 2007 Lippincott Williams & Wilkins
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nested models (e.g. age alone vs. age+ cohort) (Clayton
and Schifflers, 1987b).
The expected number of new cases for the years 2002–
2006 was estimated according to a nonlinear regression
model, proposed by Dyba et al. (1997), including the
effect of age and age-specific temporal trends. Friendly
STATA macros for the application of such method for
short-term prediction are available on the Web site
of the European Network of Cancer Registries (http://
www.encr.com.fr/stata-macros.htm). This model assumes
that the absolute change in incidence rate over time for a
given age group is often larger when the baseline rate is
larger. The age-specific absolute change of incidence is
proportional to the corresponding age-specific baseline
rate, whereas for a given time period the relative change
in incidence is the same for all age groups. Owing to these
characteristics this model preserves in the period of
prediction the age pattern of incidence existing in the
data, and the age-specific predicted rates are substantially
more precise than those for a linear model (Dyba et al.,
1997).
Several methods have been used for making predictions
of the future cancer burden; the one used in the present
analysis showed good performance when compared with
other methods (Moller et al., 2003).
We used the annual sex-specific and 5-year age-specific
population for the years 2002–2006 based on the official
data and future estimates of the Regional Office of the
National Institute of Statistics (years 2002–2003, 2008)
and the estimates based on the Waring method for
2004–2006 (Shryock et al., 1976).
Total number of expected cases and prediction intervals
are presented. Predictions of incidence for each age group
are also presented.
Results
4Table 1 shows age-specific and age-standardized mela-
noma incidence rates from the Tuscany Cancer Registry
area for three periods (1987–1991, 1992–1996 and
1997–2001).
Incidence rates increased in all age groups. The age-
specific incident rates increased in participants born in
more recent years (Fig. 1), and they also increased from
the first to the third analysed period (1987–1991,
1992–1996, 1997–2001) (Fig. 2).
The model approach used to disentangle age, period and
cohort effect showed that the model that best fitted the
data was the one including age and ‘drift’ (deviance of the
‘age+ cohort’ model – deviance of the ‘age+drift’ mod-
el= 15.7; number of parameters of the ‘age+ cohort’
model – number of parameters of the ‘age-drift’
model= 14; P-value of 15.7 on a w2distribution with
14 degrees of freedom=0.392; for the age+period
model vs. age+drift model; P-value=0.808).
The linear temporal effect (‘drift’) showed that in each
age-group, there was an increase of the risk of MM
diagnosis of about 36.6% every 5 years of period or cohort
(mean annual increase 6.4%). The model including age
and drift resulted the best also for explaining incidence
data for men and women, when analysed separately
(data not shown).
The predicted standardized incidence rate (age 15–84
years) for the period 2002–2006 was 19.2; the predicted
number of new cases was 1090 (95% prediction intervals
984–1196).
Figure 3 reports age-specific incidence predictions for
2002–2006, together with their prediction intervals.
Discussion
The results of the present study indicate that MM
incidence rates in the population covered by the Tuscany
Cancer Registry, central Italy, are still increasing. This
trend is present in all age groups, and also younger
participants, both men and women, do not show any sign
of levelling of.
The present figure contrasts with that recently found in
some northern European populations. According to data
extracted from the EUROCIM database 165 cancer
registries, a deceleration in incidence trends occurred
Table 1 Malignant cutaneous melanoma
Period
1987–1991 1992–1996 1997–2001
Age (years)
15–19 0.8 1 2.4
20–24 2 5.7 6.1
25–29 3.9 7 10.2
30–34 5.7 7.6 13
35–39 5.1 8.4 12.9
40–44 8.9 11.1 15.2
45–49 9.5 13.1 18.4
50–54 10.3 16.3 23.1
55–59 14.5 17.9 26
60–64 14.8 19.1 19.4
65–69 16.2 18 23.5
70–74 16.2 19.4 25.1
75–79 15 25.9 31.1
80–84 14.2 19.7 28.9
No. of cases 449 636 892
Standardized
Ratesa 8.3 11.6 15.9
Number of incident cases, age-specific (males and females) and age-
standardized (European population) incidence rates in the Tuscany Cancer
Registry, according to time period.
aStandardized rates are computed in the population 15–84 years.
Melanoma incidence in central Italy Crocetti et al. 51
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
recently in Northern European countries among persons
younger than 70 years; whereas in eastern and southern
Europe incidence rates were still increasing
(De Vries et al., 2003). Therefore, we are probably
observing a shift between northern and southern
European populations in terms of future scenarios about
Fig. 1
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melanoma ‘epidemic’. Earlier detection and a growing
public awareness about risk associated with excessive sun
exposure are the most plausible explanations for the
deceleration found in northern Europe (De Vries et al.,
2003).
Little is, however, known on the factors still holding up
the increasing incidence trends in Mediterranean people.
In this study, models including the effects of age, period
and birth cohort were used to adequately analyse the
rising trends.
As known, cohort effect reflects exposures that affect
rates in a specified cohort equally throughout life,
whereas period effect affects rates equally across all age
groups at a specific period (Clayton and Schifflers,
1987a). An age effect (increasing risk according to ageing)
and a linear effect are causing the increasing incidence.
Owing to the linear dependence between the linear part
of cohort and period (and age) however, the interpreta-
tion of regular incidence trend is not possible. Indeed,
only when we observe irregular changes we must consider
age-period or age-cohort models. On the contrary, this so-
called ‘drift’ effect represents a situation equally well
described by two models, age and period (linear) or age
and cohort (linear) and cannot be ascribed to either
period or cohort effect (Clayton and Schifflers, 1987a).
Although statistics does not allow one to disentangle
period from cohort effect, some suggestions may come
from the epidemiological knowledge.
The major environmental risk factor for MM is
the intermittent exposure to ultraviolet radiation (UV)
(Elwood and Jopson, 1997), especially during childhood
(Naldi et al., 2000). Such exposure has become popular
after the Second World War, and in Italy, particularly from
the second-half of the 50s to the early 60s as a
consequence of a rapid economic growth.
The present data are, however, not fully explained by the
hypothesis of increasing risk for UV exposure during
childhood only. In fact, the increase in incidence was
evidenced in all birth cohorts, also in the oldest ones, in
participants who during the 1950s–1960s were middle-
aged. Our results are consistent with the hypothesis that
UV exposure increases the MM risk independently from
the age of exposure (Elwood and Jopson, 1997). Recent
data suggest that cutaneous melanomas may arise through
two pathways, one associated with melanocyte prolifera-
tion and the other with chronic exposure to sunlight
(Whiteman et al., 2003). Australian patients with head and
neck melanomas – lentigo maligna melanoma excluded –
compared with patients with melanomas of the trunk,
were statistically significantly less likely to have more
than 60 nevi [odds ratio (OR)=0.34, 95% confidence
interval (CI)=0.15–0.79] but were statistically signifi-
cantly more likely to have more than 20 solar keratoses
(OR=3.61, 95% CI=1.42–9.17); moreover, they were
more prone to a past history of excised solar skin lesions
(OR=1.87, 95% CI=0.89–3.92) (Whiteman et al., 2003).
This finding has been confirmed in Italian patients (Carli
and Palli, 2003). This means that not only exposure in
early life, generally intermittent, but also cumulative
lifelong exposure may contribute to melanoma develop-
ment. Recent data from Crete show that in the relatively
dark-skinned population, sun exposure indices represent
the most important risk markers for cutaneous melanoma,
which contrast with data from fair-skinned Caucasian
populations in which melanocytic naevi are the main risk
factors (Lasithiotakis et al., 2004). Therefore, the change
in lifestyle with increasing exposure to UV owing to the
growing popularity of sunbathing and tanning seem to
have affected all age-groups as a period effect presumably
occurred during late 1950s–early 1960s.
On the other hand, more frequent excision of pigmented
skin lesions may contribute to explain the increasing
number of melanomas diagnosed overtime in the Tuscany
Cancer Registry area by means of a period effect. In the
Tuscany area, the awareness among population and the
development of early diagnosis activity has increased over
the last decades; a preventive campaign addressed both
to family doctors (general practitioners) and to general
population for the surveillance of pigmented skin lesions
is active in the RTTarea since the late 1980s (Carli et al.,
2002). A Pigmented Lesion Clinic working in the
Dermatology Department of University of Florence was
Fig. 3
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also implemented for rapid referral of participants with
self-detected or GP-detected suspicious lesion (Carli
et al., 2002). A clue for the effect of early diagnosis was
the growing rates of ‘thin’ lesions (r 1mm) that showed
a mean annual increase of about 16.1% from 1985 to 1997
(Crocetti and Carli, 2003). This situation probably
explains the role, if any, of the period-effect in sustaining
the incidence rates.
In conclusion, in the Tuscany Cancer Registry area MM
rates will probably go on increasing in the next future.
According to prediction model, the standardized incidence
rate (age 15–84 years) for the period 2002–2006 will be
19.2 cases per 100 000, approaching that observed in
northern European populations. Although the increasing
trend was explained by an age-drift model, the two major
explaining factors – changes in lifestyle with increasing
exposure to UV and increased early diagnosis – seem to
have acted more as period than as cohort effects.
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Prognostic variables and prognostic groups for malignant
melanoma. The information from Cox and Classification And
Regression Trees analysis: an Italian population-based study
Emanuele Crocettia, Lucia Mangonec, Giovanni Lo Scoccod and Paolo Carlib
The common way to analyse the prognostic role of
selected variables in cutaneous melanoma patients is by
means of Cox proportional hazard model. The prognostic
effect of the simultaneous presence of more than one
independent variable in the same patient is, however,
difficult to establish. This hampers the possibility of
tailoring a survival expectance for a selected patient as well
as to communicate it to the patient himself/herself. The
objectives of the study were to compare information on
cutaneous melanoma prognosis from multivariate Cox
proportional hazard model and from Classification And
Regression Trees analysis. Classification And Regression
Trees analysis is an automatic method that splits data by
means of a binary recursive process creating a ‘tree’ of
groups with different profiles according to the analysed
outcome, for example, the risk of death. This approach
automatically produces data that is easily interpreted by
clinicians. A total of 1403 invasive cutaneous melanoma
patients, 1110 from the Tuscan Cancer Registry and 293
from the Reggio Emilia Cancer Registry, Italy, were
included. Cases were incident during 1996–2001 and
followed up at the end of 2003. Cox proportional hazard
model and Classification And Regression Trees analysis
were applied to the following variables: age, sex, Breslow
thickness, Clark level, registry, subsite and morphologic
type. The Classification And Regression Trees analysis
identified 10 categories with statistically different survival;
this results were summarized into six classes of different
risks based on Breslow thickness, age and sex. The best
prognostic group (5-year observed survival, 98.1%)
included those subjected with Breslow less than 0.94mm
and age 19–44 years. The same thickness but an older age
(50–69 years) was associated with a statistically significant
different prognosis (5-year observed survival, 92.8%). The
Cox proportional hazard model found sex, age, Breslow
thickness, Clark and morphologic type to have a significant
independent prognostic value. In conclusion, compared
with the conventional approach based on Cox hazard
model, Classification And Regression Trees analysis
produces data closer to the clinical need of defining the
prognostic profile of a specific patient. This may help the
clinician both in the communication of risk and in the
follow-up strategy. Melanoma Res 16:429–433 !c 2006
Lippincott Williams & Wilkins.
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Introduction
For malignant cutaneous melanoma (CM), the identifica-
tion of prognostic factors has a crucial value for both
dermatologists and patients. According to new evidence
on effective prognostic factors, the CM staging system
has changed during recent years [1–4].
Usually, more factors act together, for example, thickness,
age, site, Clark’s level of invasion, ulceration, sex, etc. [2],
and therefore their cumulative effect should be evaluated
by means of multivariate models. The use of multivariate
Cox proportional hazard model for survival analysis is
common in the scientific literature [5]. For example, in
the PubMed library, more than 900 papers matched a
search for the terms ‘Cox AND survival AND cancer’,
among those published during the year 2005 (overall
671 163). By means of this statistical approach however,
the clinical relevance of the simultaneous presence in a
patient of more than one independent prognostic factor
cannot be easily established. This is a pity, as the
possibility for the clinician of tailoring a prognostic profile
for each patient taking into account the role of
independent survival predictors simultaneously present
would be clinically relevant both to plan follow-up and to
communicate the personal risk to the patient him/herself.
During the last two decades, a tree-building technique
has been slowly entering the literature. It is the so-called
Classification and Regression Tree (CART) analysis [6].
This is an automatic method that splits data by means of
a binary recursive process creating a ‘tree’ of groups with
different profiles according to the analysed outcome, for
0960-8931 !c 2006 Lippincott Williams & Wilkins
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example, the risk of death. Although this approach
automatically produces data that is easily interpreted by
clinicians, it does not seem to be very popular yet.
The aim of the present study was to compare malignant
melanoma survival information from both Cox and CART
approaches in a multicentric, population-based Italian
data set.
Material and methods
In the present study, invasive CM incident in the period
1996–2001 in the area of the Tuscany Cancer Registry
(RTT) and of the Reggio Emilia Cancer Registry (RECR)
were included.
Both RTT and RECR are located in central Italy and are
included in the Italian Network of Cancer Registries
(AIRT, www.registri-tumori.it). Further details on their
organization and data management are available for RTT
at http://www.cspoweb.it/rtt.asp and for RECR at http://
www.ausl.re.it/Home/DocumentViewer.aspx?ID=773&-
TIPODOC=IAP.
Overall, 1403 malignant melanoma were analysed (1110
from RTT and 293 from RECR).
Follow-up was carried out up to 31 December 2003 or
death, whichever came first. The mean follow-up time
was 4.2 years, ranging from 0 to 8 years (median follow-
up, 4.0 years).
The CART analysis was used to identify different
prognostic groups. This is an automatic method that
builds up a ‘tree’ by means of a binary recursive
partitioning of data. Full data are evaluated for all the
possible binary splits. It means that the method evaluates
the possibility of splitting each variable into two groups if
there is a statistically significant difference according to
the analysed outcome (e.g. risk of death). The process
repeats building up a tree until all groups are unsplittable
[6].
The variables included in the CART analysis were as
follows: sex (males, females), 5-year age classes, registry
(RTT, RECR), Breslow’s thickness (continue), Clark
level (2–5, missing), site (head and neck, trunk, upper
arm, lower arm, not specified), morphology [superficial
spreading (SSM), nodular, others, not otherwise speci-
fied. We chose not to analyse separately lentigo maligna
melanoma owing to their small number, n= 31].
Information on lymph node involvement was not avail-
able.
CART uses the martingale residuals of a Cox model to
calculate (approximate) w2 values for all the possible cut
points on all the CART covariates. The significant value
for cut point definition was 0.05. The minimum size of
the group was defined as 30 participants.
Once CART had identified different groups, Kaplan–
Meier survival curves were computed and compared by
means of log-rank test [7]. Only statistically significant
groups were considered for the definition of the final
groups of patients with significantly different risks of
dying.
Moreover, we analysed the prognostic role of the same
variables also in a more conventional approach by means
of the Cox conditional hazard model. Within each
variable, the statistical significance of the difference
between values was evaluated; the original variable
definition was modified according to the comparison, in
particular the site was been recoded in head and neck,
other specified, not specified.
The variables that showed a significant effect in the
univariable analysis were included in a multivariable Cox
proportional hazard model to evaluate their independent
effect. By means of a step-forward approach, the effect of
each variable in improving the fit of the model was
evaluated with the likelihood ratio test.
The product-limit estimate according to Kaplan–Meier
was used for computing overall and variable-specific
observed survival probabilities [8].
The analysis was performed by Stata 8 College Station,
Texas (www.stata.com).
Results
The analysis was based on 1403 patients with newly
diagnosed, incident CM; during the follow-up (mean
time, 50.5 months) 343 of these patients died.
The overall observed survival was 93.1% at 1-year, 82.7%
at 3-year and 74.7% at 5-year period.
In the CART analysis, 1154 patients with complete
information for sex, age, Breslow’s thickness, Clark’s
levels, registry, subsite and morphology were included
and all those variables were evaluated. The main relevant
split involved Breslow’s thickness identifying lesions
thinner and thicker than 2.25mm. The second split of
the regression tree involved age classes. The third split
was based on sex, and again on Breslow thickness, as the
fourth one (Fig. 1).
The CART analysis identified 10 prognostic groups
according to Breslow thickness, sex and age. For each of
these groups, Kaplan–Meier survival curves were com-
puted and compared by means of log-rank test. When
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there was no statistical difference in survival between
groups, they were summed. The result produced six
groups of patients with significantly different risks of
dying (Fig. 2).
In Table 1 the CART results are used to show a
straightforward way to define these six prognostic groups
according to Breslow, age class and sex. The best
prognostic group (5-year observed survival, 98.1%)
Fig. 1
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included male and female patients with Breslow thick-
ness less than 0.94mm and age 19–44 years. The same
thickness but an older age (50–69 years) was associated
with a statistically significant different prognosis (5-year
observed survival 92.8%). The prognosis was good (85.9%
at 5 years) for both men and women, with Breslow
thickness between 0.93 and 2.24mm and age 10–64 years
or for females with thickness less than 2.25mm. The next
group (5-year survival, 63.5%) included men aged 65–74
years with Breslow <2.25mm and both men and women
aged 15–69 years with Breslow Z 2.25mm. The prog-
nosis was poor (5-year survival, 53.5%) for men with
Breslow thickness < 2.25mm and age 70+ years and for
women with Breslow thickness 2.25–4.99mm and age
70+ years. The group with the worst prognosis (5-year
survival, 17.1%) included participants of 70 or more years
of age, women with Breslow Z 5.00mm, or men with
Breslow Z 2.25mm.
Data on traditional survival analysis based on univariate
approach followed by multivariate Cox regression models
are shown in Table 2. The survival was significantly
higher among women than among men, among younger
patients (< 60 years) than among older ones, for
melanoma with Breslow thickness less than 1mm than
for Z 1mm, for smaller Clark’s levels, for specified
subsites (or not-specified ones) than for head and neck
and for superficial spreading melanoma than for not
specified ones. No statistically significant differences
were found between the two registries.
Discussion
The population-based series of CM analysed in this study
yielded results that were perfectly in line with that
expected – according to the literature – in terms of
overall 5-year survival (75%) and significance of major
variables of risk of death. Indeed, the conventional Cox
hazard analysis showed that Breslow thickness, sex, Clark
level, morphology and age resulted in independent
prognostic variables [9,10].
In this study, a CART analysis of survival was performed
in order to easily investigate what happens when more
than one independent prognostic variable is present in a
patient. CART analysis enables clinicians to identify
subgroups of risk – characterized by the simultaneous
presence of more than one variable – that differ
significantly among themselves in terms of survival.
Indeed, by means of this approach, the identification of
different subgroups of risk is possible, with easier risk
communication and, eventually, a more patient-tailored
follow-up strategy.
Table 1 Malignant melanoma, 1996–2001
Group of prognosis Prognostic factors 5-year observed survival
No. Breslow (mm) Age (years) Sex %
Excellent 273 <0.94 19–49 Female/Male 98.1
Very good 189 <0.94 50–64 Female/Male 92.8
Good 318 0.93–2.24 10–64 Female/Male 85.9
<2.25 Female
Medium 209 <2.25 65–74 Male 63.5
Z2.25 15–69 Female/Male
Poor 72 <2.25 75+ Male 53.5
2.25–4.99 70+ Female
Very poor 93 Z5.00 70+ Female 17.1
Z2.25 70+ Male
Prognostic groups according to Classification And Regression Trees analysis. Each group is defined according to the characteristics of the included patients, for
example, male and female patients with Breslow lower than 0.94mm, 19–49 years old belong to the group with excellent prognosis.
Table 2 Malignant melanoma
Variable No. Crude HR 95% CI Adjusted
HR
95% CI
Sex
Women 762 1 1
Men 644 1.40 1.14–1.73 1.30 1.05–1.61
Age (annual)
< 60 784 1 1
60+ 622 3.73 2.95–4.70 2.92 2.30–3.71
Registry
Firenze 1113 1
Reggio Emilia 293 0.96 0.73–1.24
Breslow (mm)
<1 631 1 1
Z1 524 3.93 2.95–5.23 1.97 1.27–3.07
Missing 251 5.39 3.95–7.37 1.76 0.96–3.23
Clark
2 396 1 1
3 361 1.60 1.06–2.41 1.09 0.67–1.76
4 337 4.04 2.79–5.84 1.45 0.84–2.51
5 48 11.08 6.85–17.92 2.89 1.51–5.53
Missing 264 5.72 3.95–8.29 1.79 0.93–3.45
Site
Head and
neck
136 1
Other speci-
fied
1085 0.43 0.32–0.57
Not specified 185 0.91 0.63–1.32
Morphology
Superficial
spreading
903 1 1
Nodular 133 3.72 2.76–5.03 1.59 1.14–2.22
n.o.s. 225 4.14 3.21–5.33 2.23 1.61–3.08
Other 142 2.07 1.44–2.97 1.19 0.81–1.73
Crude and adjusted risk of dying (hazard ratio -HR) for several prognostic
variables with corresponding 95% confidence intervals (95% CI).
The multivariable model includes sex, age, Breslow’s thickness, Clark’s level and
morphology subtype.
n.o.s., not otherwise modified.
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In the present study, the CART analysis constructed a
pruned tree of 10 groups. Breslow thickness defined the
first and the third split [9,11]. Moreover, the cut-point
automatically identified by the software in the third split
(0.94mm) almost overlapped the well-accepted limit of
1mm used to separate thin from thick melanomas. The
original 10 groups were reduced, according to Kaplan–
Meier comparisons, into six homogeneous groups with
statistically significant different risks of dying. The
attribution of a patient to the corresponding group seems
very simple and it is based on the age, sex and Breslow.
Using this method, it is possible to define the prognosis
of a patient in a qualitative (from excellent to very poor)
and quantitative (from 98.1 to 17.1% survival at 5 years)
way. For example, facing a patient with a melanoma
thinner than 0.94mm, the prognosis significantly changes
according to age with better 5-year survival (98.1%) if the
patient is younger than 44 years than that expected if
older than 50 (92.8%, P<0.01). It is interesting that the
effect of sex as independent prognostic factor seems to
act for some subgroup, only when balanced with the
effect of major predictors of risk such as Breslow
thickness and age. Indeed, the sex was not able to
significantly modify the risk of dying facing the subgroups
at better prognosis (defined in this study excellent and
very good (5-year observed survival, more than 92%); on
the contrary, sex was statistically relevant facing the other
groups at less favourable prognosis.
The results from the present study may be influenced by
the number of cases included and by the underlying
tumours characteristics; however, the three prognostic
variables identified in the present study were the same as
that in a study including 12728 German patients [9].
The use of the results from Cox analysis seems not so
easy. In fact, Cox model produces for each variable
coefficients (b) that show the relationship between the
specific value of the variable and the outcome. The
overall risk should take into account all the computed
coefficients, according to the following formula:
exp(coefficient [e.g. sex]+ coefficient [e.g. age]+ coef-
ficient [e.g. Breslow]+ coefficient [e.g. Clark]+ etc.) in
comparison with all the variables in the reference
categories.
Although the CART approach has more closeness to the
clinical reasoning process than regression models, it is not
as common as expected. The main reason for the low
dissemination of CART seems to have been just the low
diffusion itself that had hampered both the growth of
statistical interest and knowledge of it and therefore the
availability of specific procedures within more diffused
software packages. Although it has been criticized [12],
its application has also been suggested [13], and the
method has been developed over time [14], also to
overcome the limits of traditional models [15]. As regards
the latter point, one of the advantages of CARTanalysis is
just to be a nonparametric method that works with
quantitative and qualitative data without any assump-
tions on their distributions [16].
The present method has several appeals for clinicians: its
automatic process, the easily interpretable results and the
growing availability of software packages [16]. The
number of papers that use this method to evaluate
cancer prognosis is growing, and this will stimulate
discussion and knowledge on this possibly very useful
clinical tool.
In conclusion, the present study contributes to demon-
strate the possible usefulness, in addition to traditional
approach, of the CART analysis for defining the risk
profile of a melanoma patient in a clinical set.
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Indicators of the standard of care for melanoma: Tuscany data
Emanuele Crocettia, Adele Caldarellaa, Daniela Massic, Claudio Sacchettinia,
Gianni Amunnib,d and Lorenzo Borgognonie
Formal indicators for the evaluation of the quality
of melanoma care are needed. We identified 13 process
indicators, which encompassed early diagnosis, pathology
reporting and surgical treatment. We evaluated the
adherence to these indicators using a population-based
series on incident skin melanomas (only primary
melanomas) for the year 2004 (687 cases) and for the first
semester of 2008 (539 cases). We compared the indicators
for these 2 years. The melanoma incidence increased
between 2004 and 2008. There were statistically significant
increases in the percentage of thin (r1mm) melanomas
(from 50.7 to 61.3%) and in the number of pathology
reports that mentioned ulceration (from 61.4 to 84.6%)
and margin status (from 76.8 to 84.3%). The percentage of
patients staged by sentinel lymph node biopsy was
stable (63%) and was higher for patients younger than
75 years of age (74%). The number of nodes almost
invariably exceeded the proposed site-specific cutoff
reference and, in 2008, the number of nodes removed
was always reported for lymphadenectomy. From 2004
to 2008, surgical and pathological waiting times
increased. Collection and analysis of these
indicators would enable continuous evaluation of
the quality of melanoma care in Tuscany and provide
sources for a comparative study between Italy and
elsewhere. Melanoma Res 23:283–289 !c 2013 Wolters
Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
The incidence of skin melanoma has greatly increased in
Italy during recent years [1], as in many other western
countries. In Tuscany (central Italy), cancer care is
coordinated by the Tumour Institute of Tuscany (ITT),
a network-based Institute that organizes and supervises
public health services in the community with the aim of
providing optimized cancer treatment. The ITT also
conducts studies on tumours (http://www.ittumori.it). In
particular, in 2007, it published clinical recommendations
on standardizing diagnostic and therapeutic pathways for
skin melanoma for specialists and hospitals throughout
the region. On the basis of the ITT’s recommendations, the
standard and effective treatment for cutaneous melanoma
is now surgery-based [2]. As most skin melanomas are
diagnosed early (when, in most cases, the lesion is thin) [3],
complete pathological examination and timely surgery
represent the best option for the majority of patients. To
reduce variability in cancer care procedures and improve the
general quality of care, the ITT works on the basis of
indicators. Specific indicators for breast, lung, colorectal and
ovarian cancer care are available [4].
The role of indicators in evaluating clinical care is
increasing [5,6]. However, to our knowledge, in Italy,
there are no formal indicators for care quality for
melanoma. In the USA, the four measures available in
the National Quality Measures Clearinghouse address
only a few points in the clinical course (diagnosis, imaging
and follow-up, http://www.qualitymeasures.ahrq.gov/), although
further indicators, mainly for surgical treatment, have
recently been evaluated [7].
This paper aims at evaluating the clinical care of
melanoma in Tuscany through formal indicators and
gauges whether ITT recommendations have succeeded
in instituting and improving standardized patterns of
care.
Materials and methods
Setting and study population
We first evaluated primary skin melanoma cases occurring in
Tuscany between 2004 and 2008, excluding melanomas
with unknown primary sites. We retrieved melanoma inci-
dence data for 2004 from the archive of the Tuscan Regional
Cancer Registry (RTRT), a population-based cancer regi-
stry that collects data from several information sources,
including hospital discharge notes, pathology reports, and
death certificates [8]. The RTRTwas not, however, active
in the Tuscan province of Arezzo in 2004, accounting for
330 123 out of 3 566 071 Tuscan inhabitants.
We identified melanoma cases occurring in 2008 from the
regional pathology archive (http://web.rete.toscana.it/attinew/
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?LO=00000001a6b7c8d9000000030000003400003f7a397d5a
0f0000000000012b8000000000000000000000000000000000000
000000000000000000000000000000000000000000000&MItype
Obj= application/pdf), which includes all pathology re-
ports, positive or uncertain, for cancers, as defined by
SNOMED (vers. 3) morphology codes M-8**** and
M-9****. We also collated the incidence of the term
‘melanoma’ in each pathology report from the first semester
of 2008 (from January to June). We included individuals
residing in Tuscany and restricted our interest to those with
primary melanomas, making sure that the individuals had no
pathology reports nor hospital discharge notes, nor had they
undergone any outpatient treatment for melanoma pre-
viously. When melanoma-related reports were not available
(neither in the RTRT nor in the regional pathology archive
system), as was the case for a few individuals, we searched
through the reports in the regional pathology departments.
In total, we analyzed 687 melanomas from 2004 (161, 23.4%
in situ) and 539 from the first semester of 2008 (143, 26.5%
in situ). For each patient, we collected detailed information
on pathology characteristics, diagnostic methods, staging
and type and dates of surgery.
The list of indicators
Working groups within the ITT studied specific cancers
in depth, in order to better define and exchange
experiences on specific topics and to make better clinical
recommendations. The melanoma working group is a
multidisciplinary panel of individuals and institutions,
each belonging to the regional cancer network, including
experts in melanoma (dermatologists, pathologists, sur-
geons, oncologists and epidemiologists), academic insti-
tutions and community hospitals. In 2007, the ITT
published a set of recommendations on the diagnosis and
treatment of melanoma based on the investigations of the
melanoma working group, whose components agreed
upon a consensus procedure based on scientific literature
and on their experience [2].
The ITT Melanoma Working Group (see Acknowledge-
ments) identified a preliminary set of indicators by
analysing scientific guidelines on melanoma diagnosis and
treatment, literature reviews [9–42] and panel discus-
sions. A necessary condition while selecting the indicator
was that only data from the Cancer Registry could be
used, so that a homogeneous analysis could be carried out
and objective results valid for the whole of Tuscany could
be obtained. After meetings, discussions and email
exchanges, the Group selected 13 indicators. The chosen
indicators measured the appropriateness of the clinical
care procedure on the basis of ITT recommendations [2]
and encompassed the diagnosis, pathology reporting and
surgical treatment of melanoma care.
Statistical analysis
We calculated percentages and medians for quality
measures using the w2-test or median test to compare
values between the years. The results were reported at a
regional level but were also available at subregional levels
for local use.
Results
Table 1 presents the selected quality indicators.
Table 2 compares the average regional values of each
quality indicator for 2004 and 2008.
Percentage of incident cases r1mm
The thickness of a melanoma is one of the most relevant
prognostic factors. The ITT and other recommendations
state that a pathology report must specify the thickness.
The number of new melanoma cases increased from 2004
to 2008, the standardized incidences being 14.1 and 18.4
per 100 000, respectively. Almost all the pathology reports
recorded information on Breslow’s thickness (97.5% in
2004, 513/526 and 98.0% in 2008, 388/396). The
percentage of thin (r 1mm) melanomas increased over
time from 50.7 to 61.3% (P=0.001). Moreover, there was
a significant percentage of in-situ melanomas: 23.9% (161
Table 1 Quality indicators of skin melanoma care and areas of interest
Area Main indicators
1 Early diagnosis Percentage of incident cases r1mm
2 Pathology reporting Percentage of pathology reports on incident invasive melanomas with ulceration mentioned (present/absent)
3 Pathology reporting Percentage of pathology reports on excised incident invasive melanomas with the margin status (positive/negative)
4 Surgery Percentage of patients staged by SLB
5 Surgery Percentage of patients staged by SLB <75 years of age
6 Surgery–pathology Percentage of patients with positive sentinel nodes
7 Pathology reporting Percentage of lymphadenectomies with the number of removed lymph nodes reported
8 Surgery–pathology Percentage of cervical lymphadenectomies with >15 lymph nodes removed
9 Surgery–pathology Percentage of axillary lymphadenectomies with >10 lymph nodes removed
10 Surgery–pathology Percentage of inguinal lymphadenectomies with >5 lymph nodes removed
11 Time for pathology Waiting time between the first surgery and the pathology report (time for pathology of diagnosis) (days, median)
12 Time for surgery Waiting time between the diagnostic pathology report and the second surgery (enlargement/SLB – time for surgery)
(days, median)
13 Time for overall surgical treatment in positive
SLB
Waiting time between the first melanoma diagnosis and the final lymphadenectomy in patients with a positive SLB
(days, median)
SLB, sentinel lymph node biopsy.
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out of 674 invasive and in-situ melanomas) in 2004 and
26.9% (143/531) in 2008.
Percentage of pathology reports on incident invasive
melanomas mentioning ulceration (present or absent)
Ulceration has been included in the staging process since
2002 [42]. The ITT recommendations state that patho-
logy reports must specify ulceration [2]. The percentage
of relevant pathology reports mentioning ulceration
statuses (present or absent) increased over time from
61.4% (404/526) in 2004 to 84.6% (334/396) in 2008
(P<0.001). This increase concerned both thin (from
53.1 to 82.5%, P<0.001) and thick melanomas (from
70.4 to 88.0%, P<0.001).
Ulceration was present in a decreasing percentage
of reports over time: 34.4% in 2004 (111/323) and
25.7% in 2008 (86/335) (P=0.005).
Percentage of pathology reports on excised incident
invasive melanomas with margin statuses (positive
or negative)
The margin status confirms the completeness of melanoma
excision. The ITT recommendations state that pathology
reports must specify the margin status [2]. The percentage
of the margin status (whether positive or negative)
mentioned in the pathology reports increased significantly,
from 76.8% (404/526) in 2004 to 84.3% (334/396) in 2008
(P=0.005). On stratifying for thin and thick melanomas,
an almost similar statistically significant increase was
observed (thin 79.1 vs. 85.4%, P=0.064; thick 74.3 vs.
82.7%, P=0.052).
In 2008, 92% of the excisions had negative margins.
Among the 24 cases with positive margins, 15 (62.5%)
dealt with large melanomas of the face and acral sites, for
which an incisional biopsy was planned.
Percentage of patients staged by sentinel lymph
node biopsy
Sentinel node biopsy (SLB) enables melanoma patholo-
gical staging. The sentinel node (SN) status is a major
prognostic factor. The ITT recommendations state that
SLB has to be performed when the thickness is at least
1mm, in cases of ulceration or when the Clark level is at
least IV [2]. The percentages of SLB were similar in 2004
and 2008: 63.6% (161/253) and 63.3% (95/150), respec-
tively.
Percentage of cases with sentinel lymph node biopsy
in patients <75 years old
SLB is a technique underutilized in elderly patients [43].
As it is more invasive than excision, it may sometimes not
be indicated in older patients because of the presence of
comorbidities. Moreover, most SLB trials did not include
patients above 75 years of age [17,44,45]. Among the total
number of patients who underwent SLB, the majority
were less than 75 years of age – 73.9% in 2004 (139/188)
and 74.3% in 2008 (75/101).
Percentage of patients with a positive sentinel node
The SN status is a major prognostic factor; therefore,
node/s should be correctly removed and pathologically
examined [2]. Around one-quarter of SLBs were positive
both in 2004 [26.1% (42/161)] and in 2008 [26.3%
(25/95)].
Percentage of lymphadenectomies with the number
of nodes reported
The ITT recommendations state that the pathological
report must specify the number of nodes removed after
lymphadenectomy [2]. The number of nodes with
metastases is a basic point for staging [42]. The number
of nodes was mentioned in almost all the relevant
pathology reports in both years. The number of the
nodes removed in cases of complete node dissection was
Table 2 Average regional value of the quality indicators of skin melanoma care for 2004 and 2008, probability of equality according
to testing (v2, rank sum)
Main indicators
Regional average
2004
Regional average
2008 P
1 Percentage of incident cases r1mm 50.7 61.3 0.001
2 Percentage of pathology reports on incident invasive melanomas with ulceration mentioned (present/absent) 61.4 84.6 <0.001
3 Percentage of pathology reports on excised incident invasive melanomas with the margin status (positive/
negative)
76.8 84.3 0.005
4 Percentage of patients staged by SLB 63.6 63.3 0.95
5 Percentage of patients staged by SLB <75 years old 73.9 74.3 0.95
6 Percentage of patients with positive sentinel nodes 26.1 26.3 0.97
7 Percentage of lymphadenectomies with the number of removed lymph nodes reported 98.2 100 0.51
8 Percentage of cervical lymphadenectomies with >15 lymph nodes removed 100 100 1
9 Percentage of axillary lymphadenectomies with >10 lymph nodes removed 85.7 66.7 0.20
10 Percentage of inguinal lymphadenectomies with >5 lymph nodes removed 100 100 1
11 Waiting time between the first surgery and the pathology report (time for pathology of diagnosis) (days, median) 9 13 <0.001
12 Waiting time between the diagnostic pathology report and the second surgery (enlargement/SLB – time for
surgery) (days, median)
23 26 0.084
13 Waiting time between the first melanoma diagnosis and the final lymphadenectomy in patients with a positive
SLB (days, median)
72 82.5 0.71
SLB, sentinel lymph node biopsy.
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also reported in almost all the cases, both in 2004, 98.2%
(54/55) and in 2008, 100% (24/24).
Indicators 8, 9 and 10 concern the number of lymph
nodes removed during lymphadenectomy. The number of
lymph nodes removed by lymphadenectomy could be
considered a measure of the quality of surgical care.
Percentage of cervical lymphadenectomies with >15
lymph nodes removed
In cervical lymphadenectomy, a cutoff value of 15 lymph
nodes has been adopted [46]. The number of nodes
removed exceeded the cutoff value in all cases in both years.
In 2008, the median number of excised nodes was 24.5.
Percentage of axillary lymphadenectomies with >10
lymph nodes removed
In axillary lymphadenectomy, a cutoff value of 10 lymph
nodes has been adopted [46]. The number of nodes
removed exceeded the cutoff value in 85.7% of cases in
2004 (24/28) and in 66.7% (6/9) cases in 2008. In 2008,
the median number of excised nodes was 16.
Percentage of inguinal lymphadenectomies with >5
lymph nodes removed
In inguinal lymphadenectomy, a cutoff value of five lymph
nodes has been adopted [46]. The number of nodes
removed exceeded the cutoff value for all patients in both
years. In 2008, the median number of excised nodes was 14.
Indicators 11, 12 and 13 concern the waiting time.
Waiting time between the first surgery and the
corresponding pathology report
The time between the removal of a suspected skin lesion
and the pathological diagnosis of melanoma may influ-
ence the timeliness of the necessary subsequent actions
(enlargement, SLB, etc.). The median diagnostic time
was 9 days in 2004 and 13 days in 2008 (P<0.001). On
analysing thin and thick melanomas separately, the
median time increased for thin melanomas (from 9 to
14 days, P<0.001) and was stable for thick ones (from 10
to 11, P=0.509).
Waiting time between the diagnostic pathology report
and second surgery (enlargement/sentinel node biopsy)
The ITT recommendations [2] suggest performing
enlargement or SLB within 3 months from the biopsy.
The median time was 23 days in 2004 and 26 days in 2008
(P=0.084). There were no differences with regard to
Breslow’s thickness.
Waiting time between the first melanoma diagnosis and
final lymphadenectomy in patients with positive
sentinel node (time for overall treatment in sentinel
node positive patients)
The total waiting time for the surgical treatment of a
melanoma patient is the time from the first biopsy to the
report of the lymphadenectomy (in the case of a positive
SN). It was reported to be 72 days in 2004 and 82.5 days
in 2008 (P=0.71).
Discussion
This study provides a comprehensive population-based
evaluation of the diagnostic and surgical treatment of
melanoma in the central Italian region of Tuscany. Our
proposed indicators are based on local cancer registry data
and the official regional pathology databases. The method
of computation of the indicators enables us to compare
different years or geographical/administrative areas when
the same information systems are available. The popula-
tion-based setting theoretically provides unbiased infor-
mation and shows average measures for clinical care in the
population. In Tuscany, a multilevel strategy for early
diagnosis of skin melanoma has been in use since the
1990s. The strategy includes specific initiatives for raising
awareness in the population, namely, distribution of infor-
mation packs for skin self-examination, organizing train-
ing courses for general practitioners (GP) and setting up
skin units across the region. In addition, the multi-
disciplinary ITT Melanoma Working Group has devel-
oped specific clinical recommendations to optimize the
clinical course throughout the region [2].
A hypothetical and optimal clinical course for skin
melanoma should start when an individual discovers a
changing skin lesion, the GP confirms the need for further
evaluation, the skin clinic dermatologist performs the
excisional biopsy and the pathologist reports the diagnosis,
specifying all the main prognostic factors that address the
subsequent appropriate surgery. Therefore, the aim of the
ITT Melanoma Working Group in identifying possible
melanoma indicators was to find parameters useful in
evaluating the diagnostic phase, the completeness of the
pathological reporting and the surgical treatment of the
melanoma. The indicators analysed in the present study
were selected by the ITT Melanoma Working Group on
the basis of data available in the Cancer Registry in order
to have unbiased, homogeneous and comparable informa-
tion. On the basis of the above requirements, the ITT
Melanoma Working Group analysed scientific guidelines
on melanoma diagnosis and treatment and performed
literature reviews [10–41] and panel discussions with the
purpose of identifying possible indicators of an early
diagnosis and appropriate melanoma treatment. After
discussions, meetings, reports and email exchanges, the
Melanoma Working Group selected 13 indicators on the
basis of the Cancer Registry data (Table 1). All measures
were process indicators that are among the most suitable
management tools for measuring quality [9].
During the analysed period, there was a strong increase in
melanoma diagnosis, in both the standardized and crude
rates. As they are based on the number of cases, crude
rates show the real workload of a healthcare system in
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terms of the need for diagnosis and treatment. This is the
rate that must be taken into account when the 2 years are
compared. The increased incidence was mainly driven by
the growing percentage of thin melanomas (r 1mm),
which in 2008 was 61.3% of all newly diagnosed invasive
melanomas. This indicator attests to the efficacy of early
diagnosis in the region, as a consequence of increased
awareness in the population, the role of the GP and of the
activity of the dermatologists in skin clinics (with the
support of dermoscopy). In the area of the present study,
a randomized clinical trial confirmed the usefulness of
dermoscopy in improving melanoma diagnosis and reducing
the number of pigmented skin lesions excised for
diagnostic verification [47]. The possible use of dermo-
scopy in the diagnosis of pigmented skin lesions is included
in the ITT melanoma recommendations [2,20,47].
Mortality for melanoma is still increasing in Tuscany [48].
No effective treatments for advanced melanomas were
available in Italy at the time of the study. Encouraging
results from new molecular drugs have emerged only
recently [49–51]. Therefore, early diagnosis and appro-
priate surgical treatment are the primary recourse for the
healthcare system. However, an increase in diagnostic
drift and instances of reclassification of previous severely
atypical dysplastic nevi as melanoma has been found [52].
The increased diagnoses of thin but not deadly melan-
omas [3] have a positive significance, although the
possible role of overdiagnosis of indolent pigmented
lesions should also be considered [53].
Melanoma prognosis is strictly dependent on character-
istics that may be evaluated only by a pathologist, and, for
this reason, there are indicators that address the
completeness of the pathology reports. The quantity of
information available in the pathology reports has
increased over time. In 2008, almost all reports included
Breslow’s thickness (98%), around 85% included the
presence or absence of ulceration, 84% included the
margin status for excised melanomas and all reports
included the number of nodes in patients of lymphaden-
ectomy. The latter results were as good as those recently
documented in the USA [7].
As regards the weaknesses of this study, for the patients
diagnosed in 2008, we used only the information from
pathology reports. Therefore, few cases may have been
lost and the estimates may be slightly overestimated.
Moreover, not all the relevant prognostic factors were
analysed; for example, the number of mitoses was not
included. However, the analysed data refer to 2004 and
2008, and it was only in 2009 that AJCC melanoma
staging [54] included the number of mitoses as an
important prognostic factor. For this reason, recent
melanoma guidelines, such as those in the UK [12],
include the mitotic count among the requirements for
a pathological report, and this parameter will be included
in the updated ITT recommendations for melanoma that
are to be published. They will also be included on future
indicator analyses.
About two-thirds of eligible patients had SLB. The
percentage for patients younger than 75 years (74%)
shows that this procedure was performed mainly on
nonelderly patients. Presumably, the presence of comor-
bidity in patients older than 75 years influenced the
decision of the surgeon for SLB. Once performed, an
SLN biopsy showed approximately the same rate of
positivity in 2004 as that in 2008 – about 26%. The mean
regional figure of 26% in Tuscany is higher than the
percentage of 16% reported in the Multicenter Selective
Lymphadenectomy Trial I [17] and the 19.9% reported in
an Italian Multicentre Study [55], indicating appropriate
surgical and pathological approaches. Pathology reports
always specify the number of lymph nodes removed
during lymphadenectomy in the entire region. The cutoff
values obtained by Bilimoira in recent work on melanoma
indicators in the USA [7] were adopted to evaluate the
quality of the surgical procedures in stage III patients.
Moreover, the same cutoff values made it possible to
compare the results between the two studies. The
number of nodes removed from sites in the cervical and
inguinal regions always exceeded the levels of 15 and five
nodes, respectively. As regards the axillar region, two-
thirds of patients had 10 or more nodes removed in the
first semester of 2008. However, this number is based on
just nine patients. The values registered in Tuscany are
higher than those reported in Bilimoira’s study [7].
Moreover, it has been reported in a previous American
study that less than 50% of patients with positive SLB in
the USA underwent complete node dissection [46],
whereas the percentage in Tuscany was 63%.
A crucial aspect for any public healthcare system, for both
patients and healthcare policy makers, is the waiting
time. Three indicators addressed waiting times in the
diagnostic and surgical course of melanoma. The median
time for receiving the report for a skin lesion suspected to
be a melanoma was 13 days in 2008. The length of this
period depended on the pathologist, his/her workload,
and the availability of resources. It increased from 2004
by 44%; however, the crude incidence rate (number of
melanomas) increased during the same period by about
33% and, therefore, the longer waiting time for melanoma
diagnosis resulted mainly from the increased number of
patients awaiting diagnosis. The waiting time after a
pathology diagnosis depended on the surgeons’ workload
and resources. The waiting time, for wider excision or
SLB, increased by 13% (median from 23 to 26 days)
during the aforementioned period (during which there
was an increase in melanoma incidence). In particular,
there was an increase not only in the number of thin
melanomas but also in the number of cases with
a thickness greater than 1mm (an increase of 4%).
The total surgery-related waiting time, commencing with
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the positive SLB report and ending with lymphadenect-
omy, increased by about 15% (from 72 days in 2004 to
82.5 days in 2008). The implementation of a modified
EORTC protocol in Tuscany as the standard procedure
for extensive pathological handling of SLB [56] pre-
sumably had an impact from 2004 to 2008, lengthening
the time of reporting.
Conclusion
In this study, we analyzed a set of 13 quality indicators for
evaluation of the diagnosis, surgical treatment and
pathological definition of melanoma. These indicators,
evaluated using a population-based dataset in Tuscany,
showed an increase in the number of thin melanomas
(a mark of early diagnosis), an improvement in the
completeness of the pathology reports, and good surgical
management. Some of the latter improvements may be
related to the development of ITT recommendations for
melanomas for the regional healthcare system in 2007, a
product of the regional multidisciplinary Melanoma Group.
These as well as other indicators, such as the mitotic
rate [54,57], should be monitored to identify the potential
improvements and shortcomings in melanoma care.
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